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General introduction & scope of the thesis 
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IntroductIon & Scope 
1.1 CLINICAL ChARACTERISTICS OF MIGRAINE
Migraine with and without aura
Migraine is a common, disabling, episodic neurovascular headache disorder. The disease is 
characterized by recurrent attacks of headaches and associated autonomic and neurological 
symptoms. Migraine can be divided in two major subtypes: migraine without aura (MO) and 
migraine with aura (MA). MO attacks are typically characterized by recurrent, unilateral, pulsating 
headaches of moderate to severe intensity, lasting 4-72 hours that are aggravated by physical 
activity and often accompanied with nausea and/or vomiting, phonophobia and photophobia. 
Roughly one-third of migraine patients suffer from MA. MA is discriminated from MO by the 
presence of transient focal neurological symptoms that accompany the headache attacks. Aura 
symptoms usually last between 5 and 60 minutes and nearly always include visual symptoms (for 
an example see Figure 1). Less often sensory symptoms (i.e., paraesthesia) or dysphasic speech 
disturbances are experienced and, rarely motor symptoms.1,2 Of all migraineurs, 33% have both 
types of migraine attacks.3 Patients with MA suffer from less severe headache, some even may 
have attacks of migraine aura without headache. Prior to the aura and headache phase migraine 
patients may experience premonitory symptoms, such as mood disturbances, autonomic 
symptoms and concentration problems.4 This premonitory phase can last up to 24 hours. Most 
frequently reported triggers for migraine attacks are too much or too little sleep, weather changes, 
missing a meal, certain food triggers (e.g., wine, chocolate, or cheese) and menstruation.5 Some 
patients perceive higher mental stress levels before a migraine attack, however evidence suggests 
that this is more likely part of the premonitory phase of the migraine attack than a trigger.6 Not 
the migraine attack itself, but the recurrence of attacks is clinically relevant and defines a migraine 
patient (according to ICHD-2 and 3 criteria: MO after 5 attacks without an aura and MA after 
2 attacks with an aura).7,8 As biomarkers for migraine are currently lacking, a diagnosis is based on 
a questionnaire and/or interview using diagnostic criteria that were provided by the International 
Headache Society in 1988; and in revised form in 2004 and 2013 (Table 1).7,8
CA B
Figure 1. Drawings of visual aura symptoms by migraine patients from the Erasmus Rucphen Family (ERF) study. 
(A) Before the headache starts this patient experiences flashing star-shaped features that gradually increase and 
eventually cover one hemifield. These features last 10-30 minutes. (B) This patient describes the background to 
fade during minutes after which she sees dark-brown to black stars surrounded by silver colored rays lasting 
10-15 minutes. After these visual disturbances the headache starts. (C) Before the headache this patient sees radar 
wheels which are present for 10-15 minutes. 
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Table 1. Diagnostic criteria for migraine with and without aura and familial hemiplegic migraine (ICHD-3 
beta)8
Migraine without aura
A. At least 5 attacks fulfilling criteria B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following four characteristics: 
1. unilateral location
2. pulsating quality
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) 
D. During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis.
Migraine with aura
A. At least 2 attacks fulfilling criteria B and C 
B. One or more of the following fully reversible aura symptoms
1. visual
2. sensory




C. At least two of the following four characteristics: 
1. at least one aura symptom spreads gradually over ≥ 5 minutes, and/or two or more symptoms occur 
in succession
2. each individual aura symptom lasts 5-60 minutes
3. at least one aura symptom is unilateral
4. the aura is accompanied, or followed within 60 minutes, by headache 
D. Not better accounted for by another ICHD-3 diagnosis, and transient ischemic attack has been 
excluded.
Hemiplegic migraine
A. At least 2 attacks fulfilling criteria B and C 
B. Aura consisting of both of the following:
1. fully reversible motor weakness
2. fully reversible visual, sensory and/or speech/language symptoms
C. At least two of the following four characteristics:
1. at least one aura symptom spreads gradually over ≥ 5 minutes, and/or two or more symptoms occur 
in succession
2. each individual non-motor aura symptom lasts 5–60 minutes, and motor symptoms last < 72 hours
3. at least one aura symptom is unilateral
4. the aura is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for or by another ICHD-3 diagnosis, and transient ischaemic attack and stroke 
have been excluded.
Familial and Sporadic Hemiplegic Migraine
Hemiplegic migraine (HM) is a rare autosomal dominantly inherited subtype of migraine 
with aura that is characterized by transient hemiparesis during the attacks (Table 1).8 Two 
types of hemiplegic migraine are recognized. In Familial Hemiplegic Migraine (FHM) there 
12
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is at least one first- or second-degree family member with attacks of hemiplegic migraine.7,8 
In Sporadic Hemiplegic Migraine (SHM), the family history is negative for patients with 
hemiplegic attacks. FHM and SHM attacks are clinically indistinguishable,9 suggesting a 
common pathophysiological basis. An extensive epidemiological Danish population-based 
study investigated the prevalence of hemiplegic migraine, as well as the headache and aura 
characteristics, in comparison to those in MA.10-12 The prevalence of both hemiplegic migraine 
types is 0.01%.10 The mean age at onset is around 17 years (95% CI: 15-18; range 1-45 years), 
which is lower than for familial MA, which on average starts at 21 years.11,12 Besides motor aura 
symptoms, FHM patients can have sensory (98%), visual (89%) and aphasic (72%) symptoms. 
Furthermore, 69% of FHM patients has co-occurrence with Basilar Migraine (BM).11,13 Basilar-
type migraine symptoms include dysarthria, vertigo, visual symptoms simultaneously in 
temporal and nasal fields of both eyes, ataxia, decreased level of consciousness and bilateral 
paraesthesias.7,8 In three-quarter of FHM patients, the sequence of aura symptoms in FHM is 
the following: visual - sensory - motor - aphasic - basilar-type.11 Apart from the motor aura 
symptoms, which are only experienced by FHM patients, the composition of symptoms and 
the order of appearance during an attack are very similar for FHM and MA.11,12 However, FHM 
patients are more likely to experience two or more aura symptoms, the duration of symptoms 
is longer for FHM, the presence of BM symptoms only co-occurs with FHM, and the presence 
of headache more often accompanies FHM than MA.11,12 Severe atypical FHM attacks may be 
prolonged (up to six weeks) and accompanied by confusion, decreased consciousness, fever, 
seizures, and even coma.14 A minor head trauma is reported in 9% of FHM patients as the 
initiating event.11,14 In addition, cerebral or coronary angiography can trigger attacks.14 
1.2 ThE MIGRAINE SpECTRuM
Clinical similarities indicate that a migraine spectrum exists ranging from MO to MA and 
FHM. Arguments for this spectrum are: i) apart from the hemiparesis, the aura and headache 
characteristics of FHM and MO/MA are similar; ii) within FHM families, family members can 
have attacks of MA and/or MO; iii) about two-third of FHM patients also has non-hemiplegic 
migraine attacks.15 Thus, it can be hypothesized that FHM genes and their pathways also 
provide insight in the common forms of migraine. 
1.3 WhAT hAppENS DuRING A MIGRAINE ATTACk?
Traditionally, two hypotheses exist regarding the etiology of migraine: the neuronal hypothesis 
and the vascular hypothesis.16 In the classical, purely, vascular hypothesis the migraine aura 
is caused by intracerebral vasoconstriction, whereas the headache is attributed to (rebound) 
vasodilatation of cerebral and meningeal blood vessels.17 This hypothesis has nowadays been 
abandoned.18 Instead, migraine is now considered a primary brain disorder with neuronal 
events affecting blood vessels, i.e., a neurovascular disorder. 
The aura is thought to be caused by a phenomenon termed Cortical Spreading Depression 
(CSD),19 a brief wave (lasting seconds) of intense neuronal and glial depolarization that 
13
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slowly (2-5 mm/min) propagates across the cerebral cortex.19,20 This would account for the 
spreading character and propagation rate of the aura symptoms. The wave is followed by a 
relatively long-lasting (> 20 min) neuronal suppression, which would explain the occurrence 
of positive and negative phenomena in aura symptoms.21 Functional neuroimaging studies 
revealed similarities between blood flow changes in patients during visual aura’s and CSD in 
experimental animals suggesting that CSD indeed occurs in humans.22 
The origin of the headache is considered to be related to a dysfunction of certain brainstem 
nuclei.23 Whether the first neurologic event in migraine is CSD or brainstem dysfunction is 
still a point of controversy and the two theories may not be mutually exclusive. However, in 
both scenarios, vasodilatation of cerebral and meningeal vessels, if present, is considered a 
secondary phenomenon occurring after activation of the trigeminovascular system (TGVS).24 
How does this system works? The TGVS consists of the cranial blood vessels, innervated by 
sensory afferent fibres of the ophthalmic division of the trigeminal nerve. Activation of these 
fibres leads to activation of second-order neurons in the trigeminal nucleus caudalis (TNC) and 
the two uppermost levels of the spinal cord dorsal horn, together termed the trigeminocervical 
complex. Impulses are relayed further forward to several thalamic nuclei, the ventrolateral 
area of the caudal periaquaductal grey region and the cerebral cortex, where the pain sensation 
is registered.
On a molecular level, activation of trigeminovascular efferents leads to the release of 
vasoactive neuropeptides (e.g., Calcitonin Gene Related Peptide (CGRP), Substance P, and 
Nitric Oxide (NO)), which are believed to cause neurogenic inflammation, central pain 
transmission, and headache. The role of neurogenic inflammation has never been demonstrated 
in patients, but in experimental animal models of migraine neurogenic inflammation of the 
dura and around the meningeal vessels has clearly been shown.25 These experiments also 
provided evidence that CSD can activate the TGVS and induces vasodilatation of the middle 
meningeal artery.25 A role for vasodilatation in migraine in humans is further supported by 
the fact that specific antimigraine drugs, the triptans and ergotamine, next to deactivation of 
the TGVS and inhibition of the release of vasoactive neuropeptides from perivascular nerve 
terminals, have a vasoconstrictive effect.24 Recent studies have casted considerable doubt 
on whether our idea about the role of vasodilatation in migraine is correct. For instance, 
CGRP antagonists do not have a vasoconstrictive effect, but are effective in the treatment of 
migraine.26 A study using a sensitive 3 Tesla MRA-technique, failed to show in vivo cerebral 
and meningeal vasodilatation in humans during migraine headache.27 Nevertheless, although 
this study did not provide evidence for vasodilatation of large meningeal and cerebral vessels 
during migraine headache, it does not rule out a role for small cerebral vessels.
1.4 EpIDEMIOLOGY OF MIGRAINE
Clinical epidemiology
The prevalence of migraine is more or less similar over Western countries, but varies for age 
and sex. The one-year prevalence of migraine varies between 17.1-25.0% in women and 5.6-7.5% 
in men.28,29 Onset of migraine is in more than 90% of patients below the age of 50. Peak age of 
14
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onset is 10-12 years old for males and 14-16 years old for females, although attacks may start at 
any age.28,30 The average female-to-male ratio is 3:1. The prevalence of migraine increases with 
age with a male preponderance in children under 12 and female preponderance at later ages. The 
one-year prevalence in women peaks at 35-40 years (33%) and then declines. In men, the one-
year prevalence peaks between 50-55 years (15%).28 Among active migraineurs the median attack 
frequency is 1-1.5 per month and the median attack duration is 24 hours.28,30 Approximately 5% 
of the general population have at least 18 days of migraine per year and over 1% have at least 
1 day of migraine per week.24 Each year, approximately 2.5% of patients with episodic migraine 
develop new-onset chronic migraine (with more than half of the days per month headache).31 
Migraine greatly affects the quality of life32 and is rated by WHO among the most 
disabling disorders.33 It is the most costly neurological disorder in the EU.34 Current acute 
migraine therapies are far from optimal as not all patients respond to acute therapies and 
headache recurrence is a common problem. In general, the efficacy of migraine prophylactic 
drugs is limited. At most, 50% will have a 50% reduction in attack frequency.35 In addition, 
currently available prophylactic drugs have a large risk of causing adverse effects. Therefore, 
better, especially preventative treatment options are clearly needed. In order to identify novel 
treatment targets it is important to unravel the molecular biological mechanisms involved in 
migraine. Identification of migraine genes may provide more insight into these mechanisms.
Genetic epidemiology 
Studies in families, twins and the general population showed that genetic factors play an 
important role in the pathogenesis of migraine, probably by lowering the threshold for migraine 
attacks.36,37 First-degree relatives of probands with MO have an increased risk for MO of 1.9 
and for MA of 1.4 compared with the general population. First-degree relatives of probands 
with MA had a 3.8-fold increased risk for MA, but no increased risk for MO.36 Early age at 
onset and migraine severity and disability appear to be predictors for familial aggregation.38 
In twins, families, or large (isolated) populations the proportion of genetic involvement in 
a disease can be calculated as heritability. Heritability estimates the proportion of variability 
in a trait (i.e., the phenotypic variance) that can be attributed to additive genetic factors and 
shared early environmental factors. Additive genetic effects are the sum of the independent 
effect of alleles. Thus, non-additive genetic effects caused by interaction between alleles at 
the same locus (dominance) or at two different loci (epistasis) are not measured. Heritability 
estimates in twin39-44 and family-based45 studies range from 0.33-0.53 for migraine in general, 
and 0.61-0.77 and 0.65-0.79 for MO and MA separately.39-45
Studies based on the Danish Twin Registry provided information on specific concordance 
rates for MO and MA. Concordance rates for monozygotic twins for both MO (28% vs 18%, 
p=0.04) and MA (34% vs 12%, p=0.04) are significantly higher than for dizygotic twins, 
indicating the importance of genetic factors.46,47 In a study that includes almost 30,000 twin 
pairs affected by migraine from six countries, monozygotic correlations were at least twice 
the size of dizygotic correlations, also indicating a contribution of genes to the liability of 
migraine.42 As neither the heritability estimates nor the concordance rates in monozygotic 
twins reach 100%, part of the migraine phenotype must be explained by environmental factors. 
15
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These family and twin data show that genetic factors play a role in migraine, however 
from these data no conclusion can be drawn about the pattern of inheritance. A large 
Danish population-based segregation analysis showed that MO and MA most likely have a 
multifactorial inheritance pattern, with a combination of genetic and environmental factors.45 
1.5. GENETIC FINDINGS IN COMMON FORMS OF MIGRAINE
The most widely used strategies to map genes for migraine are linkage analysis and candidate 
gene association analysis.48 These methods are aimed at identifying genetic variants with 
different effects sizes and allelic frequencies. The linkage approach generally yields genes with 
a large effect size and a low population allele frequency, whereas candidate gene association 
studies test potential migraine gene variants with a low effect size and relatively high allele 
frequencies in the population. 
Linkage studies
Linkage analysis requires DNA and clinical information of one or more (large) families containing 
multiple affected members, a genome wide scan (a narrow grid of polymorphic markers evenly 
spaced over the genome) and a statistical test (expressed as the Logarithm of the odds (LOD) 
score) to find out which markers are inherited along with the disease in the families. When a 
chromosomal region (locus) is transmitted with the disease phenotype within families, this 
region is likely to contain the gene of interest. Linkage analysis has been successful in FHM (where 
one gene with a large effect size is implicated in one family), where it lead to the identification of 
three genes.49-51 For complex migraine (MO and MA) linkage analyses can also be performed, but 
the power is much more limited compared to monogenic disorders. The contribution of genes 
to the total disease risk is small or modest, making it hard to detect them. Linkage studies have 
identified migraine susceptibility loci on chromosomes Xq24-q28, 1q31, 4q21, 4q24, 6p12 -p21.1, 
10q22-q23, 11q24, 14q21.2-q22.3, 15q11-q13 and 19p13.52-64 With the exception of a few loci (4q21-
q24 and 10q22-q23), none have been clearly replicated and for all migraine loci the causative gene 
still needs to be identified. Next to the small effect size of the variants involved, this is likely due to 
genetic heterogeneity but also clinical heterogeneity in the end-diagnosis of migraine. 
Association studies
Association studies are aimed at detecting genetic variants that are more common in people 
with migraine than in unaffected persons, ideally from the same population, i.e., allele 
frequencies are compared. Association studies may be targeted to a biological candidate gene 
or performed with a genome wide scan. The genetic variants examined are usually single 
nucleotide polymorphisms (SNPs), DNA variants that represent variation in a single base.48 
Genetic association studies have greater power than linkage studies to detect genes with a small 
effect and require collection of large numbers of cases and controls, instead of large families. 
A significantly increased frequency of an allele of a polymorphism would suggest either that it 
directly affects the risk of migraine or that the polymorphism is located very close to the locus 
involved in the disorder and is transmitted with this disease locus (i.e., linkage disequilibrium 
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(LD), the non-random association of alleles at two or more loci on a chromosome that is 
gradually lost over generations by recombination). Alternatively, the association is false positive 
and due to some underlying stratification or admixture (substructure) of the population. 
Although a large number of candidate gene association studies were performed in 
migraine, many are of limited value because of important limitations (e.g., small sample size 
and consequent low power to detect association, no correction for multiple testing, and/or 
no clear description of migraine subtypes). Association studies have investigated the possible 
association between migraine and polymorphisms in genes with a hypothesized function 
in migraine pathways. Amongst others, genes with a neurotransmitter function (mainly 
serotonin, dopamine) or involvement in hormonal, inflammatory or vascular pathways have 
been investigated (for review see de Vries et al., 2009).65 The only variant to date that was 
found to be associated with migraine with aura in several, but not all66-68 studies is the C677T 
polymorphism of the MTHFR gene (methylenetetrahydrofolate reductase).69 At the start of 
this thesis, Genome Wide Association studies for migraine had not been published yet.
Genetic isolates
An alternative approach to study genetics of migraine is to make use of a genetically isolated 
population. Genetic isolates have several advantages compared to outbred populations. In an 
isolate genetic variability is reduced because a small number of founders, the occurrence of 
population “bottlenecks” (such as famine, wars, or infectious disease epidemics) and the absence 
of migration leading to more inbreeding and genetic drift.70 This makes it more likely that 
patients in an isolate have a disease due to a similar underlying genetic defect that is inherited 
from a common ancestor. Isolates may vary in genetic diversity, depending on the extent of 
genetic drift and founder effects.71 Another advantage of genetically isolated populations is that 
subjects generally have a more uniform lifestyle, culture and environment, which are therefore 
better controlled. This makes it more likely that a difference between healthy and diseased 
subjects reflects genetic effects instead of environmental effects. Extensive genealogical records 
allow reconstruction of extended pedigrees and the collection of unascertained phenotype data 
prevents selection bias for specific diseases. A disadvantage of isolates may be that some genetic 
variants are isolate-specific and findings cannot be extrapolated to the general population. 
However, a genome wide linkage study on depression in ERF showed that this does not account 
for all variants, as the results found in ERF could be replicated in an independent population.72 
In this thesis, migraine is studied a Dutch genetic isolate (The Erasmus Rucphen Family 
(ERF) study). The advantage of the ERF isolate compared to the Finish and Icelandic isolates73 
is that it is a much younger isolate (i.e., 10-20 generations) with high levels of LD,74 making it 
particularly useful in the mapping of complex diseases such as migraine.75 
1.6 GENETIC FINDINGS IN MONOGENIC FORMS OF MIGRAINE
Two types of monogenic migraine forms exists. Monogenic FHM, a migraine subtype at the 
severe side of the migraine spectrum and monogenic migraine syndromes in which migraine 
is part of the clinical spectrum. 
17
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Genetic and clinical spectrum of FHM and the relation with migraine 
relevant diseases
FHM is genetically heterogeneous: three genes have been identified. Clinically, hemiplegic 
migraine attacks of the three subtypes (FHM1, FHM2, and FHM3) cannot be distinguished. 
FHM may present as ‘pure’ FHM or be associated with various comorbid diseases. As FHM 
families exist without mutations in any of the three FHM genes, at least a fourth and probably 
more FHM genes exist. All three FHM gene products are intimately involved in the modulation 
of ion transport across neuronal and glial cell membranes, suggesting that FHM, and possibly 
also common types of migraine, at least in part, are cerebral ‘ionopathies’.
FHM1 is caused by mutations in the CACNA1A gene located on chromosome 19p13.51 
CACNA1A encodes the pore-forming α1 subunit of voltage-gated neuronal CaV2.1 (P/Q-type) 
calcium channels and is involved in the modulation of release of neurotransmitters at peripheral 
and central synapses. To date, over 50 CACNA1A mutations have been associated with a wide 
variety of symptoms. Almost twenty FHM1 gene mutations are known that represent a broad 
clinical spectrum. More than half of them are associated with cerebellar signs (i.e., slowly 
progressive ataxia, dysartria and gaze-evoked nystagmus).14 About 20% of FHM1 families 
have cerebellar signs.14 Epilepsy can also be part of the clinical spectrum of FHM1 mutation 
carriers.76 Several CACNA1A mutations are associated with a decreased level of consciousness 
during FHM attacks77-79 or even coma,14,80-83 sometimes in combination with seizures.80,83 
CACNA1A mutations can also cause Episodic Ataxia type 2 (EA2) and Spinocerebellar Ataxia 
type 6 (SCA6).51,84 Whereas FHM1 is caused by missense mutations, EA2 mutations mostly 
are nonsense, frameshift, or splice site,51 and rarely missense mutations.85 SCA6 is a so-called 
polyglutamine disorder caused by small expansions of a CAG repeat located in the distal end 
of the CACNA1A gene.84 In rare cases, epilepsy (i.e., absence and generalized tonic-clonic 
seizures) has also been reported in EA2 patients.86,87 
FHM2 is caused by mutations in the ATP1A2 gene that is located on chromosome 
1q23. ATP1A2 encodes the α2-subunit of Na+/K+ pumps.49 Sodium potassium ATPases are 
responsible for translocating sodium ions out of the cell, while they import potassium ions. The 
release of sodium ions provides a steep sodium gradient essential for the import of glutamate 
through glutamate transporters. Thus, ATPases, directly or indirectly, modulate re-uptake of 
potassium and glutamate from the synaptic cleft into glia cells. Over 35 ATP1A2 mutations have 
been identified. With the exception of a few, FHM2 mutations are mostly missense mutations 
located in the large intracellular loop, which harbors important regulatory domains for ion 
transport. Although most FHM2 mutations are associated with pure FHM,49,88-91 additional 
clinical features have also been reported in ATP1A2 mutation carriers. In clear contrast to 
FHM1, cerebellar signs are very rare in FHM2.92-94 Other FHM2 associated clinical features 
include, epilepsy,49,95,96 permanent mental retardation,95 prolonged hemiplegia,97 coma,90 and 
alternating hemiplegia of childhood (AHC). Alternating hemiplegia of childhood is a rare 
neurological disorder, with unknown etiology, that resembles FHM and initially was regarded 
as a migraine variant.98 A link between FHM and alternating hemiplegia of childhood (AHC) 
was shown by the identification of an ATP1A2 mutation in a Greek family with atypical 
AHC.99,100 In contrast, the screening of the FHM genes CACNA1A and ATP1A2 gene in a set 
18
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of typical AHC patients did not reveal any causal mutations.101,102 ATP1A2 mutations were also 
found in basilar-type migraine103 and the common forms of migraine.104 
FHM3 is caused by specific missense mutations in the SCN1A gene that is located on 
chromosome 2q24.50 SCN1A encodes the α1-subunit of neuronal NaV1.1 voltage-gated sodium 
channels that play an important role in the generation and propagation of action potentials. 
The FHM3 gene was originally identified in three related German families with the Q1489K 
mutation.50 An association of SCN1A with FHM is rather surprising because over 150 mutations 
in this gene are known to cause childhood epilepsy (i.e., severe myoclonic epilepsy of infancy 
(SMEI) or generalized epilepsy with febrile seizures (GEFS+)).105,106 With the identification of a 
second SCN1A L1649 mutation in an FHM family of North American decent, the link between 
SCN1A and FHM was firmly established. 
FHM gene mutations can also be found in SHM patients, although the chance of identifying 
a causal mutation is much lower compared to FHM. Whereas in a Dutch clinical-based SHM 
sample of 39 SHM patients the prevalence of ATP1A2 mutations was 15 %, only in 1 % ATP1A2 
mutations were identified in 100 patients from a Danish population-based sample.107,108 The 
prevalence of CACNA1A gene mutations in SHM patients lies between 1 and 5 %.107-109 The 
chance of identifying an ATP1A2 or CACNA1A mutation is further increased by early age at 
onset and presence of additional symptoms (such as ataxia or epilepsy).110 No SCN1A mutations 
have been identified in SHM patients.107 
Examples of monogenic syndromes associated with complex 
migraine
Migraine can also be part of the clinical spectrum of other monogenic syndromes. Hence, 
the identification of genes for these syndromes may further our understanding of the 
mechanisms involved in migraine. The monogenic syndromes CADASIL (Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) and HVR 
(Hereditary Vascular Retinopathy) (later renamed RVCL (Retinal Vasculopathy with Cerebral 
Leukodystrophy) and CHARIOT (Cerebral Hereditary Angiopathy with Vascular Retinopathy 
and Impaired Organ Function caused by TREX1 mutations)) are described below. 
CADASIL 
The clearest example of a monogenic syndrome in which migraine is prominent is Cerebral 
Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy 
(CADASIL). CADASIL is an autosomal dominant late-onset arteriopathy that is clinically 
characterized by recurrent transient ischemic attacks (TIAs) and strokes and cognitive 
decline, psychiatric symptoms and dementia.111 In about one-third of patients migraine 
with aura occurs, often as the presenting symptom several years before the onset of other 
symptoms.112 CADASIL has distinct neuroradiological features that are usually manifest prior 
to the first stroke.113,114 The most important features are white matter hyperintensities (WMH) 
and lacunar infarcts. WMHs are symmetrically distributed in the deep and periventricular 
white matter. Typical for CADASIL is the bilateral involvement of the anterior temporal 
lobes and external capsule. Histopathologically, CADASIL is characterized by the deposition 
of granular osmiophilic material (GOM) in the basement membrane and surrounding 
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extracellular matrix of vascular smooth muscle cells (VSMCs) as well as the degeneration and 
eventual disappearance of VSMCs. CADASIL is caused by mutations in the NOTCH3 gene, 
located on chromosome 19q13.2-p13.1 encoding a cell surface receptor protein that, in human 
adult tissue, is solely expressed in vascular smooth muscle cells.115,116 The pathophysiological 
mechanism that leads to increased aura prevalence in CADASIL is unknown, however 
increased CSD susceptibility, involvement of the migraine brainstem area or a direct shared 
genetic susceptibility have been suggested.117 
Hereditary Vascular Retinopathy (later renamed RVCL and CHARIOT)
A second monogenic cerebrovascular syndrome where migraine is part of the clinical spectrum 
is hereditary vascular retinopathy (HVR).118,119 HVR was reported in a large Dutch family 
and is primary characterized by a vascular retinopathy. Besides, migraine and Raynaud’s 
phenomenon segregates in this family. HVR was mapped to chromosome 3p21.1-p21.3.120 
Genetic testing revealed that two additional families with overlapping clinical features were 
also linked to this locus: cerebroretinal vasculopathy (CRV)121 and hereditary endotheliopathy 
with retinopathy, nephropathy and stroke (HERNS).122 Although many genes in the linked 
region were sequenced, the causal gene had not been identified at the start of this thesis. 
Despite being linked to the same locus, there seemed a considerable variation in clinical 
symptoms between families. For example, nephropathy appeared specific for HERNS. The 
occurrence of cerebral mass lesions was reported in both the HERNS and CRV family, but not 
in the HVR family, where only a minor degree of cerebral white matter change was observed 
in some patients. Migraine was most prominent in the HVR family. The presence of different 
3p21 haplotypes suggested that the clinical variation might be caused by different mutations 
in the same gene, although the presence of different retinopathy genes in the same region 
could not be excluded.120 Two other families with a similar phenotype were also reported in 
the literature.123,124 In a German case report in addition to retinopathy and an intracerebral 
mass lesion, the elevation of liver enzymes and colonic teleangiectasias was striking.123 An 
Australian family presented with a clinical picture that resembled that of HERNS.124 As 
migraine and Raynaud’s phenomenon were also present in branches of the Dutch HVR family 
without retinopathy, one can speculate whether the genetic defect underlying the retinopathy 
may also (at least in part) be responsible for the increased prevalence of migraine and Raynaud’s 
phenomenon. A genetic, family-based, association study demonstrated that the chromosome 
3 locus indeed seem to enhance the susceptibility for Raynaud’s phenomenon and migraine in 
the HVR family.125 
1.7 COMpLEx MIGRAINE AND uSE OF COMORbID 
DISEASES TO IDENTIFY GENETIC FACTORS
Research into comorbidity of the common forms of migraine may provide insight in shared 
epidemiological risk factors or pathophysiological mechanisms involved in both diseases. The 
term comorbidity refers to the greater than coincidental association of two conditions in the 
same individual.126 Comorbidity itself is no evidence for a shared etiological background between 
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two diseases.127 First of all, the association may be spurious, for example as a consequence 
of biased ascertainment or diagnostic uncertainty. Second, a simple unidirectional causal 
relationship may underlie the association. Third, shared environmental risk factors may play a 
major role. It can also be that comorbidity may be caused by a common genetic predisposition. 
Identification of such shared genetic risk factors may define previously unexpected biological 
pathways that link diseases together.128 The study of comorbidity of migraine with and without 
aura may provide useful endophenotypes for genetic studies. Endophenotypes may assure more 
robust and consistent phenotyping of patients, decreasing clinical heterogeneity. Furthermore, 
endophenotypes may be helpful in the identification of genetic risk factors by reducing genetic 
heterogeneity. Migraine has been associated with a wide range of neurological, psychiatric and 
cardiovascular conditions.126 A clear example is epilepsy, which is found to be comorbid with 
common migraine in population based studies,129,130 and often co-occurs with FHM. A possible 
shared genetically determined pathophysiological pathway is suggested by the finding that many 
epilepsy genes as well as the known FHM genes encode ion transporters.76,131 Besides epilepsy, in 
this thesis, depression and the association with cardiovascular diseases are under discussion. 
Depression 
Depression, like migraine, is a chronic episodic disorder. A depressive episode according to the 
DMS-IV criteria is characterized by a period of at least 14 days with depressed mood or loss of 
interest or pleasure combined with cognitive and vegetative symptoms leading to impairment in 
social, occupational or other important areas of functioning.132 For clinical practice, various well 
validated screening instruments for depression have been developed that measure depressive 
symptoms, such as the Hospital Anxiety and Depression Scale (HADS) and the Centre for 
Epidemiological Studies Depression scale (CES-D).133,134 These scales can be used for scientific 
purposes as well because they enable efficient assessment of depression in large populations.
Migraine and depression co-occur more frequently within subjects than to be expected 
by chance. Population-based studies range considerably with respect to the increased risk of 
depression in migraineurs, but in most studies odds ratios are at least doubled and consistently 
higher for patient with MA than for MO. 
In migraineurs comorbid depression is often associated with chronification of migraine,135,136 
decreased quality of life137 and the development of medication overuse headache.135-137 
The pathogenesis of both conditions, especially how episodes are being triggered and how 
symptoms may become chronified, is poorly understood. Interestingly, the comorbidity is 
bidirectional. Not only migraine patients have an increased risk to develop depression, but 
depressive patients also have an increased risk to develop migraine.138 This bidirectional 
relationship suggests that migraine and depression share common etiological factors. This 
might be due to shared genetic factors, however this has never been investigated.
Cardiovascular disease
Several observational studies have shown that migraine, specifically MA, is a risk factor for 
ischemic stroke. A meta-analysis from 2005 of eleven retrospective case-control and three 
prospective cohort studies showed pooled increased relative risks of 1.83 (95% Confidence 
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Interval (CI) 1.06-3.15) for MO, and 2.27 (95% CI 1.61-3.19) for MA.139 This risk was higher 
in young female migraineurs below 45 years old and highest when using oral contraceptives. 
Additional support for an association between migraine and ischemic stroke comes from 
imaging studies. In the population-based CAMERA study evidence was presented that MA 
patients have a fourteen-fold increased risk of silent infarct-like lesions in the posterior 
circulation territory of the brain (i.e., the cerebellar region), a risk which increases with 
increasing attack frequency.140 The specific MRI characteristics of these lesions suggest an infarct 
origin.141 Also, from the CAMERA study it became clear that in women with migraine the risk 
for deep white matter lesions is increased compared to controls, with no difference between 
MO and MA patients. This risk also increases with higher attack frequency. Whether vascular 
changes in migraine are restricted to the cerebral vasculature or also systemically present is 
not yet clear. Systemic vascular dysfunction is suggested by the association of migraine with 
an unfavorable cardiovascular risk factor profile,142 prothrombotic and vasoactive factors,143,144 
and the relation with systemic endothelial dysfunction.145 The reported association of migraine 
with ischemic heart disease points to systemic vascular dysfunction, although at the start of 
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SCOpE OF ThE ThESIS
In this thesis clinical and genetic aspects of migraine and related syndromes are investigated. 
The studies described can be divided in three main parts. 
The first part focuses on syndromes associated with FHM gene mutations. FHM may 
manifest in a ‘pure’ form or present as a more extensive syndrome with additional clinical 
features (chapter 2). The clinical spectrum of FHM1-3 and the relation with closely related 
migraine relevant diseases such as Alternating hemiplegia of Chilhood (AHC) (chapter 3), 
Early Seizures and Cerebral Edema after Trivial Head Trauma (ESCEATHT) (chapter 4), 
epilepsy (chapter 5 and 6) and episodic ataxia (chapter 7) is studied. The description of this 
clinical spectrum is important to learn more about the genotype-phenotype correlation and 
because of the implications for genetic testing. In addition, these studies may finally lead to 
more insight in the common forms of migraine, by providing pathofysiological clues.
In the second part a monogenic syndrome is studied where migraine is part of the clinical 
spectrum. Chapter 8 describes the identification of TREX1 as the causal gene for Retinal 
Vasculopathy with Cerebral Leukodystrophy (RVCL), formerly known as HVR, HERNS, CRV, 
and later (chapter 9) renamed CHARIOT. Next, in chapter 9, the clinical spectrum and the 
genotype-phenotype correlation is evaluated in eleven CHARIOT families with five different 
TREX1 mutations. How the mutated TREX1 gene causes disease is unknown. Therefore, in 
Chapter 10 we explore the hypothesis whether endothelial dysfunction plays a role by using 
clinical tests assessing hemodynamic changes in TREX1 mutation carriers compared to 
a control group and patients with CADASIL. The identification of the underlying gene and 
the study of the functional consequences and the clinical spectrum of CHARIOT may also 
improve our insight in (novel) pathways involved in migraine. 
For the last part of this thesis migraine patients were identified in the Erasmus Rucphen 
Family (ERF) study, a genetically isolated population in the South-West of the Netherlands. 
The study of migraine and comorbid disorders can be used to define endophenotypes that are 
more robust and thought to have reduced genetic and clinical heterogeneity. Consequently, 
identification of genetic risk factors may be more successful. Comorbidity of migraine with 
depression (chapter 11) and atherosclerosis (chapter 12) was investigated. For depression it 
was also studied whether shared genetic factors underlie the comorbid relation with migraine.
A general discussion of the findings presented in this thesis and suggestions for future 
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Of the 18 missense mutations in the CACNA1A gene which are associated with familial 
hemiplegic migraine type 1 (FHM1), only mutations S218L, R583Q and T666M were identified 
in more than two independent families. Including the four novel families presented here, 
of which two represent de novo cases, the R1347Q mutation has now been identified in six 
families. A genotype-phenotype comparison of R1347Q mutation carriers revealed a wide 
clinical spectrum ranging from (trauma-triggered) hemiplegic migraine with and without 
ataxia, loss of consciousness and epilepsy. R1347Q is the third most frequent mutation in 
hemiplegic migraine patients and should therefore be screened with priority for confirmation 
of clinical diagnosis. This study clearly demonstrates that the availability of multiple families 
better reflects the full clinical spectrum associated with FHM1 mutations.
34
2
clInIcal Spectrum of CACNA1A mutatIon r1347Q 
INTRODuCTION
Familial hemiplegic migraine (FHM) is a rare autosomal dominant inherited subtype of 
migraine with aura, mainly characterized by transient hemiparesis during the attacks.1 The 
disease is genetically heterogeneous as mutations in three genes, CACNA1A (FHM1), ATP1A2 
(FHM2) and SCN1A (FHM3) are involved,2-5 and FHM families exist who are not linked to 
these genes. Mutations in all three genes cause a broad spectrum of clinical symptoms (for 
review see Kors et al., 20046). FHM1 mutations are associated with clinical symptoms of 
hemiplegic migraine, ataxia, attacks of confusion, alterations of consciousness, epilepsy, fever 
and even fatal brain edema.7-11 
To date 18 FHM1 mutations in the CACNA1A gene have been reported, of which six are 
recurrent. The T666M mutation has been found in 21 unrelated families, R583Q was identified 
in seven families and S218L in three; mutations R1347Q, R1668W, I1710T and I1811L were 
reported twice. 
The identification of recurrent mutations and comparison of detailed clinical information 
of mutation carriers make genotype-phenotype correlations feasible. Moreover, the detection 
of mutation-specific clinical symptoms could benefit diagnostic testing. Here, we present four 
unrelated families carrying the R1347Q CACNA1A mutation, establish R1347Q as the third 
most frequent recurring CACNA1A mutation and describe an expansion of the clinical spectrum 
associated with this mutation. 
MATERIALS AND METhODS
Clinical diagnosis
Diagnoses were made by neurologists according to the International Classification of Headache 
Disorders-second edition (ICHD-II) criteria.1 All subjects gave informed consent. 
Mutation analysis
Genomic DNA was isolated from peripheral blood cells according to standard methods.12 All 
47 exons of the CACNA1A gene were analysed using direct sequencing analysis. Exons were 
amplified by PCR using exon-specific primer sets and genomic DNA of each proband. Details 
of intron-exon structure, primer sequences and conditions are available from the authors upon 
request. Double-strand sequencing was done by Cycle sequencing (Prism Big Dye Terminators 
Cycle Sequencing kit, Applied Biosystems, Foster City, CA) using the dideoxy termination 
method and an ABI3700 sequencer (Applied Biosystems, Foster City, CA). 
Carrier detection
For detection of the R1347Q mutation (nt 4040 G>A, CACNA1A reference sequence: X99897), 
exon 25 was amplified by PCR using primers that were extended with an M13-tail (underlined): 
“exon25F” (5’ TGTAAAACGACGGCCAGTCTACCCAACCTGACCTCTGC-3’) and “exon25R”
 (5’-CAGGAAACAGCTATGACCCCATACACGATGGCTAGGATG-3’), resulting in a 329-bp 
product. Subsequently, PCR products were digested with restriction enzyme Hinf I using 
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standard protocols, and electrophoresed on a 3% agarose gel. The R1347Q mutation causes a 
loss of a Hinf I site, which results in an undigested product of 329 bps for the mutant allele and 
wild-type products of 124 and 205 bps.
Haplotype analysis
For haplotyping, genetic markers D19S221, D19S1150 and D19S226 were tested. For primer 
sequences and PCR conditions, see http://gdbwww.gdb.org/. After PCR, amplified products 
were separated using an ABI 3700 DNA sequencer. All genotypes were analyzed and 
independently double scored using Genescan and Genotyper 2.1 software (Applied Biosystems, 
Foster City, CA).
RESuLTS
Pedigrees of the four hemiplegic migraine families are shown in Figure 1. We identified a 
heterozygous nt 4040 G>A substitution in exon 25 (CACNA1A reference sequence: X99897), 
in the probands of all four families. The mutation causes an Arginine to a Glutamine 
substitution at codon 1347 that is located in the S4 segment of the protein domain III (see 
Figure 2). The R1347Q mutation co-segregated in all eight family members with hemiplegic 
migraine from whom DNA was available. In addition, the mutation was found in one person 







































Figure 1. The pedigrees of the four R1347Q families.The arrow indicates the proband. Circles indicate females, 
squares indicate males. The following symbols indicate the clinical diagnosis: black lower half: hemiplegic migraine; 
black upper right quadrant: migraine with aura; black upper left quadrant: migraine without aura. The presence or 
absence of the R1347Q mutation is indicated by “R1347Q” and “WT” (wild-type), respectively.
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Figure 2. Schematic representation of the Cav2.1α1 calcium channel subunit protein encoded by the CACNA1A 
gene. Each of the four protein domains (I to IV) has six transmembrane segments (S1-S6). The location of the three 
most frequent recurrent mutations is indicated.
relation between the families, indicating that all mutations occurred independently (data 
not shown). The mutation was not found in 200 control chromosomes by restriction enzyme 
analysis with Hinf I.
Family 1
The proband (II-1) was a 54-year-old male who since the age of three had hemiplegic migraine 
attacks, with a frequency of one every four to six weeks. Severe hemiplegic migraine attacks 
could last up to a week. During these attacks he could only be aroused briefly by vigorous 
stimulation and had an elevated temperature. From the age of three he gradually developed 
gait ataxia and dysarthria over the years. After the FHM attacks his gait ataxia and dysarthria 
worsened for days to weeks, but subsequently returned to the pre-ictal level. Interictal 
examination at the age of 51 showed saccadic pursuit eye movements, mild dysarthria, 
abnormal tandem gait, dysdiadochokinesis, intention tremor on finger-to-nose testing and 
overshoot on finger chase testing. Cerebral MRI showed evidence of cerebellar atrophy. The 
patient died at age 54 of a colon carcinoma. No autopsy was performed. His mother, now 
aged 82, has suffered from migraine without aura since puberty and recently started to have 
attacks of visual aura always followed by a non-migrainous headache (ICHD-II 1.2.2). The 
sister of the proband has migraine with visual aura since the age of 34. Mother and sister never 
experienced migraine attacks associated with hemiplegia.
Family 2 
The proband (II-2) is a now 54-year-old male who has suffered from attacks of hemiplegic 
migraine since the age of three. Some attacks were associated with drowsiness and fever. 
Cerebral MRI scans were unremarkable. Interictal neurological examination at age 47 
showed mild cognitive deterioration, saccadic ocular pursuit, gaze-evoked nystagmus, 
mild limb ataxia and more marked gait ataxia. Since the age of 47 he has been treated with 
acetazolamide which has dramatically reduced the number of attacks. His mother (I-2) 
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suffers from hemiplegic migraine and has a marked interictal gait ataxia. His eldest sister 
(II-1), who suffered from schizophrenia, died at the age of 19 in her sleep after a presumed 
epileptic attack. His youngest sister (II-4) suffers from typical attacks of hemiplegic migraine 
associated with mild confusion and disorientation, somnolence, general malaise and deafness. 
Interictal neurological examination at age 38 showed saccadic ocular pursuit, mild dysarthria, 
mild symmetrical limb ataxia and marked gait ataxia. Her son (III-1) now aged 18 has had a 
total of about 10 attacks of migraine with hemisensory symptoms since the age of five, but no 
weakness was reported. Some episodes were provoked by head trauma. Between episodes he 
has a gaze-evoked nystagmus to the left, mild dysarthria and mild gait ataxia. Her daughter 
(III-2), now aged 17 had episodes of blurred vision and paraesthesia in both upper and lower 
limbs, followed by weakness, and accompanied by headache, nausea and vomiting. Attacks 
are often brought on by flickering light. She had episodes of loss of consciousness, which were 
considered to be of epileptic origin and were successfully treated with valproate.
Family 3 
Family 3 is a Jewish family that was originally reported in 1997.13 The proband (I-1) is a 
70-year-old male who has had attacks of hemiplegic migraine since the age of 26. He currently 
has an attack once every three to four months. None of the attacks has ever been accompanied 
by seizures. Interictal neurological examination reveals dysmetria on finger-to-nose testing, 
dysdiadochokinesis and an abnormal tandem gait. One of his children, II-6, now aged 29, 
has had three attacks of hemiplegia with dysarthria lasting between five and fifteen minutes 
not accompanied by headache. His interictal neurological examination is normal. Individual 
II-7 is a now 27-year-old woman who has suffered from attacks of hemiplegic migraine once 
every three months since the age of six. Attacks are sometimes associated with focal seizures 
always on the same side as the hemiplegia. She never experiences seizures independently from 
hemiplegic attacks. She has progressive ataxia. Individual II-1, aged 36 years, has had two 
events of acute hemiplegia at the ages of five and six years. She has a normal neurological 
examination. Her 17-year-old son (III-1) has had attacks of hemiplegic migraine since the age 
of three years now occurring once every three to six months. In addition, he has progressive 
ataxia. He also suffers from focal (tonic or clonic) seizures, independent of the hemiplegic 
migraine attacks, which can be secondary generalized. Three other daughters of I-1 do not 
suffer from any type of migraine. 
Family 4 
The proband (II-1) of this family is a 13-year-old girl. Her first attack of hemiplegic migraine 
occurred when she was nineteen months old. Later she had on average one to two attacks 
a year; the last one occurring two years ago. The attacks are always precipitated by trivial 
head trauma and include severe headache accompanied by nausea and vomiting, hemiplegia, 
hemianesthesia, psychotic alterations and stupor. Attacks always completely resolved within 
three days. She has a normal psychomotor and mental development. An MRI made 6 years 
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DISCuSSION
We identified the CACNA1A R1347Q mutation in four unrelated hemiplegic migraine families. 
This makes R1347Q the third frequently occurring FHM1 mutation. The mutation changes a 
positively charged Arginine to a neutral Glutamine and is located in the S4 segment of the 
third protein domain. The positively charged amino acids of the S4 segment act as the ‘voltage 
sensor’, which detect changes in the membrane electrical field. Mutations that neutralize 
highly conserved Arginine residues (i.e., R192Q, R195K, R583Q R1347Q, and R1677W) affect 
channel functioning by altering the voltage dependence14 and are associated with disease. 
The R1347Q mutation was previously identified in four hemiplegic migraine patients: two in a 
Portuguese family15 and two in a German family.16 All patients also had progressive cerebellar ataxia. 
With the present study, the total number of families with the R1347Q mutation has increased to six 
and the total number of mutation carriers to 13. Three additional hemiplegic migraine patients - 
two with ataxia - likely have the mutation, but genetic confirmation was not possible. 
The newly identified R1347Q families reveal a broader clinical spectrum than previously 
reported. Attacks start at a young age in the majority of patients (range 19 months- 26 years; 
median four years) and the frequency of attacks is highly variable, from two attacks in a lifetime 
to one attack per month. Most mutation carriers had attacks of hemiplegic migraine: six with 
and three without interictal cerebellar signs. Patient III-1 in family 2 had no weakness during 
attacks, but hemisensory symptoms. In two patients attacks were triggered by head trauma and 
in two other patients attacks were associated with altered consciousness and fever. The young 
proband from family 4 had psychotic alterations and stupor. The proband of family 1 suffered 
from remarkably long hemiplegic attacks, which could last up to a week. After the attacks, 
there was often a temporary worsening of gait ataxia and dysarthria. The hemiplegic attacks of 
the proband of family 2 responded to acetazolamide, which has been reported before.17
Epilepsy now also appears to be part of the phenotypic spectrum of R1347Q, being present 
in two hemiplegic migraine patients of family 3. Patient II-7 had focal seizures ipsilateral to the 
hemiplegia during hemiplegic migraine attacks. Patient III-1 suffered from focal seizures that 
occurred independently from hemiplegic migraine attacks. CACNA1A mutations have been 
associated with epilepsy; in most cases occurring during hemiplegic attacks.7-11;18,19 In only one 
FHM1 family did epileptic seizures occur independently from hemiplegic migraine attacks.10 
In conclusion, although hemiplegic migraine and progressive ataxia are the predominant 
clinical features in these families, the R1347Q mutation, like other FHM1 CACNA1A 
mutations, shows considerable phenotypic variation. Identification of recurrent mutations 
has implications for genetic screening, as they should be screened with priority, that is before 
screening the entire CACNA1A gene.
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Familial hemiplegic migraine (FHM) and alternating hemiplegia of childhood (AHC) are 
severe neurological disorders that share clinical features. Therefore, FHM genes are candidates 
for AHC. We performed mutation analysis in the CACNA1A gene in a monozygotic twin pair 
with clinical features overlapping with both AHC and FHM and identified a novel de novo 
CACNA1A mutation. We provide the first evidence that a CACNA1A mutation can cause 
atypical AHC, indicating an overlap of molecular mechanisms causing AHC and FHM. These 
results also suggest that CACNA1A mutation scanning is indicated in patients with a severe 
neurological phenotype that includes paroxysmal (alternating) hemiplegia.
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INTRODuCTION
Alternating hemiplegia of childhood (AHC) and familial hemiplegic migraine (FHM) are 
clinically very similar disorders.1,2 AHC is typically characterized by episodes of alternating 
hemiplegia or quadriplegia and progressive neurological features beginning before the age 
of 18 months.1 FHM is a rare subtype of migraine with aura associated with hemiparesis 
and in some cases ataxia, mental retardation, movement disorders or other neurological 
abnormalities.3 For FHM, three genes have been identified: CACNA1A, ATP1A2 and SCN1A, 
which all play a role in ion transport.4-6
Except for one Greek family with atypical AHC and an ATP1A2 mutation, no genes have 
been identified for AHC.7,8 Here we describe a monozygotic twin pair suffering from a complex 
phenotype of early-onset ataxia, alternating hemiplegia, epilepsy, migraine-like attacks and 
mental retardation, which clinically overlaps with both AHC and FHM. We identified a novel 




Standardized criteria were used for the diagnosis of FHM3 and AHC.1 All subjects gave 
informed consent. This study was approved by the local ethics committee of the University of 
Greifswald.
Genetic analysis
Genomic DNA was isolated from peripheral leucocytes using a standard salting out extraction 
method.9 The 47 coding exons and adjacent sequences of the CACNA1A gene were scanned for 
mutations by direct sequencing. In brief, all exons were amplified by polymerase chain reaction, 
using genomic DNA as a template. Direct sequencing was done by Cycle Sequencing (Prism 
Big Dye Terminators Cycle Sequencing kit; Applied Biosystems, Foster City, CA, USA) using 
the dideoxy termination method and an ABI3700 automated sequencer (Applied Biosystems). 
One hundred healthy controls were screened by direct sequencing. Detailed information is 
available from the authors upon request.
RESuLTS
The monozygotic German twin brothers, now aged 17 years, were spontaneously born at 
term after an uneventful pregnancy. Their complex clinical features are summarized in the 
Table 1. 
One twin brother (patient I in Table 1) was severely affected and had a delayed psychomotor 
development. He is still not able to walk without support and is not able to speak. Between the 
ages of 2 and 7 years he suffered from generalized atonic seizures up to three times daily, 
often followed by unconsciousness lasting from seconds to several hours. Subsequently, he 
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developed mental and psychomotor regression with ataxic and athetotic limb movements. 
At age 11 years, when he was hospitalized because of severe constipation and abdominal 
pain, episodes of abrupt stops in movement, tachycardia and swallowing automatisms were 
observed. Ictal EEG recordings showed mainly occipitotemporal bilateral synchronic sharp–
slow wave activity (not shown). At the age of 12 years he experienced a period of alternating 
hemiplegia, starting on the left side and accompanied by fever. Cerebral magnetic resonance 
imaging (MRI) showed ictal right cortical swelling (Fig.  1). After 12 days the left-sided 
symptoms resolved, but there after right-sided weakness occurred, which lasted for days. EEG 
revealed slow wave activity over the left hemisphere (data not shown). As he is still not able 
to express himself, the presence and severity of migraine symptoms (headache, phonophobia, 
photophobia, nausea) are difficult to assess. At present, he is tetraspastic with athetotic and 
ataxic movements, and has intermittent convergent strabismus. 
The other twin brother (patient II in Table 1) was delivered shortly after his twin brother. 
Early infant psychomotor development was delayed. At the age of 1.5 years he was able to 
speak single words. Between the ages of 3 and 8 years he suffered twice a year from atonic 
episodes accompanied by loss of consciousness for 1 h, followed by ataxia. Ictal EEGs showed 
no signs of epilepsy (data not shown). Since the age of 10 years he has experienced several 
episodes of right- or left-sided hemiplegia, and one episode with alternating hemiplegia for 
several days. One of the hemiplegic episodes was accompanied by reduced consciousness 
and fever and lasted several weeks. Cerebral single photon emission computed tomography 
showed ictal left-sided hypoperfusion in the parieto-frontotemporal cortex (Fig. 2). At the age 
of 12 years, treatment with flunarizine was started, with doubtful effect. During hemiplegic 
Table 1. Clinical features in monozygotic twins compared with AHC and FHM
AHC FHM1 Patient I Patient II
Onset of (alternating) hemiplegic attacks 0-18 months* >2 yr to adolescence** 10 yr 12 yr
Hemidystonic spells + − − −
Quadriplegia + − + −
Choreoathetosis + − + −
Ataxia + + + +
Nystagmus + + − −
Strabismus + − + +
Mental retardation + − + +
Autonomic symptoms + + + +
Positive effect of Sleep + − − −
Epilepsy + + + +
Aura symptoms − + NA +
Migrainous headache − + NA +
(+) or (−) indicates presence or absence of a symptom, respectively. NA indicates not applicable due to inability of 
verbal expression of the patient. * Typically alternating hemiplegia. ** Typically non-alternating hemiplegia.
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attacks he complained of frontal throbbing headache with nausea, sometimes accompanied 
by phonophobia. Ophthalmic examination shows a strabismus. Except for the twin pair, no 
other family members suffer from attacks of hemiplegia, epilepsy or migraine. 
Monozygosity of the twins was confirmed and false paternity was excluded by genetic, 
multimarker analysis (data not shown). Extensive metabolic screening in both twins revealed 
no abnormalities. Cerebral MRI, showing diffuse ictal swelling in patient I (see above), was 
without severe abnormalities in either of the twins, and did not reveal cerebellar atrophy. 
Direct sequencing of all 47 exons of the CACNA1A gene revealed a heterozygous 5361 G>T 
substitution (Genbank Ac. no. X99897) in exon 33 in both twins. This point mutation resulted 
in an amino acid change from a valine to a phenylalanine at position 1696. The mutation is 
located within the transmembrane segment S5 of the fourth domain, which together with 
segment S6 forms the inner part of the pore of the Cav2.1α1 subunit. The parents did not carry 
the mutation, indicating that V1696F is a de novo mutation. Screening of 100 subjects from the 
general Dutch population with no history of migraine or epilepsy was performed by sequence 
analysis of exon 33 and was negative.
Figure 1. Fluid-attenuated inversion recovery (FLAIR) image shows ictal diffuse cortical swelling of the right hemi-




We have identified a novel de novo CACNA1A V1696F mutation in two monozygotic twin 
brothers with complex clinical features in part fulfilling the criteria of both AHC1 and 
FHM3 (Table 1). The presence of hemiplegia and other aura symptoms as well as migrainous 
headache are in favour of FHM. Episodes of alternating hemiplegia, developmental delay, 
mental retardation, choreoathetotic movements, strabismus and chronic ataxia are supportive 
of AHC. The severity of the phenotype, interictal symptoms and the relatively young age at 
onset of these patients are, in particular, very rare for FHM1 and more common in AHC. As 
no positive effect of sleep was observed and the age at onset was after 18 months, we name this 
overlap syndrome ‘atypical AHC’. Although both monozygotic twin brothers are genetically 
Figure 2. Single photon emission computed tomography (SPECT) scan shows ictal left- shows ictal left-sided hy-
poperfusion contralateral to the hemiparesis in the parietofrontal (severe) and temporal (mild) cortex of Patient II.
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identical, their clinical symptoms and attack frequency vary in severity, with patient I being 
more severely affected. 
Several lines of evidence indicate that V1696F is the disease-causing mutation in this 
family. Val1696 is highly conserved across multiple calcium channel homologues and across 
species (data not shown). The mutation was not identified in a large number of control 
chromosomes. The mutation occurred de novo, thus strengthening the evidence that it is the 
V1696F mutation that caused the disease. In a French FHM family another mutation affecting 
the same residue Val1696 (V1696I) caused hemiplegic migraine without cerebellar signs.10 
Finally, electrophysiological analysis of mutant Cav2.1α1 containing Iso1696 has revealed 
that loss of the valine residue is associated with altered channel kinetics compatible with a 
phenotype of an increased Ca2+ influx.11 
Notably, change of Val1696 to a phenylalanine (V1696F) or an isoleucine (V1696I) causes 
phenotypes of different severity. Two out of three V1696I mutation carriers had hemiplegic 
migraine without cerebellar signs or other severe neurological features.10 Both V1696F 
mutation carriers, however, had a very severe phenotype of atypical AHC. Apparently, 
substitution of the valine residue for a bulky phenylalanine in the transmembrane domain has 
a more dramatic effect on channel functioning.
Previously, sporadic patients with typical AHC have been scanned for mutations in the 
CACNA1A (FHM1), ATP1A2 (FHM2) and SLC1A3 genes, but no mutations were found.12-14 
Now, we present the first CACNA1A mutation in patients with atypical AHC. 
Previously an ATP1A2 mutation was identified in a Greek family with atypical AHC, with 
a similar overlapping FHM/AHC phenotype.7,8 Of note, both CACNA1A and ATP1A2 are 
involved in ion transport, and mutations in these genes are predicted to increase concentrations 
of K+ and glutamate in the synaptic cleft as a result of either increased neurotransmitter 
release (CACNA1A mutations) or impaired removal of K+ and neurotransmitter (ATP1A2 
mutations).15,16 Elucidating the molecular basis in this German family with complex clinical 
features strengthens the evidence for a common pathogenesis of FHM and AHC. 
Our results suggest that in severely affected paroxysmal (alternating) hemiplegic patients 
with mental retardation and an age at onset of alternating episodes beyond 18 months, 
CACNA1A mutation scanning is indicated.
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AbSTRACT
Objective: To study the clinical spectrum of CACNA1A S218L mutation carriers with special 
attention for “early seizures and cerebral edema after trivial head trauma” (ESCEATHT), a 
combination of symptoms which resembles the “juvenile head trauma syndrome”.
Patients and Methods: We sequenced all exons of CACNA1A in two patients with ESCEATHT. 
Both patients also had hemiplegic migraine and ataxia. Subsequently, we screened the literature 
for S218L mutation carriers.
Results: In both patients we found a de novo S218L mutation in the CACNA1A gene. In 
addition, we identified 11 CACNA1A S218L carriers from literature. From these 13 S218L 
mutation carriers, twelve (92%) patients had ataxia or cerebellar symptoms. Nine (69%) had 
hemiplegic migraine that could be triggered by trivial head trauma. Three mutation carriers 
had the complete ESCEATHT phenotype. Seven (54%) had seizures (four had early post 
traumatic seizures) and five (38%) had edema as detected by MRI/CT. 
Conclusions: The CACNA1A S218L mutation is associated with FHM, ataxia and/or 
ESCEATHT. A minority of S218L mutation carriers have the complete ESCEATHT phenotype, 
but a high percentage of patients had one or more ESCEATHT symptoms. As the S218L 
mutation enhances the propensity for cortical spreading depression (CSD), we postulate a role 
for CSD not only in hemiplegic migraine, but also in early seizures and cerebral edema after 
trivial head trauma. As this combination of symptoms is part of the unexplained “juvenile 
head trauma syndrome”, a similar molecular mechanism may underlie this disorder. 
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INTRODuCTION
Post-traumatic seizures are classified as early, when they occur within a week after head injury.1 
Early seizures may increase the probability of epilepsy later in life.2,3 The risk of early post-
traumatic seizures increases with greater severity of the injury, the presence of intracranial 
haemorrhage, and a younger age.1,4,5 Early seizures may occur, although rarely, after trivial 
head trauma, then usually in combination with sometimes very severe cerebral edema.4,6-8 In 
children, this is often called “juvenile head trauma syndrome”.6-8 Apart from a young age, the 
risk factors and the pathogenetic mechanisms for “early seizures and cerebral edema after 
trivial head trauma” (ESCEATHT) are unknown.3
Epilepsy is a common comorbid disorder in patients with migraine with aura.9,10 The 
increased risk is bidirectional and there are several clinical, therapeutical, genetic and 
electrophysiological similarities between both episodic brain disorders, suggesting common 
pathogenetic pathways.9,10 Indeed, genes for Familial Hemiplegic Migraine (FHM) - 
a hereditary subtype of migraine with aura in which attacks are associated with hemiparesis 
- have also been implicated in epilepsy.10 Seizures are not uncommon in patients with 
FHM1,- 2 and -3.10,11 Notably, trivial head trauma is a known trigger for attacks of both FHM12 
and migraine with aura (MA).13,14 Three genes have been identified for FHM, all encoding 
proteins involved in ion transportation: CACNA1A (FHM1),15 ATP1A2 (FHM2),16 and SCN1A 
(FHM3).17 The CACNA1A gene encodes the α1-subunit of Cav2.1 (P/Q-type) Ca
2+ channels 
that modulate neurotransmitter release.18 CACNA1A is expressed at the neuromuscular 
junction and throughout the central nervous system, in particular in cerebellar Purkinje 
cells. Functional studies of FHM1 mutations predict enhanced neuronal excitability and 
have shown increases of neuronal Ca2+ influx, neurotransmitter release, and propensity to 
cortical spreading depression (CSD).19,20 CSD is a brief (seconds) wave of intense neuronal 
and glial depolarization that is slowly (2-5 mm/min) propagating over the cerebral cortex. 
A wave is associated by transient loss of membrane ionic gradients and by massive surges 
of extracellular potassium, neurotransmitters, and intracellular calcium. The depolarization 
wave is followed by a potent, relatively long-lasting (> 20 min) neuronal suppression.21 
These electrophysiological and secondary molecular events are accompanied by transient 
neuronal swelling and loss of dendritic spines due to temporary tissue hypoxia,22 and cerebral 
edema as a result of increased permeability of blood vessels through upregulation of matrix 
metalloproteinases.23 In humans, CSD is the likely underlying electrophysiological substrate 
of the migraine aura.24
One particular type of CACNA1A mutation, the S218L mutation, was found in patients 
who suffered from particularly severe attacks of FHM which were triggered by trivial head 
trauma and were associated with often fatal excessive cerebral edema.12,25,26 In a transgenic 
animal model, the S218L mutation greatly enhances the propensity for CSD.19
Based on the above clinical observations and experimental findings, we hypothesized that 
FHM1 gene mutations (e.g., the S218L mutation) may confer an increased risk of (symptoms 
of) ESCEATHT, probably through increased susceptibility for CSD. We investigated this in 





Subjects were interviewed and clinical headache diagnoses were established according to 
International Headache Society criteria (ICHD-2 criteria).27 Seizures were classified according 
to the criteria of the International League Against Epilepsy (ILAE).28 ESCEATHT in this study 
was defined as an episode with Early Seizures (within 7 days after head trauma) and associated 
Cerebral Edema (on MRI or CT-scan) After a Trivial Head Trauma. This study was approved by 
the ethical committee of the Leiden University Medical Centre. All individuals gave informed 
consent. Clinical details of affected family members are shown in the results section. 
Search for other S218L mutation carriers
We screened the literature for publications describing patients with the S218L mutation and 
reviewed the clinical descriptions.12,25,26,29
Mutation analysis
Genomic DNA was isolated using a standard salting out extraction method.30 Direct sequencing 
of all exons of the CACNA1A gene was performed with genomic DNA of both patients, using 
the dideoxy termination method and an ABI3700 sequencer (Prism Big Dye Terminators Cycle 
Sequencing kit; Applied Biosystems, Foster City, USA). Detection of the CACNA1A S218L 
mutation was performed as described previously.12
RESuLTS
In Table 1 we present the clinical data of thirteen patients with the CACNA1A S218L mutation: 
two are new cases (patients 1 and 2) and the remaining patients were from the literature of 
which seven were published by us. 
Genetic testing of new cases
The CACNA1A S218L mutation located in exon 5 was identified in both patients (1 and 2). 
Mutation screening was negative in their parents, indicating that the mutation had occurred de 
novo. For both patients, false paternity was excluded by haplotype analysis of genetic markers 
of the chromosome 19p13 CACNA1A locus (data not shown).
Clinical description Patient 1
This now 11 year-old girl of Dutch origin was born after 36 weeks of pregnancy. Shortly after birth 
spontaneous apneas were observed but after resuscitation and artificial ventilation for 24 hours 
she breathed spontaneously. When she grew up, psychomotor and mental development appeared 
to be delayed and she developed severe ataxia. At age three, she suffered a fall on the back of her 
head, without initial loss of consciousness. After 30 minutes she became comatose and developed 
left-sided hemi-convulsions for approximately 2 hours. Subsequently, a left-sided paresis with 
hemispatial neglect was present for one week. She recovered completely. A cerebral Magnetic 
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Resonance Imaging (MRI) performed two days after hospital admission showed edema in the right 
parieto-occipital cortex and to a lesser extent in the right temporal and (posterior) frontal cortex. 
Increased signal on diffusion-weighted images showed that the edema likely is of cytotoxic origin 
(Fig. 1). Also extensive cerebellar atrophy was present (Fig. 2). At the age of four, she developed 
a prolonged period of stupor after a trivial head injury, which was not further documented. 
Figure 1. Coronal Diffusion Weighted Image (b=1,000s/mm2) of patient 1 performed during the first coma episode 
at age three with left-sided hemi-convulsions and subsequent left sided paresis. Increased signal in the right parieto-
occipital cortex indicates cytotoxic oedema. A: anterior; R: right; L: left; P: posterior.
Figure 2. T2 sagittal brain MRI of patient 1 at age three showing marked cerebellar atrophy. 
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1 Sporadic Female HM* Yes No Yes Two complex partial 
seizures 
Yes (3) Yes/Yes Mild mental 
retardation
This article
2 Sporadic Male HM* Yes No Yes Single generalized 
seizure 
Yes (15) Yes /No - This article
3 Family I
 
Male HM* Yes Yes Yes No No Yes/Yes Hallucinations [12; 29]
4 Family I Male HM* Yes No Unknown No No Yes/Yes Mild mental 
retardation
[12; 29]
5 Family I Male HM* Not reported No Unknown Single generalized 
seizure 
Unknown (59) Yes/Yes Psychotic 
episodes
[12; 29]
6 Family I Female MA Yes No No No No Yes/Yes MA [12; 29]
7 Family II Female No No No Yes Single generalized 
seizure/seizures after 
birth§




8 Family II Female No No No No No No Yes/Unknown Hypotonic after 
birth, squint
[12] 
9 Family II Male HM* No No No No No Yes /Unknown - [12] 
10 Sporadic Female HM* Yes No Yes At least one partial 
seizure 
No (5)# Yes /No Hallucinations [25]
11 Family III Male HM* No No No 5 episodes of GTC 
seizures
Yes (5) Yes/Yes - [26] 
12 Family III Female HM* No No Unknown No No Unknown/Yes - [26] 
13 Family III Male No No No Unknown Simple febrile seizures, 
once secondary GTC 
seizure
No (2, 4) No/Unknown - [26] 
HM: hemiplegic migraine; MA: migraine with aura; AAO: age at onset; GTC: generalized tonic-clonic; §: seizures 
not well documented; #: seizures occurred more than 7 days after head trauma; ¥: trivial head trauma included fall 
on the back of head, heading the ball during soccer, hitting the head.
Patients 1, 2 and 7 suffered from episodes of early seizures and cerebral edema after trivial head trauma (ESCEATHT).
Patient 5 suffered from hemiplegic migraine attacks and in addition had one attack starting with a generalized 
tonic-clonic seizure followed by aphasia and right hemiparesis; it is unknown whether cerebral edema was present 
or whether trivial head trauma preceded this attack.
Patient 10 had at least one partial seizure during a prolonged comatose episode.
Patient 11 had 5 episodes of GTC seizures triggered by mild head trauma at age of 5 years; no MRI/CT scan was 
made; seizures ceased spontaneously. At age 15 and 17 years, patient 11 had an hemiplegic migraine attack, the latter 
associated with coma, no cerebral edema was seen on CT and MRI scan. 
Patient 13 had a few episodes of simple febrile seizures between ages 2 and 4 years old and 1 secondarGTS during 
fever; no trivial head trauma was described.
At the age of 6 years, a third episode occurred. Two minutes after a fall, of which it is unclear 
whether she had hit her head, she lost consciousness and was transported to the hospital. Some 
minutes after admission, and 30 minutes after the trauma, she developed a seizure with right-sided 
rhythmic clonic contractions and gaze deviation to the right. The seizure was successfully treated 
with phenytoin. Remarkably during the recovery phase it was noticed that there was a left-sided 
hemiparesis, which resolved in a few days. Her parents did not have epilepsy, migraine or ataxia. 
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No (5)# Yes /No Hallucinations [25]
11 Family III Male HM* No No No 5 episodes of GTC 
seizures
Yes (5) Yes/Yes - [26] 
12 Family III Female HM* No No Unknown No No Unknown/Yes - [26] 
13 Family III Male No No No Unknown Simple febrile seizures, 
once secondary GTC 
seizure
No (2, 4) No/Unknown - [26] 
HM: hemiplegic migraine; MA: migraine with aura; AAO: age at onset; GTC: generalized tonic-clonic; §: seizures 
not well documented; #: seizures occurred more than 7 days after head trauma; ¥: trivial head trauma included fall 
on the back of head, heading the ball during soccer, hitting the head.
Patients 1, 2 and 7 suffered from episodes of early seizures and cerebral edema after trivial head trauma (ESCEATHT).
Patient 5 suffered from hemiplegic migraine attacks and in addition had one attack starting with a generalized 
tonic-clonic seizure followed by aphasia and right hemiparesis; it is unknown whether cerebral edema was present 
or whether trivial head trauma preceded this attack.
Patient 10 had at least one partial seizure during a prolonged comatose episode.
Patient 11 had 5 episodes of GTC seizures triggered by mild head trauma at age of 5 years; no MRI/CT scan was 
made; seizures ceased spontaneously. At age 15 and 17 years, patient 11 had an hemiplegic migraine attack, the latter 
associated with coma, no cerebral edema was seen on CT and MRI scan. 
Patient 13 had a few episodes of simple febrile seizures between ages 2 and 4 years old and 1 secondarGTS during 
fever; no trivial head trauma was described.
Clinical description Patient 2
Since the age of eight years, this now 19 year-old boy of Dutch origin suffers from attacks of 
hemiplegic migraine 4 to 6 times a year. At the age of 1.5 years he fell off his bike and hit his 
head. He initially was conscious and alert but within three to four hours became somnolent 
and started vomiting. There were no focal neurological signs. He recovered spontaneously from 
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this episode within 24 hours. At the age of 15 he developed a headache while playing soccer and 
heading the ball several times. Shortly thereafter, he became agitated, restless and developed 
aphasic speech. In the hospital his initial Glasgow coma score was 7 with a hemiparesis on the 
right side. A cerebral MRI scan showed a swollen left hemisphere with perfusion defects, but no 
parenchymous abnormalities or cerebellar atrophy (Fig. 3). Diffusion-weighted imaging showed 
increased signal indicating that the edema was of cytotoxic origin. Seven days after admission he 
suffered from a generalized seizure. A post-ictal EEG showed generalized slowing, but no epileptic 
activity. Phenytoin was started. Recovery of clinical symptoms was gradually within several 
weeks. At discharge, he still had cognitive disturbances and dysphasia. Only after several weeks 
he recovered fully. Several years later, he again got kicked against the head while playing soccer 
and became drowsy and confused. This time he developed neither hemiparesis nor seizures. This 
attack spontaneously resolved within five hours. His motor development is slightly delayed and he 
is ataxic. He is currently following secondary school without obvious learning difficulties. 
Clinical spectrum in S218L patients from literature
A review of the literature revealed eleven additional case descriptions of S218L mutation 
carriers (Table 1, patients 3-13). In five out of eleven cases (45%), seizures were reported that 
occur in three patients after trivial head trauma (27%). In two patients (patients 7 and 11), 
post-traumatic seizures were generalized. In patient 10, seizures were of the partial type. 
Patient 7 had a particularly severe phenotype. After a trivial head injury, she developed an 
early post-traumatic generalized seizure that was followed by extensive cerebral edema that 
resulted in a fatal coma.12 Also patient 10 had a severe phenotype after a trivial head injury 
Figure 3. T2 axial brain MRI of patient 2 showing severe left-sided cortical edema. MRI was performed during 
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and did not entirely recover from a period of prolonged coma during which she had a partial 
seizure.25 Finally, patient 11 suffered from five separate episodes of generalized tonic-clonic 
seizures that were all triggered by trivial head injury.26 Edema detected with MRI or CT-scan 
and associated with coma episodes was present in three patients of which two also had post-
traumatic seizures. Ten patients showed cerebellar atrophy (91%) or ataxia and eight had 
migraine with (7) or without (1) hemiplegia. A family history of migraine was reported in 
10 patients (originating from three families). 
DISCuSSION
We screened two patients with ESCEATHT for mutations in the CACNA1A gene. Both proved 
to carry a de novo CACNA1A S218L mutation, which we previously showed to be associated 
with FHM1 and mild head trauma-triggered severe and sometimes fatal cerebral edema.12 In 
the literature we identified eleven additional S218L mutation carriers, of which seven were 
published by us.12 Twelve (92%) of mutation carriers displayed cerebellar symptoms and nine 
(69%) carriers had attacks of hemiplegic migraine. A minority of S218L mutation carriers 
had the full ESCEATHT phenotype (23%), but a high percentage of patients had one or 
more symptoms of ESCEATHT. Seven had seizures (54%), of which at least four (31%) were 
early seizures provoked by mild head trauma and of which three (23%) were associated with 
cytotoxic cerebral edema.12,25,26 One patient had only edema without early seizures and one 
patient had trauma triggered early seizures without cerebral edema. In 6 out of 7 patients, 
seizures occurred in childhood (range 2 to 16 years) except for a patient who had seizures at 
the age of 59 years. Ten (77%) cases were familial and three (23%) sporadic. The three sporadic 
cases occurred de novo. 
As earlier studies had not systematically looked for the presence of the complete spectrum 
of ESCEATHT symptoms, the true prevalence of early seizures and cerebral edema might be 
higher. Of note, in four patients (patients 4, 5, 12 and 13), no MRI or CT scan was made during 
attacks, therefore the presence of cerebral edema could not be investigated. Although, most 
S218L patients have a severe phenotype (with or without ESCEATHT), there is always the 
possibility that some cases with a mild phenotype may not have been included in this study, 
because of a possible publication bias. 
The present findings suggest a possible pathogenetic role for Cav2.1 Ca
2+ channels and 
CSD also in ESCEATHT. FHM1 mutations have been shown to increase the cellular influx 
of Ca2+ leading to enhanced release of neurotransmitters such as glutamate and a reduced 
trigger threshold for CSD.20,31 The S218L mutation causes rather dramatic changes in Cav2.1 
Ca2+ channel function, matching the severe clinical phenotype and the observation that 
seemingly harmless events may trigger attacks with sometimes fatal cerebral edema.12,25,26,29 
Detailed electrophysiological studies revealed a particularly low threshold for activation and 
a very slow inactivation of S218L-mutated Cav2.1 Ca
2+ channels.32 This would predict a vastly 
increased propensity for CSD as was seen in transgenic mice in which we introduced the S218L 
mutation.19 As a result of the S218L mutation, even weak and otherwise harmless stimuli may 
readily depolarize mutated Cav2.1 Ca
2+ channels and trigger multiple and prolonged waves 
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of CSD that are associated with severe and protracted cytotoxic cerebral edema and cell 
loss.12 Enhanced release of glutamate will increase the activation of NMDA receptors, further 
affecting brain cells (e.g., through accumulation of intracellular Ca2+ and production of nitric 
oxide) and further worsening cell swelling. Trivial head trauma may also cause mechanical 
strain through transient mitochondrial dysfunction and delayed long lasting small neuronal 
depolarizations, thereby increasing neuronal vulnerability.33 Notably, CSD has already been 
implicated in the pathophysiology of epilepsy.34,35 Both CSD and epilepsy are characterized 
by spreading of neuronal depolarization.21 The particular activation characteristics of S218L-
mutated Cav2.1 Ca
2+ channels may link CSD and epileptic seizures. 
Although several carriers of other CACNA1A mutations have epilepsy as part of their 
hemiplegic migraine attacks, the combination with cerebral edema was only reported for the 
Y1384C mutation.36,37 As attacks were not precipitated by trivial head trauma, a diagnosis of 
ESCEATHT is not applicable for this patient. For the FHM2 ATP1A2 gene, several mutations 
(e.g., G301R and G615R) are associated with cerebral edema during severe attacks of 
hemiplegic migraine,38,39 but a diagnosis of ESCEATHT (that includes early seizures and the 
trigger factor trivial head trauma) is only reported for the G615R mutation.38 It remains an 
open question to what extent findings in S218L mutation carriers also have implications for 
common MA. As none of the severe associated clinical features is common in MA patients, 
it seems that the presence of mutated CaV2.1 channels results in particularly severe CSDs in 
S218L mutation carriers. 
In conclusion, we postulate that CSD in S218L mutation carriers, in addition to hemiplegic 
migraine, is involved in causing early seizures and cerebral edema after trivial head trauma. 
Increased susceptibility to CSD might also play a role in the “juvenile head trauma syndrome”, 
which is remarkably similar to ESCEATHT.6-8 Although the full syndrome of ESCEATHT is 
present in only a minority of S218L mutation carriers, an important conclusion from this study 
is that they are at risk for developing the complete devastating phenotype. We propose that 
patients with this syndrome, especially when associated with permanent cerebellar symptoms 
and a history of migraine, are screened for the CACNA1A S218L mutation. Preventative 
therapeutic advice should be given to avoid activities that can cause even mild head trauma 
(i.e., contact sports) or wear a protective helmet. 
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ATP1A2 mutatIon In fmh and febrIle SeIzureS
INTRODuCTION
Febrile seizures are the most common form of convulsions between the age of 6 months and 
5 years,1 but genetic factors have not been identified. Here we investigated the molecular 
basis of febrile seizures in a small family with co-occurring hemiplegic migraine2 and febrile 
seizures (Fig. 1). Intermittent ataxia and diffuse encephalopathic episodes are also present in 
this family. 
Figure 1. Pedigree of the FHM2 family. The arrow indicates the proband. Squares indicate male subjects and circles 
indicate female subjects. To indicate clinical diagnosis; with lower-half–filled symbols represent FHM and dou-
ble-lined symbols represent febrile seizures. Individuals heterozygous for the ATP1A2 mutation are indicated by 












Using direct sequencing (see Vanmolkot et al., 20033), we identified a novel de novo 
heterozygous 2563 G>A substitution in exon 18 resulting in an amino acid change from a 
glycine to an arginine at position 855 in the ATP1A2 FHM2 gene4 that encodes the α2 subunit 
of Na+, K+-ATPase pumps. Only, the proband (III-1), the affected mother (II-2), and affected 
brother (III-2) carry this ATP1A2 mutation. Gly855 is evolutionary conserved (Fig. 2A), and 
the mutation was not identified in 300 control chromosomes.
An ouabain challenge assay5 for the mutant p.Gly855Arg construct, unlike wildtype, 
showed complete loss of cell survival, indicating that the mutation has functional consequences 
at the protein level (Fig. 2B).
CLINICAL DESCRIpTIONS
This now 13-year-old proband (III-1) (Fig. 1) experienced, from the age of 9 months to 3 years, 
five complex febrile seizures and one simple febrile seizure. The complex seizures either lasted 
more than 15 min or started focally. There were also episodes of several seizures occurring 
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sequentially. From the age of 7 months to 5 years, he also experienced several nonfebrile 
seizures, which typically had a focal onset and were secondary generalized. These seizures 
usually lasted up to 5 min, but sometimes were prolonged (up to 40 min), and at times occurred 
in clusters. Seizures stopped at age 5.
From age 2.5, he experienced headache attacks accompanied by transient hemiparesis as 
well as frequent unprovoked episodes of ataxia lasting a few minutes to days. In addition, 
he had episodes of rapidly progressive drowsiness down to Glasgow Coma scale (GCS) 6–7, 
without any focal neurologic deficits or epilepsy. The patient has ongoing behavioral problems 
and mild learning difficulties.
His now 3-year-old half-brother (III-2) had one complex (focal) febrile seizure lasting 
15 min when he was 7 months old. Since the age of 21 months he had episodes of hemiplegia, 
and recurrent encephalopathic episodes often preceded by headache and hemiplegia, and one 
episode of unsteadiness after minor head injury. The mother (II-2), now age 31 years, had two 
simple febrile seizures at age 2 and also had attacks of hemiplegic migraine. The father of the 
proband (II-1) and the father (II-3) of his half-brother and their grandparents (I-1 and I-2) 
never had hemiplegic migraine, ataxia, or seizures. 
CONCLuSION
We feel that the ATP1A2 p.Gly855Arg mutation is the causal mutation in this family for a 
number of reasons: (1) FHM and febrile convulsions were present only in the three mutation 
carriers and not in non–mutation carriers; (2) the mutation was not identified in a panel of 
150 healthy control individuals, and (3) functional studies revealed that the mutant has a 
Figure 2. Genetic and functional data on mutant p.Gly855Arg. (A) Alignment of amino acid sequences of several 
vertebrate sodium-potassium ATPase a-subunits; Gly855 is represented as a black box. (B) Upper panel shows 
Western blot analysis of transfected HeLa cells. Lower panel shows graphic representation of ouabain cell survival 
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deleterious effect on cell survival. Febrile seizures are reported in only some mutation carriers 
of three FHM2 families.3,6,7 Future identification of additional families with co-occurring 
hemiplegic migraine and febrile seizures may shed light on the association between ATP1A2 
gene mutations and febrile seizures. We, therefore, recommend genetic analysis of the ATP1A2 
gene in patients with febrile seizures.
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Almost all mutations in the SCN1A gene, encoding the α1 subunit of neuronal voltage-
gated NaV1.1 sodium channels, are associated with severe childhood epilepsy. Recently, two 
mutations were identified in patients with pure familial hemiplegic migraine (FHM). Here, we 
identified a novel SCN1A L263V mutation in a Portuguese family with partly co-segregating 
hemiplegic migraine and epilepsy. The L263V mutation segregated in five FHM patients, three 
of whom also had epileptic attacks, occurring independently from their hemiplegic migraine 
attacks. L263V is the first SCN1A mutation associated with FHM and co-occurring epilepsy 
in multiple mutation carriers, and is the clearest molecular link between migraine and 
epilepsy thus far. The results extend the clinical spectrum associated with SCN1A mutations 




SCN1A mutatIon cauSeS fhm and epIlepSy
INTRODuCTION
Both migraine and epilepsy are complex episodic neurological diseases with genetic and 
environmental factors playing a role in their pathogenesis.1,2 Epidemiological studies have 
indicated that there is a clear bidirectional increased risk of migraine and Epilepsy.3 This 
suggests that migraine and epilepsy, at least in part, may share pathophysiological mechanisms.4 
Most genes that are involved in rare monogenetic forms of epilepsy encode subunits of 
channels transporting sodium, potassium or chloride ions (for a recent review see Heron et 
al, 20072). Gene identification in migraine has been successful only for familial hemiplegic 
migraine (FHM), a rare, monogenic, autosomal dominant subtype of migraine with aura with 
unilateral motor weakness during the aura phase.5 All three FHM genes identified thus far 
are involved in ion transport.6 The FHM genes encode subunits of CaV2.1 calcium channels 
(CACNA1A: FHM1),7 sodium-potassium ATPases (ATP1A2: FHM2)8 and Nav1.1 sodium 
channels (SCN1A: FHM3).9
Despite their comorbidity, co-occurring migraine in epileptic mutation carriers has not 
been mentioned, probably because migraine in a patient or family with epilepsy will often be 
regarded coincidental because of the high prevalence of migraine in the general population. 
Epilepsy, however, has specifically been reported in some FHM mutation carriers.10 In FHM1 
mutation carriers, seizures may occur during severe hemiplegic migraine attacks.11 Seizures 
have been described in two FHM1 I1710T mutation carriers in one family independently of 
hemiplegic attacks12 and causing status epilepticus during hemiplegic migraine attacks in a 
sporadic patient.13 Several carriers of FHM1 mutation S218L, which is associated with severe 
FHM attacks triggered by trivial head trauma, had epileptic seizures.14,15 In FHM2 mutation 
carriers various types of childhood and adult epilepsy have been reported with different FHM2 
mutations.8,16-18 In rare cases, epilepsy is part of particularly severe phenotypes with alternating 
hemiplegia, coma with permanent cerebellar signs or mental retardation.19-21
A recent molecular link between migraine and epilepsy has come from the identification of 
the first two FHM mutations in SCN1A, a well-known epilepsy gene.9,22 Over 150 mutations in 
the SCN1A gene have been reported with generalized epilepsy with febrile seizure plus additional 
symptoms (GEFS+) and severe myoclonic epilepsy of infancy (SMEI).23,24 Both diseases are severe 
epileptic phenotypes occurring in childhood. The majority of SMEI mutations occur de novo 
and are either nonsense or frameshift mutations resulting in protein truncation and consequent 
loss-of-function or missense mutations with a wide range of functional consequences.25 The 
milder GEFS+ phenotype is mostly caused by missense mutations, showing either loss- or 
gain-of-function effects.26 Up to now, no associated migraine has been reported for any of the 
epilepsy mutations. It is not known why most SCN1A mutations cause childhood epilepsy, 
whereas only two cause hemiplegic migraine. A clinical continuum of migraine and epilepsy is 
probably associated with SCN1A mutations as a result of altered neuronal excitability.27 
Here we describe the first SCN1A mutation with several mutation carriers with partly co-
segregating FHM and epilepsy, which provides additional support for the clinical continuum 
hypothesis. Our results underscore the complex relation of migraine and epilepsy and provide 





We investigated a Portuguese FHM family with partially co-segregating epilepsy (Fig.1A). All 
subjects were interviewed and the clinical headache diagnoses were established according to 
International Headache Society criteria (International
Classification of Headache Diseases criteria),5 whereas seizures were classified according 
to the criteria of the International League Against Epilepsy.28 Diagnoses were made prior 
to genetic analyses by a neurologist experienced in migraine and epilepsy. This study 
was approved by the ethics committee of the Hospital Geral de Santo António, Porto. All 
individuals gave written informed consent. Clinical details of affected family members are 
shown in Table 1. Six patients suffered from typical hemiplegic migraine attacks, with an 
age of onset varying from 10 to 18 years and an attack frequency of less than one to three per 
year. None of the patients reported (inter)ictal cerebellar abnormalities. Generalized tonic-
clonic seizures (and in one case additional complex partial seizures) were co-segregating with 
hemiplegic migraine in three family members (i.e., II-2, II-5 and III-4), and probably in one 
deceased person (I-1) [seizures similar to those of the other family members were reported 
by his wife (I-2)]. Onset of seizures was between 4 and 8 years. Interictal EEG recording 
was unremarkable in patients II-2, II-5 and III-4. Structural lesions in these patients were 
excluded on the basis of computed tomography (i.e., II-2 and II-5) or magnetic resonance 
imaging (i.e., III-4) investigations (data not shown). Febrile convulsions were not reported 
in any of the family members. Epileptic seizures occurred independently from FHM attacks, 
and the age at onset was generally somewhat later than for the FHM attacks. Treatment with a 
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Figure 1. Pedigree of the Portuguese family with FHM and epilepsy. (A) Symbols with lower half filled represent 
individuals with FHM; the individual with the upper-left quarter filled has migraine without aura; double lined 
symbols represent individuals with epileptic seizures. The arrow indicates the proband. The “+” shows individu-
als that were clinically evaluated; “ha” indicates that clinical information was obtained heteroanamnestically. The 
presence of the heterozygous mutation is indicated by L263V / WT and the absence by WT / WT (wild type). 
(B) Electropherogram of the relevant part of exon 6 showing the heterozygous C>G nucleotide change (L263V) in 
the proband (Mutant) and healthy subject (WT) are shown.
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of < 60 kg, was successful with respect to both epileptic and hemiplegic attacks as patients 
remained attack free. Patient III-4 occasionally had epileptic attacks when treated with a 
daily dose of 600 mg of carbamazepine, but he did not tolerate a higher dose. Psychomotor 
development of all individuals was normal.
Haplotype analysis
Genomic DNA was isolated from peripheral leucocytes using a standard salting-out extraction 
method.29 The involvement of the FHM1 (19p13) locus was excluded on the basis of genetic 
markers D19S221, D19S1150, D19S226 as described before.7
In addition, involvement of the FHM2 and FHM3 loci was investigated by analysing 
genetic markers D1S2624, D1S2707, D1S2844 (FHM2; 1q23)16 and D2S156, D2S2330 and 
D2S2381 (FHM3;2q24),9 respectively (data not shown). Oligonucleotide primer sequences 
were obtained from the Human Genome Database (http://www.gdb.org/). Polymerase chain 
reaction (PCR) amplification was performed using standard conditions. PCR products 
were detected on an automated fragment run analyser (ABI 3700 DNA sequencer; Applied 
Biosystems, Foster City, CA, USA). All genotypes were analysed and independently scored 
by M-J.C. and K.R.J.V. using Genescan and Genotyper 2.1 software (Applied Biosystems). 
Haplotype was constructed evaluating the segregation and assuming a minimal number 
of recombinations.
Table 1. Summary of the clinical features of SCN1A mutation carriers
II-2 II-4 II-5 III-2 III-4
Hemiplegia attacks
Age/Age at onset (years) 59/14 57/16 52/18 35/12 12/10
Aura characteristics* +/+/+/- +/+/+/+ +/+/+/+ -/+/+/+ +/+/+/+
Duration 15 min-1 h 1 h 1 h 1 h 15 min-1 h
Frequency (per year) < 1 2-3 1 1-2 > 1
Headache Bilateral Bilateral Bilateral Unilateral Unilateral
Pain character Throbbing Throbbing Non-throbbing Throbbing Non-throbbing
Severity Severe Severe Mild Moderate Moderate
Nausea/vomiting +/+ +/+ -/- +/- +/+
Photophobia/Phonophobia +/+ +/+ +/+ -/- +/+
Seizures/epilepsy
Age at onset (years) 6 N.A. 4 N.A. 8
Type of epilepsy GTC and CP - GTC - GTC
Frequency (per year) 1-3 N.A. 1-3 N.A. 1-4
Treatment (daily dose of 
carbamazepine in mg)
400 N.A. 400 N.A. 600
*Characteristics of aura: visual symptoms/sensory symptoms/hemiplegia/aphasia; “-”: absent; “+”:present; GTC: 




All exons and flanking intronic regions of the ATP1A2 and SCN1A genes were amplified by 
PCR, using genomic DNA of the proband as a template. Direct sequencing was performed 
on PCR products using Cycle Sequencing (Prism Big Dye Terminators Cycle Sequencing kit; 
Applied Biosystems) and an ABI3700 DNA sequencer (Applied Biosystems). Sequencing was 
performed in the forward and reverse direction. For detection of the SCN1A mutation L263V 
(C→G, nt position 787, Ac. no. NM_006920), exon 6 was amplified by PCR using primers ‘E6F’ 
(5′-TTGCTTCTCCACTAGCGTTG-3′) and ‘E6R’ (5′-ACTTGAGGGGCTGGATATCC-3′), 
resulting in a 489-bps product that was subjected to direct sequencing. One hundred and fifty 
healthy controls (i.e., Portuguese blood donors without migraine history) were screened for 
the SCN1A mutation by direct sequencing.
RESuLTS
Haplotype analysis in the Portuguese family was compatible with both the FHM2 (i.e., 1q24) 
and FHM3 (i.e., 2q24) locus as single haplotypes co-segregated with disease in all five FHM 
patients for which DNA was available (data not shown). Sequence analysis of the ATP1A2 
gene did not reveal a causative mutation. In contrast, in the SCN1A gene a novel heterozygous 
missense mutation was identified, changing a single nucleotide in exon 6 (nt 787 C→G) (Fig. 1B). 
This C to G nucleotide transversion replaces a leucine for a valine at position 263 of the Nav1.1 
a1 subunit (Fig. 2A). The L263V mutation co-segregated with hemiplegic migraine in all five 
FHM individuals and was absent in 300 control chromosomes. Notably, three of the five FHM 
patients with the L263V mutation also had epileptic seizures. Patient I-1 most probably is the 
fourth patient from this family suffering from hemiplegic migraine and epilepsy, but no DNA 
was available to confirm the presence of the L263V mutation. No other associated neurological 
symptoms such as ataxia were reported for any of the family members. Taxonomy analysis 
showed a strong evolutionary conservation of Leu263 amino acid among different voltage-
gated sodium channels a subunits (Fig. 2B).
DISCuSSION
Here we report a novel L263V missense mutation in the SCN1A gene encoding the α1 subunit 
of voltage-gated sodium NaV1.1 channels in a Portuguese family with FHM and partially co-
segregating epilepsy. Several factors indicate that L263V is the causative mutation in this family 
with FHM and epilepsy: (i) L263V co-segregated in all five patients with hemiplegic migraine, 
three of them also had epilepsy (a fourth, deceased person probably had the mutation and 
epilepsy); no phenocopies or cases of incomplete penetrance were observed; (ii) L263V was 
absent in 300 control chromosomes; and (iii) Leu263 shows strong evolutionary conservation 
among several voltage-gated sodium channel subunit homologues across species; and (iv) its 
location in transmembrane domain DIS5 of the protein suggests an important functional 
role. α1 subunits of NaV1.1 sodium channels consist of four homologous domains (DI–DIV), 
each containing six highly conserved transmembrane segments (S1–S6), which form the 
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central pore of the sodium channel.30 Mutation L263V is located in the highly conserved 
S5 segment of the first domain (DIS5). S5 and S6 segments and S5-S6 linkers are important 
for ion selectivity and gating kinetics of the channel.31-32 No particular functional role has 
been established for DIS5, but closely located mutation I252N has been found associated with 
SMEI.33 Various other missense SCN1A mutations have been identified in S5 segments and are 
associated with different epileptic phenotypes of GEFS+34,35, SMEI36,37 or SMEB (borderline 
SMEI).37–39 
The L263V mutation is the third FHM3 mutation. The first two FHM3 mutations, Q1489K 
and L1649Q, were identified in large German and US families, respectively, and are associated 
with FHM without additional neurological features such as epilepsy or ataxia.9,22 Only in three 
of the 18 Q1489K mutation carriers with hemiplegic migraine were seizures reported that 
occurred only during infancy [two patients (in different families) with one episode; one patient 
with more attacks].9 The Portuguese family with the L263V mutation displays co-occurring 
hemiplegic migraine and generalized tonic-clonic epilepsy with a high penetrance. It is not 
clear how this mutation can cause epilepsy in certain attacks and hemiplegic migraine in other 
attacks. A detailed analysis of the functional consequences of the L263V mutation and the two 
other FHM3 mutations is underway to answer that question. 
Figure 2. Location of FHM3 SCN1A mutations and conservation of Leu263. (A) Schematic representation in the 
Nav1.1 a1 subunit with the location of the FHM3 mutations. (B) Evolutionary conservation of the relevant part 
of the D1S5 transmembrane segment. Amino acid numbering for each sequence is presented. The gray box (with 
L) represents conservation of residue Leu263. Protein accession numbers are as follows: Homo sapiens: SCN1A 
(P35498), SCN2A2 (Q99250), SCN3A (Q9NY46), SCN4A (P35499), SCN5A (Q14524), SCN7A (Q01118), SCN8A 
(Q9UQD0), SCN9A (Q15858), SCN10A (Q9Y5Y9), SCN11A (Q9UI33); Rattus norvegicus SCN1A (P04774); Gallus 
gallus: SCN1A (ENSGALP00000017793) and SCN3A (ENSGALP00000017960); and Takifugu rubripes SCN8A 
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chapter 6
In conclusion, this study has strengthened the molecular link between migraine and 
epilepsy, supporting the existence of a continuum of chronic episodic disorders. In addition, it 
has expanded the clinical spectrum associated with FHM3 SCN1A mutations.
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chapter 7
AbSTRACT
Background: Episodic ataxia (EA) is variably associated with additional neurologic 
symptoms. At least 4 genes have been implicated. Recently, a mutation in the SLC1A3 gene 
encoding the glutamate transporter EAAT1 was identified in a patient with severe episodic 
and progressive ataxia, seizures, alternating hemiplegia, and migraine headache. The mutant 
EAAT1 showed severely reduced uptake of glutamate. The syndrome was designated EA6 and 
shares overlapping clinical features with EA2, which is caused by mutations in CACNA1A.
Objective: To test the role of the SLC1A3 gene in EA.
Design: Genetic and functional studies. We analyzed the coding region of the SLC1A3 gene 
by direct sequencing.
Patients: DNA samples from 20 patients with EA (with or without interictal nystagmus) 
negative for CACNA1A mutations were analyzed.
Main Outcome Measures: We identified 1 novel EAAT1 mutation in a family with EA and 
studied the functional consequences of this mutation using glutamate uptake assay.
Results: We identified a missense C186S mutation that segregated with EA in 3 family 
members. The mutant EAAT1 showed a modest but significant reduction of glutamate uptake.
Conclusions: We broadened the clinical spectrum associated with SLC1A3 mutations to 
include milder manifestations of EA without seizures or alternating hemiplegia. The severity of 
EA6 symptoms appears to be correlated with the extent of glutamate transporter dysfunction.
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INTRODuCTION
Episodic ataxias (EAS) are rare genetic disorders characterized by recurrent episodes of 
cerebellar ataxia variably associated with additional neurologic features. Different subtypes of 
EA are defined on the basis of genetic loci and clinical manifestations.1
The most common and best characterized subtypes of EA are EA1 and EA2. EA1 is caused 
by missense mutations in the KCNA1 gene encoding a subunit of neuronal Kv1.1 K
+ channels.2 
EA1 usually presents with short-lasting attacks that often are triggered by exertion, stress, 
or startle. Patients show persistent interictal motor unit activity (myokymia). EA2 is caused 
by mutations in the CACNA1A gene encoding the pore-forming subunit of neuronal Cav2.1 
Ca2+ channels.3 Mostly, nonsense, frameshift, splice site, and missense mutations have been 
described, resulting in either a complete loss4 or partial impairment5,6 of Cav2.1 channel 
function. The episodes in EA2 last longer than in EA1, up to several hours,7 and are often 
associated with vertigo and migrainous headache and can be triggered by exercise, fatigue, and 
stress.8 Acetazolamide may prevent attacks.9 Between attacks, nystagmus usually occurs. Many 
patients have interictal ataxia in addition to the attacks. The EA3, EA4, and EA5 subtypes are 
rarer and less well-defined disorders compared with EA1 and EA2.1 
The EA6 subtype was identified in a 10-year-old patient with a severe phenotype of 
episodic and progressive ataxia, seizures, alternating hemiplegia, and migraine headache.10 A 
heterozygous de novo P290R missense mutation was identified in the SLC1A3 gene by use of a 
candidate gene approach. SLC1A3 encodes the glial excitatory amino acid transporter EAAT1, 
which is involved in glutamate removal from the synaptic cleft.11,12 Functional analysis of the 
mutant EAAT1 protein showed marked reduction of glutamate uptake in vitro.10
In the present study, we performed a mutation analysis of the SLC1A3 gene (OM/M 600111) 
in 20 patients with EA2-like symptoms but without CACNA1A mutations. In 1 family, we 
found an EAAT1 mutation that segregated with the disease in 3 patients. Functional studies 
revealed a moderate impairment of glutamate reuptake.
METhODS
Patients
We investigated 20 patients who were referred for molecular confirmation of EA2 in whom 
no mutations were found in the CACNA1A gene. These patients showed typical EA2-like 
symptoms, including interictal nystagmus but no myokymia, attacks of mild ataxia with a 
duration of several hours, and a positive response to acetazolamide. Except for 2 patients from 
the United States, all patients came from Europe, mostly the Netherlands. Family members 
of the proband with the SLC1A3 mutation (Fig. 1) underwent neurologic examination by 
experienced neurologists (S.L.M.B. and A.H.S). All patients gave informed consent, and the 




Genomic DNA was isolated from peripheral leukocytes using a standard salting out extraction 
method.13 All exons and flanking intronic regions of the SLC1A3 gene were amplified by 
polymerase chain reaction (PCR), using genomic DNA as a template. Direct sequencing was 
performed by cycle sequencing (Prism Big Dye Terminators Cycle Sequencing kit; Applied 
Biosystems, Foster City, California) using the dideoxy termination method and an ABI3700 
automated sequencer (Applied Biosystems). Two hundred healthy controls were screened for 
the mutation by PCR analysis of exon 5 and subsequent restriction digestion of PCR products 
with restriction enzyme AluI. 
Functional studies
Functional studies10 on glutamate uptake of wild-type and mutant EAAT1 were performed 
as described previously. In brief, full-length wild-type complementary DNA (EAAT1-WT) 
was cloned into a mammalian expression vector pcDNA3.1 (Invitrogen; Carlsbad, California). 
The mutant construct (EAAT1 186S) was generated by performing sitedirected mutagenesis 
(QuikChange; Stratagene; La Jolla, California). For functional analyses of the SLC1A3 C186S 
mutation, 2 μg of wild-type (EAAT1-WT) or mutant (EAAT1-186S) EAAT1 complementary 
DNA constructs were transfected into COS7 cells. One day after transfection, the cells were 
dissociated and plated onto 60-mm-diameter tissue culture dishes. The cells were incubated 
with 1.5 mL of 1μM L-glutamic acid containing 1 μCi/mL of L-[3,4-3H]-glutamic acid for 
2 minutes at room temperature. A total of 4 independent and masked experiments were 
performed, each in triplicate.
Figure 1. Pedigree of the episodic ataxia family with the EAAT1 186S mutation. Episodic ataxia is indicated by a 
filled black square or circle for males or females, respectively. C186S indicates heterozygosity for the mutation. WT 
indicates homozygosity for the wild-type allele.
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RESuLTS
Genetic studies and clinical features associated with EAAT1 mutation
Mutation analysis of the SLC1A3 gene in 20 patients revealed in 1 patient a heterozygous c.556 
T_A substitution (SLC1A3 reference sequence; GenBankNM004172) that changed a cysteine 
to a serine at position 186 (C186S) of the EAAT1 protein (Fig. 2A and 2B). The mutation was 
absent in 200 Dutch control individuals. C186S was identified in the proband (III-3), clinically 
affected family members II-3 and III-4, and 1 asymptomatic family member (III-2) (Fig. 1).
Clinical information of the affected family members is summarized in the Table. The 
proband (III-3) is a 35-year-old man who has had episodes of ataxia since early childhood. 
Attacks gradually changed over time. Initially, vertigo, nausea, and vomiting were the most 
bothersome symptoms. Later in life, truncal and gait ataxia during the attacks became more 
prominent. Attacks are often associated with nausea, vomiting, photophobia, phonophobia, 
vertigo, diplopia, slurred speech, and blurred vision. No headache was reported. Typically, 
Figure 2. EAAT1 C186S mutation. (A) Schematic representation of the EAAT1 protein and the location of the 
mutated Cys186 amino acid in transmembrane segment 4b (indicated by a black dot) (the structure is adapted from 
Yernool et al14). (B) Conservation of the mutated residue Cys186 highlighted in gray. The protein sequences were 
obtained from GenBank (Homo sapiens, NP_004163; Bos taurus, NP_46411; Mus musculus, NP_683740; Rattus nor-
vegicus, NP_062098; salamander, O57321; Danio rerio, NP_997805; Drosophila melanogaster, NP_477428; human 
EAAT2, AY066021; human EAAT3, NP_004161; human EAAT4, NM_005062; human EAAT5, NP_006662). 
(C) Glutamate uptake assay in COS7 cells expressing mutant EAAT1-186S (mean [SEM], 88.2[5.5]) or wild-type 
EAAT1-186C (mean [SEM], 107.8 [6.9]). The results are the mean (SEM) of the 4 experiments, each in triplicate. 
The values are picomoles of glutamate transported per milligram of protein per minute of incubation. Asterisk 
indicates significant reduction of glutamate uptake compared with wild type (p=0.029).
Error bars indicate SEM. HP indicates helical hairpin.
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attacks were provoked by emotional stress, fatigue, or consuming alcohol or caffeine. Attack 
duration was usually between 2 and 3 hours. Currently, his average attack frequency is once 
a month. Interictal neurologic examination revealed a horizontal gaze-evoked nystagmus 
without gait or truncal ataxia. Interictal electroencephalographic recording revealed no 
epileptic activity, and magnetic resonance imaging revealed no abnormalities (data not shown). 
His mother (II-3) and sister (III-4) were also diagnosed as having EAs. The 56-year-old mother 
(II-3) has had episodes of ataxia similar to those of the proband since elementary school. Her 
attacks are also associated with vertigo, nausea, vomiting, photophobia, phonophobia, and 
slurred speech. The attacks were not associated with headache. She now has approximately 
10  attacks per year, which may last for several hours and can be triggered by stress. The 
28-year-old sister (III-4) has had episodes of ataxia since the age of 14 years. Associated 
symptoms include vertigo, nausea, vomiting, and mild photophobia. Sometimes, the day 
after an attack, she experiences bilateral headache not associated with nausea, vomiting, 
phonophobia, or photophobia. Reported triggers are exercise, fatigue, and stress. Currently, 
she has on average 6 attacks a year. Typically, attacks last several hours. Acetazolamide 
significantly reduced the frequency of attacks in all 3 affected family members. His 40-year-
old cousin (III-2) is an asymptomatic carrier of the C186S EAAT1 mutation. He experienced 
4 attacks of migraine without aura and has tensiontype headache, but does not exhibit signs 
or symptoms related to ataxia. Individuals I-1, I-2, and II-2 were considered healthy based on 
limited heteroanamnestic information. His grandfather had died at the age of 98 years. His 
grandmother had complained about dizziness, but no neurologic examination was performed 
during her lifetime. No relevant clinical information is available for individual II-2, who died 
of an unrelated cause. Non-mutation carrier III-1 is asymptomatic.
Table. Summary of clinical features of patients with episodic ataxia carrying the EAAT1 C186S Mutation
Clinical Feature Mother (II-3) Proband (III-3) Sister (III-4)
Age at examination, y 56 35 28
Age of onset, y <10 3 14
Ataxia +  + +
Vertigo +  + +
Diplopia/Visual blurring -/- +/+ -/-
Nausea/Vomiting +/+ +/+ +/+
Photophobia/Phonophobia +/+ +/+ +/-
Attack duration Hours Hours Hours
Attack frequency ~ 10 / year 1-2 / month ~ 6 / year




Response to acetazolamide + + +
Interictal gaze evoked nystagmus - + -
Headache - - +
92
7
EAAT1 mutatIon cauSeS epISodIc ataxIa
Functional study of EAAT1 mutation C186S
To investigate the functional consequences of the EAAT1 C186S mutation, radioactive 
glutamate uptake assays were performed in COS7 cells. The low level of endogenous glutamate 
uptake activity has long established the COS7 cells as being well suited for functional studies 
of glutamate transporters.15 We measured glutamate uptake in COS7 cells transfected with 
the wild-type (EAAT1-186C) or the mutant construct (EAAT1-186S). An 18% reduction 
in glutamate uptake was observed in cells expressing the mutant (mean [SEM], 88.2[5.5]) 
compared with the wild-type (mean [SEM], 107.8[6.9]) EAAT1, measured in picomoles per 
milligram of total protein per minute of incubation (p=0.029; Fig. 2C).
COMMENTS
We scanned the SLC1A3 gene for mutations in 20 patients with EA2-like symptoms without 
CACNA1A mutations because of overlapping clinical features between EA2 and EA6. We found 
a novel nucleotide change c.556T_A in the SLC1A3 gene, resulting in EAAT1 mutation C186S, 
in a family with EA and interictal nystagmus but without migraine, seizures, cerebellar atrophy, 
or alternating hemiplegia. Our genetic and functional data suggest that mutation C186S is 
pathogenic. First, the mutation C186S segregated with all 3 symptomatic family members but 
was not identified in a large panel of controls. The asymptomatic mutation carrier (III-2) had 
migraine without aura, but given the relatively high prevalence of migraine it is unlikely that 
these attacks are caused by the EAAT1 mutation. Therefore, he likely represents a nonpenetrant 
case of EA. Second, Cys186 is highly conserved among species (Fig. 2B). Our functional 
studies revealed a reduced glutamate reuptake for the mutant EAAT1 (Fig. 2C). Cys186 
resides in transmembrane segment 4B (Fig. 2A) on the outer perimeter of the human EAAT1 
transporter protein that is implicated in intersubunit contact.15 The 4B-4C loop was recently 
shown to undergo substrate-dependent conformational changes and has been hypothesized 
to be important in stabilizing the trimeric structure of the transporter and coordinating the 
cooperativity for sodium binding.16 Clinical severity of EA6 appears to be well correlated with 
glutamate reuptake capability of mutant EAAT1. The P290R mutation leads to a complete 
loss of glutamate reuptake and is associated with a severe EA phenotype with months-long 
attacks, seizures, and alternating hemiplegia.10 In contrast, the C186S mutation has a mild 
effect on glutamate reuptake and is correlated with a milder EA phenotype. Although it is 
hard to predict from cellular studies how a mild increase in extracellular glutamate will affect 
cerebellar functioning in patients, it is well known that ion and neurotransmitter pathways 
are complex and tightly regulated. Subtle changes in these pathways have been associated with 
clinical manifestations.17,18 Since we found a mutation in only 1 of 20 patients with CACNA1A-
negative EA2-like symptoms, other genes must be involved. Likely candidate genes are 
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TREX1 mutatIonS cauSe rVcl
Autosomal dominant retinal vasculopathy with cerebral leukodystrophy is a microvascular 
endotheliopathy with middle-age onset. In nine families, we identified heterozygous 
C-terminal frameshift mutations in TREX1, which encodes a 3’-5’ exonuclease. These 
truncated proteins retain exonuclease activity but lose normal perinuclear localization. These 
data have implications for the maintenance of vascular integrity in the degenerative cerebral 
microangiopathies leading to stroke and dementias.
We have previously described three families sharing common features of retinal and 
cerebral dysfunction. Visual loss, stroke and dementia begin in middle age, and death occurs 
in most families 5 to 10 years later. These diseases map to 3p21.1-p21.3 (ref. 1) and are called 
cerebroretinal vasculopathy (CRV),2 hereditary vascular retinopathy (HVR)3,4 and hereditary 
endotheliopathy, retinopathy, nephropathy and stroke (HERNS).5 We now designate these 
illnesses as autosomal dominant retinal vasculopathy with cerebral leukodystrophy (RVCL) 
(OMIM 192315). The neurovascular syndrome features a progressive loss of visual acuity 
secondary to retinal vasculopathy, in combination with a more variable neurological picture.1-7 
In a subset of affected individuals, systemic vascular involvement is evidenced by Raynaud’s 
phenomenon and mild liver (micronodular cirrhosis)2,5 and kidney (glomerular) dysfunction.5 
This retinal vasculopathy is characterized by telangiectasias, microaneurysms and retinal 
capillary obliteration starting in the macula. Diseased cerebral white matter has prominent 
small infarcts that often coalesce to pseudotumors. Neuroimaging studies demonstrate 
contrast-enhancing lesions in the white matter of the cerebrum and cerebellum. Histopathology 
shows ischemic necrosis with minimal inflammation and small blood vessels occluded with 
fibrin.5 The white matter lesions resemble post-radiation vascular damage.2 Ultrastructural 
studies of capillaries show a distinctive, multilamellar subendothelial basement membrane.5 
By combining haplotypes in the three RVCL families, we narrowed the disease gene to a 3-cM 
region between markers D3S1578 and D3S3564 that encompassed ~10 Mb, containing over 120 
candidate genes.1 We then sequenced the full coding region and intron-exon boundaries of 33 
candidate genes within this region (Supplementary Table 1). 
Here we report the identification of mutations in TREX1 (NM_033627), encoding DNA-
specific 3’ to 5’ exonuclease DNase III. In the CRV2 and HVR3,4 pedigrees, a heterozygous 1-bp 
insertion (3688_3689insG) leads to V235fs and a consequent premature stop. In HERNS,5 a 
heterozygous 4-bp insertion (3727_3730dupGTCA) results in a frameshift at T249 (Fig. 1a, b). 
Next, we examined six families with putative RVCL (Supplementary Table 2).2,6,7 In each, 
we identified frameshift mutations affecting the C terminus of TREX1. In three, the alteration 
was V235fs, the same as that in the CRV and HVR pedigrees. Haplotype analysis suggests 
that they are not related (data not shown). We did not detect any of the mutations in panels 
of chromosomes matched by ancestry or location (Supplementary Methods). In the CRV 
and HERNS families, all affected individuals over the age of 60 (but none of the unaffected 
individuals over the age of 60) carried a TREX1 mutation (100% penetrance). In the HVR3,4 
family, 10 of the 11 mutation carriers over 60 years of age have retinopathy. 
TREX1 (DNase III) is a DNA-specific 3’ to 5’ exonuclease ubiquitously expressed in 
mammalian cells.8-10 It is thought to function as a homodimer, with a preference for single-
stranded DNA and mispaired 3’ termini.8 TREX1 is a part of the SET complex11 that normally 
resides in the cytoplasm but translocates to the nucleus in response to oxidative DNA damage.12
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Recently, homozygous mutations in TREX1 have been reported to cause Aicardi-Goutière 
syndrome (AGS).13 AGS is a rare, familial, early-onset progressive encephalopathy featuring 
basal ganglia calcifications and cerebrospinal fluid lymphocytosis, mimicking congenital viral 
encephalitis.14 Notably, mutations associated with AGS disrupt the enzymatic sites in TREX1. 
This loss of exonuclease function13 (Fig. 1) is hypothesized to cause the accumulation of altered 
DNA that triggers a destructive autoimmune response.13 No phenotype was reported for the 
heterozygous carriers of these mutations; however, a heterozygous mutation in TREX1 causing 
familial chilblain lupus has been reported recently.15
The distinctive clinical course and pathology of RVCL compared with AGS suggests 
separate disease mechanisms. The frameshift mutations observed in RVCL are downstream 
of the regions encoding the catalytic domains, whereas in AGS, homozygous mutations occur 
that alter exonuclease function. The heterozygous mutations observed in RVCL did not impair 
the enzymatic activity of TREX1 (Fig. 2a), in comparison with the R114H substitution in AGS.13
To investigate how the RVCL TREX1 proteins differ from the wild type, we performed 
expression studies using confocal microscopy on cells transfected with TREX1 tagged with 
a fluorescent protein (Fig. 2b and Supplementary Fig. 1). The wild-type TREX1 labeled with 
Figure 1. Diagram of TREX1 protein. (a) TREX1 has three exonuclease domains. Mutations in italics are associated 
with AGS13, and those in boldface at the C terminus are associated with RVCL. (b) Comparison of the amino acid 
sequence of the C terminus of wild-type (WT) TREX1 with RVCL associated mutations. The abnormal sequence 
introduced by the frameshifts is depicted in gray.
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fluorescent protein (FP-TREX1) localized to the perinuclear region. In contrast, the TREX1 
proteins FP-V235fs and FP-T249fs were diffusely distributed in the cytoplasm and the nucleus, 
as was the case for the fluorescent protein alone (Fig. 2b and Supplementary Videos 1-4 online). 
Protein blotting confirmed that the expressed proteins were of the correct size (Fig. 2c). These 
results suggest a perinuclear targeting signal within the C terminus of TREX1. Consequently, 
we generated a construct containing the C-terminal 106 amino acid residues of TREX1 (FP-C-
106). This protein showed a perinuclear localization pattern identical to that of the wild-type 
TREX1 protein (Fig. 2b). The TREX1 protein containing amino acid change R114H, found 
in AGS, also had the same pattern as the wild-type protein. In contrast, the protein with the 
alteration closest to the C terminus of TREX1, FP-287fs, was diffusely distributed, like the 
other two truncated proteins (data not shown).
The TREX1 proteins found in individuals with RVCL lack part of the C terminus. In 
haploinsufficient individuals, this may prevent an interaction with the SET proteins and 
therefore may prevent formation of the SET complex. The SET complex is hypothesized to 
target DNA repair factors, including TREX1, to damaged DNA under conditions of oxidative 
Figure 2. Functional consequences of RVCL associated TREX1 mutations. (a) Assessment of 3’-5’ exonuclease 
activity using equivalent amounts of purified recombinant proteins expressed in E. coli. (b) Confocal microscopy 
of HEK293T cells showing transiently expressed fluorescent protein (FP)-tagged TREX1 proteins (green), TOPRO3 
staining of nuclei (red) and overlay (yellow). Similar expression patterns were obtained for wild-type protein and 
for proteins derived from constructs containing mutations associated with AGS and RVCL in CHO, HL-60 and 
HeLa cells (data not shown). (c) Protein blot analysis of untransfected cells (1) and cells transfected with enhanced 
yellow fluorescent protein (eYFP) (2), wild-type TREX1 (3), TREX1 mutants (4,5) and the C-terminal 106 amino 
acids (6), all linked to eYFP.
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stress.11,12 Lack of sufficient TREX1 associated with the SET complex may result in failure of 
granzyme A-mediated cell death.12 Alternatively, the dissemination of untethered TREX1 
in the nucleus and cytoplasm may have detrimental effects, specially on endothelial cells. 
The clinical syndromes in these families and the study of their mutations should deepen 
our understanding of exonuclease function, homeostasis of the endothelium and events 
leading to premature vascular aging. RVCL and cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy (CADASIL) represent two examples of 
monogenic disease featuring a cerebral microangiopathy for which the genetic defects are now 
known and from which we can gain new insights into the origin of strokes and dementia. We 
obtained consent from all participants in this study, and the study was approved by the Office 
for Protection of Research Subjects at UCLA and the Human Research Protection Office at 
Washington University School of Medicine.
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Supplementary Fig. 1. Schematic representation of FP constructs expressed in mammalian cells. The FP was cloned 
at the amino-terminus of TREX1 and mutants. A carboxyl-terminal segment of the last 106 amino acids of wild-type 
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Supplementary Table 1. The 32 candidate genes sequenced prior to the discovery of TREX1 as the causative 
gene for RVCL
Gene Name Gene ID OMIM
AMIGO3 Adhesion molecule with Ig-like domain 3 386724 N/A
ATRIP ATR interacting protein 11277 606605
CACNA1D Voltage-dependent L-type calcium channel subunit alpha-1D 776 114206
CACNA2D2 Calcium channel voltage dependent, alpha- 2/ Delta Subunit 2 9254 607082
CCR1 Chemokine (C-C motif) receptor 1 1230 601159
CCR2 Chemokine (C-C motif) receptor 2 1231 601267
CCR3 Chemokine (C-C motif) receptor 3 1232 601268
CCR9 Chemokine (C-C motif) receptor 9 10803 604738
CELSR3 Cadherin, EGF LAG seven-pass G-type receptor 3 1951 604264
CSPG5 Chondroitin sulfate proteoglycan 5 10675 606775
CTNNB1 Catenin (cadherin-associated protein), beta 1, 1499 116806
CX3CR1 Chemokine (C-X3-C motif) receptor 1 1524 601470
CXCR6 Chemokine (C-X-C motif) receptor 6 10663 605163
DAG1 Dystroglycan 1 (dystrophin-associated glycoprotein 1) 1605 128239
ENTPD Ectonucleoside triphosphate diphosphohydrolase 3 956 603161
GNAT1 Guanine nucleotide binding protein, alpha transducing activity 
polypeptide 1 2779 139330
GPX1 Glutathione peroxidase 1 2876 138320
LAMB2 Laminin, beta 2 (laminin S) 3913 150325
MAP4 Microtubule-associated protein 4 4134 157132
PH4 PH-4 hypoxia-inducible factor prolyl 4-hydroxylase 54681 N/A
PLXNB1 Plexin B1 5364 601053
RASSF1 Ras association (RalGDS/AF-6) domain family 1 11186 605082
RHOA Ras homolog gene family, member A 387 165390
RIS1 TMEM158 transmembrane protein 158 (RIS-1 Ras-induced 
senescence 1) 25907 N/A
RPL29 Ribosomal protein L29 6159 601832
RPSA Ribosomal protein SA 3921 150370
SEMA3F Semaphorin 3F 6405 601124
Scotin Scotin 51246 607290
SEMA3B Sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphoring) 3B 7869 601281
STAB1 Stabilin 1 23166 608560
TRAIP TRAF interacting protein 10293 605958
VIPR1 Vasoactive intestinal peptide receptor 1 7433 192321
N/A, not applicable. GeneID, and OMIM identities are indicated.
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Supplementary Table 2. Mutations identified in TREX1 in RVCL
# Mutation Frameshift Reference
Geographical
(Background)
1 3688_3689insG V235 Grand et al North America (European)
2 3688_3689insG V235 Storimans et al
Terwindt et al
Netherlands
3 3727_3730dupGTCA T249 Jen et al North America
(Chinese)
4 3688_3689insG V235 Grand et al North America
(Ashkenazi-Jewish)
5 3691_3692insA T236 Weil et al Germany
6 3835_3836insA R284 Cohn et al Australia
7 3688_3689insG V235 Unpublished North America
8 3688_3689insG V235 Unpublished Australia
9 3843_3844insG L287 Unpublished Netherlands










The appropriate universal sequencing primer was used for either reading the forward or reverse strand of 
all amplicons. Forward sequencing primer (5’-GTAAAACGACGGCCAGT-3’); reverse sequencing primer 
(5’-CAGGAAACAGCTATGACC-3’). Incubation conditions: temperature, 60°C; Mg2+concentration, 1.5 mM.
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SuppLEMENTARY VIDEOS 1-4 LEGENDS 
Supplementary Video 1. 
Confocal microscopy video showing functional consequences of RVCL-associated TREX1 
mutations as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) 
and TOPRO3 stained nuclei (blue). Fluorescence expression pattern of fluorescent protein 
(FP) alone. The protein is diffusely distributed in the cytoplasm and in the nucleus.
Supplementary Video 2. 
Confocal microscopy video showing functional consequences of RVCL-associated TREX1 
mutations as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) 
and TOPRO3 stained nuclei (blue). Fluorescence expression pattern of wild type TREX1 
tagged with the fluorescent protein (FP-TREX1). This fusion protein is found in a perinuclear 
compartment and is excluded from the nucleus.
Supplementary Video 3. 
Confocal microscopy video showing functional consequences of RVCL-associated TREX1 
mutations as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) 
and TOPRO3 stained nuclei (blue). Fluorescence expression pattern of mutant TREX1, tagged 
with the fluorescent protein (FP-V235 fs). The mutant form of TREX1 exhibits an expression 
pattern identical to the fluorescent protein (FP) alone.
Supplementary Video 4. 
Confocal microscopy video showing functional consequences of RVCL-associated TREX1 
mutations as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) 
and TOPRO3 stained nuclei (blue). Fluorescence expression pattern of carboxyl-terminal 106 
amino acids of TREX1 tagged with the fluorescent protein (FP-C-106). This fusion protein 
is found in a perinuclear compartment and is excluded from the nucleus. This pattern is 
identical to the native exonuclease, implicating this short stretch of amino acids in mediating 
the perinuclear localization of the protein.
SuppLEMENTAL METhODS
Samples
We analyzed DNA samples from nine families with clinical symptoms of RVCL 
(Supplementary Table 2). Informed consent was obtained from all patients, in accordance 
with procedures and regulations of the Institutional Review Boards.
Mutation detection
Genomic DNA was isolated from peripheral blood leukocytes or immortalized cell lines 
from consenting subjects as approved by IRB. In specific cases (Washington University 
Genome Sequencing Center), Phi29-based whole genome amplification was performed 
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on genomic DNA samples. Gene sequences of candidate genes were extracted from 
GenBank (www.ncbi.nlm.nih.gov) and Ensembl (www.ensembl.org) databases. Primers to 
amplify the coding exons and exon-intron boundaries of candidate genes were designed 
with the PrimerDesign script that is based on the use of the Primer 3 program. Universal 
(forward and reverse) tails were added to the 5’ ends of amplification primers to serve as the 
sequencing primer sites (primer sequences and PCR conditions are available on request). 
Direct sequencing of purified PCR products was done by using dye-terminator chemistry 
and electrophoresed on a MegaBase500 (Amersham Biosciences, Princeton, NJ) capillary 
sequencer or either the ABI3700 or ABI3730 automated sequencer (Applied Biosystems, 
Foster City, CA). The sequence traces were assembled and scanned for variations from the 
reference sequence using the PolyScan informatics suite or Vector NTI suite 9.0.0 program 
(Invitrogen, Carlsbad, CA). The tagged variations were then manually reviewed. All detailed 
protocols are available on request.
For further mutational analysis of TREX1, primers were designed to amplify the 
coding exons of TREX1 (Supplementary Table 3). Purified PCR amplification products 
were sequenced using dye-terminator chemistry and electrophoresed on a MegaBase500 
(Amersham Biosciences, Princeton, NJ) capillary sequencer or an ABI3700 sequencer (Applied 
Biosystems, Foster City, CA). Sequencing was analyzed using PolyPhred. Anonymized control 
samples were screened by sequencing. Controls were matched with the ethnic origins of the 
mutations. The RVCL TREX1 mutations were not detected in 192 Caucasian (HD100CAU, 
Coriell), 192 Chinese (HD100CHI, Coriell) and 300 Dutch control alleles.
Haplotype analysis
For 20 microsatellite markers in the chromosome 3p21.1-p21.3 region, standard PCRs were 
performed using a PTC200 thermal cycler (Bio-Rad Laboratories, Foster City, CA). PCR 
products were analyzed on an ABI3700 sequencer (Applied Biosystems, Foster City, CA) 
and genotypes were assigned using GENESCAN and GENOTYPER software (Applied 
Biosystems, Foster City, CA). Two investigators scored genotypes independently. In addition, 
13 SNPs in the region closely f lanking TREX1 were typed by direct sequencing. Disease 
haplotypes were constructed by inspection of segregation.
Molecular cloning, mutagenesis, expression, and purification of E. coli 
proteins 
Mutations (V235fs, T249fs and R114H) were constructed using the cDNA clone encoding 
TREX1 variant 1 (Origene TC304415) as a template for site-directed mutagenesis. Oligos 
used for mutagenesis were as follows: 
V235fs (5’ ATGTATGGGGGTCACAGCCTCTG 3’ and 5’ CAGAGCGTGTGACCCCCATACA 
TG 3’) 
T249fs (5’ TCTGCTGTCAGTCACAACCACTGC 3’ and 5’ CAGTGGTTGTGACTGACAGCA 
GATG 3’) 
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In the case of TREX1, V235fs, T249fs and R114H, the inserts were subcloned by PCR 
using the TREX1 cDNA clone as a template into the E. coli expression vector pET28a+-1 
{a derivative of pET28a+ (Novagen) created in house} containing an N- terminal 6x His 
epitope tag. Correct clones were transformed into the E. coli strain BL21CodonPlus (DE3)-
RIL (Stratagene, La Jolla, CA). Cells containing the TREX1 plasmids were grown at 37°C 
to an Absorbance600 of 0.6. Isopropyl-1-thio-β-D-galactopyranoside was added to a final 
concentration of 1 mM and the cultures incubated at 37°C for an additional 3h. Cells 
were then harvested and the pellets were stored at -80°C. For purification of recombinant 
proteins, cells were resuspended in cold sonication buffer (50 mM Tris pH 8.0, 500 mM 
NaCl, 10% glycerol, 5 mM beta mercaptoethanol, 1 mM imidazole, and 1 mM PMSF). The 
cell suspension was sonicated and centrifuged at 15,000 g at 4°C for 20 min to obtain a cleared 
lysate. His-tagged proteins were batch adsorbed to Ni-NTA Agarose (Qiagen, Valencia, 
CA) for 1 h at 4°C. The beads were washed extensively in wash buffer (sonication buffer 
containing 25 mM imidazole) and packed into a 5 ml polypropylene (Qiagen) column. After 
additional washes, fractions were collected during elution with five column volumes of 
elution buffer (sonication buffer containing 250 mM imidazole). Fractions containing His-
TREX1 proteins were identified by SDS-PAG electrophoresis and Western blotting with an 
anti-HIS-HRP conjugated antibody (Clontech, Mountain View, CA) or, alternatively, with 
Coomassie Brilliant Blue staining. The samples were pooled, concentrated and aliquots of 
the purified proteins frozen at -80°C.
Exonuclease assays
1 µg of Poly(dA) (GE Healthcare, Princeton, NJ) was labeled at the 3’ end with 32P dATP (GE 
Healthcare) using Terminal Transferase (Roche Diagnostic Corp., Indianapolis, IN). Reactions 
containing 50 mM Tris pH 8.5, 4 mM MgCl2, 1 mM DTT, 10 µg BSA, 0.01 g radiolabeled 
poly(dA) substrate, and recombinant exonuclease TREX1 protein were incubated in a total 
volume of 100 l at 37°C. Aliquots were removed at the indicated times and ethanol precipitated 
in the presence of 50 µg denatured calf thymus DNA (Sigma-Aldrich, St. Louis, MO). Ethanol-
soluble radioactivity released into the supernatant was measured by scintillation counting.
Generation of N-terminally-tagged TREX1 constructs
To directly visualize TREX1 within the living cell, all TREX1 forms were N-terminally 
tagged with the enhanced yellow fluorescent protein (eYFP). For clarity, the epitope tag is 
designated hereafter as fluorescent protein (FP) tag. At the wavelength employed it gives green 
fluorescence. The FP coding sequence was excised via EcoRI/BsrGI from sT-DAF-eY.1 This 
fragment was utilized in a three-fragment ligation with EcoRI/XbaI-digested CD59dGPI2 and 
the respective BsrGI/XbaI-digested PCR- derived TREX1 forms (see below). This resulted in 
amino-terminal tagging of TREX1 FP-TREX1, FP-V235fs and FP-T249fs). Wild-type FP was 
expressed from the second cistron of sT-DAF. Wild-type TREX1 (FP-TREX1) was used as a 
template DNA to generate the Aicardi-Goutières R114H mutant (FP-R114H) by site-directed 
mutagenesis as described above. To study the effect on cellular localization of the carboxyl-
terminus of TREX1, a FP-tagged fusion protein containing the last 106 amino acids of native 
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TREX1 was generated (FP-C106). A 646 bp BsrGI/BsaI fragment was excised from FP-TREX1, 
to remove the entire amino-terminus including all exonuclease sites. The cohesive ends were 
then blunted and the linearized 4532 bp fragment relegated, resulting in FP-C106. All PCR-
derived DNA fragments and ligation products were verified by DNA sequencing.
Connfocal Microscopy
HEK293T cells (7 x 105 on cover slides in 6-well plates) were transiently transfected overnight 
with 1.5 µg of each construct using TransIT-293 (Mirus, Madison, WI), according to 
manufacturer’s directions. Following two washes in PBS, the cells were fixed for 30 min at 
room temperature (RT) in PBS containing 2% paraformaldehyde. Following two washes in 
PBS, the cover slides were incubated for 30 min at RT in PBS containing a 1/2000 dilution of 
Topro3 (Molecular Probes, Carlsbad, CA) to visualize the nuclei, washed again with PBS and 
mounted on slides over night with ProLong Gold (Molecular Probes). Samples were examined 
using a Zeiss LSM 510 laser scanning confocal microscope and images were processed using 
Image Examiner Software (Zeiss, Jena, Germany).
Expression, SDS-PAGE, and Western blotting
Following overnight transient transfection of HEK293T cells (described above), cells were 
washed with PBS, lysed with 1% Nonidet P-40, 0.05% SDS in PBS with 2 mM PMSF for 15 min 
at 4ºC, and centrifuged at 12,000 g for 10 min. Supernatants were immediately evaluated or 
frozen at -80 ºC. The Western blot was loaded with 5 x 105 cell equivalents per lane on non-
reduced and electrophoresed (10% SDS-PAG). Following transfer to nitrocellulose, the blots 
were probed with 1:4000 dilution of monoclonal anti-GFP antibody JL-8 that recognizes both 
GFP and YFP (Clontech Laboratories) and then HRP donkey anti-mouse IgG (Amersham 
Biosciences).
Accession codes
GenBank: cDNA and amino acid numbering was determined using the TREX1 protein 
AAK07616 and nucleotide sequence NM_033627 (with the A at 2986 as the first base of the 
initiating ATG codon).
URLs
The UCSC Genome Browser is available at http://genome.ucsc.edu/. The Marshfield 
chromosome 3 genetic map is found at http://research.marshfieldclinic.org/genetics.
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Background: We have shown that Cerebroretinal Vasculopathy (CRV), Hereditary Vascular 
Retinopathy (HVR), and Hereditary Endotheliopathy, Retinopathy, Nephropathy and Stroke 
(HERNS) are one disease caused by C-terminal frame-shift mutations in the DNA exonuclease 
TREX1. Here we define the clinicopathologic spectrum of this newly recognized and commonly 
misdiagnosed syndrome which we have renamed CHARIOT.
Methods: Standardized review of clinical, radiological, pathological and genetic findings in 11 
unrelated families with CHARIOT. 
Findings: We identified five distinct TREX1 mutations in 78 subjects. Sixty-five mutation 
carriers had the characteristic clinical syndrome, similar across all mutations, of a vascular 
retinopathy followed by progressive focal neurological symptoms in association with white 
matter hyperintensities and contrast-enhancing frontoparietal mass lesions, often featuring 
massive edema. Mean (± SD) age at diagnosis was 42·9 ± 8·3 and at death 53·1 ± 9·6 years. Other 
cerebral manifestations were migraine (59%), cognitive decline (56%), psychiatric disturbances 
(42%) and seizures (17%). Non-cerebral involvement was typically mild and included anemia 
(74%), impaired liver (70%) and renal (50%) function, hypertension (60%) and Raynaud’s 
phenomenon (40%). Pathological examination demonstrated a systemic vasculopathy with 
luminal narrowing and multi-laminated basement membranes. Presymptomatic mutation 
carriers (N=13; mean age: 35·1 ± 10·6 years) had Raynaud’s phenomenon (54%), migraine 
(42%) and psychiatric symptoms (23%).
Interpretation: CHARIOT is an autosomal dominant, progressive, systemic small-vessel 
disease mainly characterized by progressive blindness due to vascular retinopathy, relentless 
neurological decline caused by cerebral mass and white matter lesions, and premature death. 
We propose diagnostic criteria to aid clinical recognition of this new disease.
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INTRODuCTION
Cerebroretinal Vasculopathy (CRV),1 Hereditary Vascular Retinopathy (HVR)2, 3 and Hereditary 
Endotheliopathy, Retinopathy, Nephropathy and Stroke (HERNS)4 are autosomal dominant 
diseases initially described as independent entities. By concentrating on shared features of 
vascular retinopathy and brain lesions our international consortium mapped a common locus 
to chromosome 3p21·1-p21·35 and subsequently identified pathogenic heterozygous C-terminal 
frame-shift mutations in the TREX1 gene. TREX1 encodes a 3′-5′ DNA exonuclease involved in 
clearing cytosolic nucleic acids.6 Thus, the three diseases were united into a single disorder and 
termed Retinal Vasculopathy with Cerebral Leukodystrophy.6 Here we report a retrospective 
analysis of 78 TREX1 mutation carriers from 11 unrelated families and provide the first 
comprehensive characterization of its genetic, clinical, neuro-radiological and pathological 
spectrum. The disease is commonly misdiagnosed as brain tumor, multiple sclerosis, or a 
central nervous system vasculitis. Prompted by the emerging clinical picture, pathogenesis, 
and absence of “leukodystrophy”, we renamed the disease CHARIOT: Cerebral Hereditary 
Angiopathy with vascular Retinopathy and Impaired Organ function caused by TREX1 
mutations. To facilitate clinical recognition of CHARIOT, we formulated diagnostic criteria.
METhODS
We retrospectively evaluated medical records of 78 TREX1 mutation carriers (35 females; 
43 males) from 11 unrelated families from The Netherlands (3 families; n=37), USA (5 families; 
n=32), Australia (2 families; n=5), and Germany (1 family; n=4). Some genetic and clinical data 
from families 1-5 and 7-11 have been previously published in brief;1-9 family 6 was recently 
identified and not reported before (Supplementary Table S1 and S2).
The institutional ethics committee at each participating institution approved the study 
and all living subjects provided written informed consent. Demographic and relevant clinical 
information was obtained from the medical records prior to September 1, 2009. All patients 
were personally interviewed and examined by one or more of the authors.
Vascular retinopathy was diagnosed from ophthalmologic reports of fundoscopic 
examination and fluorescein angiography. Cerebral lesions were identified by review of images 
on brain computed tomography (CT) or magnetic resonance imaging (MRI). Migraine,10 liver 
and renal dysfunction, anemia, Raynaud’s phenomenon11 and hypertension were diagnosed 
according to established international criteria. Pathological findings were obtained from 
biopsy and autopsy reports in families 1, 2, 5 and 7-11. Neuropathologic data of families 1 and 
7-9 have in part been previously published.1, 4, 8, 9






Five distinct C-terminal frame-shift TREX1 mutations were identified (Chapter 8, Figure 1a). 
A clinical diagnosis of CHARIOT was made in 65/78 mutation carriers based on the presence 
of vascular retinopathy (n=64) or cerebral mass lesion with unknown retinopathy status (n=1) 
(Mutation carriers with symptomatic CHARIOT; MC+). Thirteen mutation carriers did not 
have vascular retinopathy or cerebral mass lesions at the time of inclusion in the study (MC-). 
Clinical, demographic, and neuro-radiological characteristics of living and deceased mutation 
carriers are summarized in Table 1. The clinical phenotype was similar across all mutations 
(Supplementary Table S1).
Mutation carriers with symptomatic CHARIOT (MC+)
Initial presentation and diagnosis (Table 1)
All 65 MC+ had developed a vascular retinopathy and/or cerebral mass lesion by middle 
age. Mean (± SD) age at clinical diagnosis was 42·9 ± 8·3 years (range 25-61). At the time 
of diagnosis, visual disturbances were present in 50/65 (77%) MC+; ten of them also had 
neurological symptoms. Asymptomatic retinopathy was discovered on screening because of 
neurological symptoms (n=4) or a family history of CHARIOT (n=5). For the remaining six 
MC+, documentation of initial symptoms (n=3) or visual function and retinal examinations 
were unavailable at the time of diagnosis (n=3). Thus, retinopathy was present at initial 
diagnosis in all MC+ with available data. Although the majority sought medical attention 
because of visual symptoms, a quarter did so because of neurological symptoms. A typical case 
of CHARIOT is described in the legend of Figure 1.
Vascular Retinopathy
Visual symptoms attributable to retinopathy included decreased acuity and field defects. 
Retinopathy could be visualized by fundoscopy, but was better appreciated with fluorescein 
angiography. Early stages were characterized by telangiectasias, micro-aneurysms and 
cotton wool spots (Fig. 2A, B) and, in the later stages, by perifoveal capillary obliteration and 
neovascularization (Fig. 2C, D). Histopathologic examination of the retina at autopsy (n=8) 
was consistent with scattered micro-infarcts. The retinal arteries had thickened hyalinized 
walls (Fig. 3A) and there were focal areas of disruption to the ganglion cells and inner nuclear 
layer of the retina, usually accompanied by vascular changes. In some, the pathologic process 
had progressed to retinal hemorrhage and neovascularization. 
Cerebral Manifestations
All MC+ showed progressive focal neurological symptoms and/or cognitive impairment in 
association with an ever-increasing number and size of brain lesions (Table 1). Of the MC+ 
who were still alive at the time of the study, 12/30 (40%) had focal neurological symptoms and 
11/29 (38%) had cognitive impairment, manifesting as bradyphrenia, apathy, irritability, and 
impaired memory and judgment. Of the MC+ who had already died, 28/29 (97%) had focal 
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Number of mutation carriers 30 35 13
Age at last follow-up or death
Mean ± SD (yr) 47·3± 8·1 53·1± 9·6 35·1± 10·6
Range (yr) 34-62 32-72 18-58
Major signs/symptoms*
Retinopathy 100 (30/30) 100 (34/34) 0 (0/12)
Age at diagnosis retinopathy
Mean ± SD (yr) 41.2± 8.4 43.7± 7.7 N/A
Range (yr) 25-56 30-61 N/A
Cerebral
Focal neurological 40 (12/30) 97 (28/29) 0 (0/13)
Cognitive decline 38 (11/29) 75 (21/28) 8 (1/13)
Migraine 48 (12/25) 75 (12/16) 42 (5/12)
Seizures 7 (2/27) 26 (7/27) 0 (0/12)
Psychiatric 31 (9/29) 52 (17/33) 23 (3/13)
Neuroradiology*
White matter disease 95 (19/20#) 100 (28/28) 33 (1/3)
Mass occupying lesions 75 (15/20) 91 (21/23^ )̂ 0 (0/3)
White matter hyperintensities** 95 (18/19) 100 (16/16) 33 (1/3)
Calcifications*** 71 (5/7) 45 (9/20) Not Tested
Other organs involved*
Liverv 65 (11/17) 74 (17/23) Not Tested
Kidneyv 50 (9/18) 50 (13/26) 0 (0/1)
Possible associations*
Anemia 67 (8/12) 77 (17/22) Not Tested
Hypertension 47 (9/19) 68 (21/31) 0 (0/2)
Raynaud’s phenomenon 52 (14/27) 30 (10/33) 54 (7/13)
Gastrointestinal bleeding/telangiectasias 3 (1/30) 24 (8/34) 0 (0/13)
MC+: Mutation carriers with retinopathy or cerebral mass lesions; MC-: Mutation carriers without retinopathy 
or cerebral mass lesions. * Unless indicated otherwise, the disease manifestations presented in the table are 
shown as percentage of subjects followed by the number of subjects. The denominator varies according to the 
number of individuals with available data. # One subject with no evidence of white matter hyperintensities had 
an MRI done within 1 year of diagnosis with retinopathy. ^ Ten mutation carriers are from family 1 (mutation 
V235fs), 2 mutation carriers from family 11 (mutation L287fs), 1 from family 8 (mutationT249fs, this patient 
committed suicide at age 30). ^^ Five patients were excluded since the last neuroimaging available was more than 




Figure 1. Presentation and progression of a typical case of CHARIOT.
At age 52, this man (family 2, V235fs mutation) reported progressive bilateral loss of vision. Ophthalmologic 
evaluation revealed a vascular retinopathy. At age 58 he developed a slowly progressive right-sided hemipare-
sis. He became intermittently irritable and passive and complained of headaches. His medical history revealed 
Raynaud’s phenomenon and paroxysmal atrial fibrillation. In the left frontal white matter, there was a rim-en-
hancing lesion with mass-effect and surrounding edema on MRI (gadolinium enhanced T1-weighted in A1, non-
enhanced T1-weighted in A2). This lesion demonstrated focal calcifications on CT (not shown). Two smaller 
rim-enhancing lesions were noted periventricularly in the right frontal (T1-weighted in A3, non-enhanced T1-
weighted in A4) and parietal lobes (gadolinium enhanced T1-weighted in A5, non-enhanced T1-weighted in 
A6). A biopsy of the left fronto-parietal lesion revealed tissue necrosis. Dexamethasone (60 mg for 10 days) 
was started with slight improvement of the hemiparesis. Four months later, his headaches became worse and he 
developed word-finding difficulties and a wide-based gait in addition to his right-sided hemiparesis. Routine 
laboratory investigation showed a mild anemia and mildly impaired renal and liver function. There was a mild 
increase in cerebrospinal fluid protein with normal cell count and no oligoclonal bands. Antinuclear antibod-
ies, extractable nuclear antigens, anticardiolipin IgG and IgM and anti-neutrophilic cytoplasmic antibodies 
were negative. On MRI, the left frontal lesion had diminished in size, showed now only minimal enhancement, 
although the surrounding edema and/or gliosis remained as a large zone of confluent T2 hyperintensities, with in 
this small nodular foci of faint enhancement (gadolinium enhanced T1-weighted in B1, FLAIR in B2).
Half a year later his condition worsened and he became easily agitated with emotional lability, disorientation, apathy 
and urinary incontinence. Additionally, he developed a left-sided hemiparesis with facial weakness and could walk 
only with assistance. MRI showed at the location of the pre-existing punctate enhancing white matter lesion now 
a large irregularly rim-enhancing lesion with central necrosis, and a large zone of surrounding edema extending 
in the corpus callosum, basal ganglia and parietal and temporal lobe, with some mass-effect of the right lateral 
ventricle; the pre-existing lesion adjacent to the parietal horn of the right lateral ventricle did not change signifi-
cantly (gadolinium enhanced T1-weighted in C1, FLAIR in C2). A second biopsy showed mainly necrotic tissue. 
Corticosteroids provided temporary improvement of his gait. A repeat MRI two months later showed persistence 
of the right frontal lesion (gadolinium enhanced T1-weighted in D1 and D2). Open biopsy and partial debulking of 
the right frontal lesion was performed. Pathology showed largely necrotic tissue with scattered inflammatory cells, 
mainly around the vessel walls, which were thickened with adventitial fibrosis. In the following year, his condition 
deteriorated and he died of aspiration pneumonia at age 60. An autopsy was performed (data included in Figure 3).
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neurological symptoms on examination prior to death and at least 21/28 (75%) had cognitive 
impairment. The single deceased MC+ without focal neurological symptoms or cognitive 
impairment died of heart disease two years after diagnosis of retinopathy. 
Formal neuropsychological testing was performed in six MC+ with cognitive decline: five 
had dementia and one had mild cognitive impairment. In the five MC+ tested because of mild 
subjective complaints or scientific interest, no abnormalities were found.
Other brain symptoms included: migraine (24/41; 59%), seizures (9/54; 17%), and personality 
changes and psychiatric complaints, in particular depression and anxiety (26/62; 42%) (Table 1). 
In the 22 migraineurs in whom the subtype could be determined, six (27%) had migraine with 
aura and 16 (73%) had migraine without aura. In 14/17 (82%) migraineurs with a recorded age 
of migraine onset, the attacks had begun well before the visual or cerebral symptoms.
Premature death
Thirty-five MC+ were deceased at a mean age of 53·1 + 9·6 years (range 32-72), primarily from 
complications of the neurological decline. One MC+ had died of heart disease. Mean survival 
time from symptom onset was 9·0 + 6·7 years (range <1-26 years).
Neuroimaging
Neuroimaging was available for 48 MC+: both MRI and CT for 14, only MRI for 21, and only 
CT for 13. All lesions were restricted to the white matter with sparing of gray matter. Two types 
of lesions were regularly observed, often together: (i) focal, non-enhancing T2-hyperintense 
lesions scattered throughout the periventricular and deep white matter; and (ii) mass lesions 
that were T2-hyperintense and T1-hypointense, enhanced with gadolinium contrast, and 
usually were surrounded by extensive edema displacing adjacent structures leading to sulcal 
effacement (Fig. 1 and 4). 
White matter hyperintensities typically were present early in the clinical course and were 
detected on MRI in all MC+ except for one who had been diagnosed with retinopathy for less 
than a year (34/35; 97%). Although non-specific, the lesions were excessive for the relatively 
young patient age and indicative of CHARIOT when found in combination with retinopathy 
and a family history of CHARIOT symptoms.
Mass lesions were observed in 36/43 (84%) MC+, sometimes at initial diagnosis but 
more frequently with advanced disease (Table 1). They were commonly associated with focal 
neurological symptoms (31/36; 86%). In all individuals with mass lesions, there was a lesion in 
the fronto-parietal lobe (26/26; 100%); additional lesions were sometimes seen in the cerebellum 
(1/26) and occipital lobe (1/26). The space occupying lesions usually grew with time, but also 
could remain stable or diminish in size (Fig. 4a).12 Often they developed superimposed on pre-
existing white matter hyperintensities. In five cases, restricted diffusion was observed, which 
was most pronounced at the center of the lesions and could persist for months. In 14/27 (52%) 
cases calcifications were seen on CT. Hemorrhage was not a typical feature (1/36).
Neuropathology
Neuropathologic examination was performed on 13 autopsy and 7 biopsy specimens from 
20 MC+. The gross pathology at autopsy demonstrated minimal to marked involvement of 
the periventricular white matter, particularly the fronto-parietal lobes and occasionally the 
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brainstem and cerebellum. Microscopic examination showed similar findings for both mass 
lesions and the smaller, scattered lesions seen on neuroimaging. Multiple, often confluent, foci 
of coagulation necrosis were identified in the white matter with sparing of the grey matter. The 
larger affected areas had extensive necrosis with focal calcification (Fig. 3B).
On microscopic evaluation a striking vasculopathy affecting the medium and small caliber 
arteries characterized these necrotic foci and adjacent white matter (Fig. 3B). Fibrinoid necrosis, 
adventitial fibrosis, luminal narrowing and mural hyalinization with collagenous material 
were hallmarks of the vasculopathy (Fig. 3B, C, D). Occasionally, vascular telangiectasias 
were observed. In some cases, a modest chronic inflammatory cell infiltrate, consisting 
predominantly of perivascular and parenchymal lymphocytes and plasma cells, was found 
near ischemic lesions. The cellular infiltrate was most consistent with a reaction to ischemic 
brain tissue without evidence of destruction or invasion of the vascular wall.
Focal calcifications and reactive astrocytosis were frequent findings. Myelin loss was substantial 
at autopsy. Neurofilament immunolocalization showed concomitant axon loss and frequently large 
numbers of swollen axonal spheroids, consistent with an ischemic process. Electron microscopy 
showed irregular thickening and splitting of the basement membranes in vessel walls (Fig. 3E), 
especially in the media with signs of smooth muscle cell and pericyte degeneration.
Figure 2. Fundoscopic (A and C) and fluorescein angiogram (B and D) images of the vascular retinopathy. Right 
eye of a 33-year-old man with cotton-wool spots (arrows, A), extensive areas of capillary obliteration with non-per-
fusion (arrows, B), and intraretinal microvascular abnormalities (arrowheads, B). Right eye of a 48-year-old woman 
with a neovascular membrane (arrowheads, C) and preretinal hemorrhage (arrow, C). Temporal to the macula, 
vascular sheathing and occlusion is present (asterix, C). The same eye shows profuse leakage from the membrane on 
the disc (arrow, D) and a large avascular region involving the fovea (arrowheads, D).
122
9
the clInIcal Spectrum of charIot/rVcl
Figure 3. Representative histopathologic findings in the retina, brain and kidney. Microscopic examination of 
various organs shows a characteristic vasculopathy. The vessels of the inner layers of the retina often demonstrate 
damage to the walls with occasional deposition of amorphous material [arrow; panel A, hematoxylin and eosin 
(H&E) stain; vitreous (Vit); nerve fiber layer (NL); ganglion cell layer (GCL); inner plexiform layer (IPL); inner 
nuclear layer (INL); outer plexiform layer (OPL)] or thickened collagenous walls. The brain also shows a prominent 
vasculopathy in the white matter, most often adjacent to and in sites of coagulation necrosis. Small to medium sized 
vessels demonstrate vascular wall thickening with varying degrees of luminal narrowing (arrows; panel B; H&E; 
brain). In some cases, this progresses to a frank fibrinoid necrosis. In areas with extensive white matter ischemic 
damage, granular calcifications are particularly evident (dark blue staining in lower left of panel B). The vasculopa-
thy may result in luminal obliteration leading to parenchymal necrosis (panel C; H&E; brain). There is concentric 
collagenous thickening of the vessel walls, mostly involving the medial layer of the vessels (panel D;Trichrome stain; 
brain). Ultrastructural examination of affected vessel walls in the brain demonstrates multilaminated basement 
membranes with duplication of the lamina densa [arrowheads; panel E; electron microscopy; lumen (lum); endo-
thelial cell (en)] in contrast to that found in unaffected regions (arrowhead; panel F; electron microscopy). In the 
kidney, the vasculopathy is manifested by arteriosclerosis (arrow; panel G; H&E) and glomerulosclerosis.
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Figure 4a. Characteristic dynamic changes over time of contrast-enhancing cerebral mass lesions and white 
matter hyperintensities in a patient with CHARIOT. The first MRI shows punctate T2-hyperintense periventricu-
lar lesions (0 months, Axial FLAIR). Nineteen months later, a right frontal rim-enhancing lesion with associated 
calcification (unenhanced CT) and perifocal edema (gadolinium enhanced T1-weighted MRI) has developed on 
the location of a pre-existing punctate white matter hyperintensity. MRIs at two, five and eleven months after corti-
costeroid treatment for several weeks with clinical improvement show progressive reduction of the cerebral edema 
and contrast enhancement (gadolinium enhanced T1-weighted MRIs). Note the slight contrast-enhancement (at 
19-30 months) and associated calcification also in the punctate T2 hyperintensities periventricularly on the left site. 
Other affected organs
Liver
Liver-chemistry was abnormal in 28/40 (70%) MC+, typically showing modest elevations of 
alkaline phosphatase and gamma glutamyltransferase. Histologic examination of biopsy and 
autopsy specimens showed pathologic changes in 13 MC+ of whom three had normal laboratory 
parameters. The predominant finding was nodular regenerative hyperplasia (Supplementary 
Fig. S1). Other findings included micro- or macro-vesicular steatosis, periportal inflammation 
and portal or bridging fibrosis.
Kidney
In 22/44 (50%) MC+ renal disease was manifested clinically by a mild to moderate increase in 
serum creatinine (< 2·0 mg/dL) and/or proteinuria (< 2 g/24hr). Pathological findings on biopsy 
or autopsy specimens were noted in 18 MC+ including five who had normal laboratory values. 
The predominant lesions were arteriolosclerosis or arteriolonephrosclerosis and focal to diffuse 
global glomerulosclerosis (Fig. 3G). In one patient, renal disease was detected prior to retinopathy.
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Figure 4b. Cerebral MRI scans of patients with different frame-shift mutations.
V235fs: Axial T1-weighted (left) and axial gadolinium enhanced T1-weighted (right) MRI images of a 59-year-old 
man (family 2) with a right frontal rim-enhancing lesion with mass-effect and surrounding edema.
T236fs: Axial T1-weighted (left) and axial gadolinium enhanced T1-weighted (right) images of a 40-year-old 
man (family 7) showing a left frontal rim-enhancing lesion, a smaller rim-enhancing lesion left parietal, and an 
enhancing punctateright frontal periventricular white matter hyperintensity.
T249fs: Axial (left) and coronal (right) gadolinium enhanced T1-weighted images (family 8) show a left frontal 
rim-enhancing lesion with mass-effect and some enhancing punctate T2 hyperintensities in the right frontal lobes.
R284fs: Axial T1-weighted (left) and FLAIR (right) images of a 32-year-old woman (family 10) showing a large right 
frontal rim-enhancing lesion and non-enhancing periventricular white matter hyperintensities frontal left.
L287fs: Saggital T1-weighted images of a 58-year-old man (family 11) reveal small and medium sized non-enhanc-
ing periventricular and subcortical white matter hyperintensities.
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Other possible clinical associations
Other findings observed in MC+ more frequently than in the general population included 
anemia, hypertension, and Raynaud’s phenomenon (Table 1). Normocytic and normochromic 
anemia (25/34; 74%) was typically mild to moderate (hematocrit 27-36%). Of those with anemia, 
six had documented microscopic gastrointestinal bleeding or telangiectasias. Hypertension 
was present in 30/50 (60%) MC+, often with concomitant renal disease (18/26; 69%). Raynaud’s 
phenomenon found in 24/60 (40%) MC+ was mild, without ischemic injury or pulp infarcts, 
and did not require treatment. Autoimmune markers were positive in 3/18 (17%) MC+. Anti-
nuclear antibodies were detected by immunofluorescence on Hep2 substrate in two subjects 
(speckled pattern with a titer of 1:80 and 1:640 respectively) and anti-cardiolipin IgG by ELISA 
in a third.
Mutation carriers without retinopathy or cerebral lesions (MC-)
Thirteen TREX1 mutation carriers had no evidence of retinopathy or cerebral lesions at the 
time of their last examination. Their mean age at last follow-up was 35·1 + 10·6 years (range 
18-58). The most common clinical symptoms noted were Raynaud’s phenomenon (7/13; 54%), 
migraine (5/12; 42%), and psychiatric complaints (3/13; 23%). One MC- committed suicide 
in his twenties. Three MC- underwent MRI scans, which showed only mild white matter 
hyperintensities in one at 45 years of age.
DISCuSSION
We present here the genetic and clinicopathologic spectrum of CHARIOT, a newly recognized 
autosomal dominant, systemic small vessel disease caused by C-terminal frame-shift mutations 
in TREX1. We identified 5 different mutations in 78 subjects from 11 unrelated families and 
found a strikingly similar disease profile. CHARIOT should be considered in individuals in 
middle age with a vascular retinopathy and neuropsychiatric symptoms, particularly if similar 
features are present in family members. Brain imaging will often reveal contrast-enhancing 
mass lesions, white matter hyperintensities and focal calcifications. Genetic testing of TREX1 
can confirm the diagnosis or identify pre-symptomatic patients. Proposed diagnostic criteria 
and other supporting features for CHARIOT are summarized in Table 2. 
Based on our extensive clinical experience of over 20 years with CHARIOT, once patients 
develop retinopathy, all will suffer progressive neurological decline and most will die within 
ten years, usually from pneumonia or sepsis in the setting of severe general debilitation. To 
date, no mutation carrier has lived a normal lifespan without developing CHARIOT, thus 
suggesting 100% penetrance and premature mortality. The 13 MC- were on average ten years 
younger than the MC+ and thus may still develop the full CHARIOT syndrome.
Many patients with CHARIOT also have migraine and Raynaud’s phenomenon, typically 
preceding the onset of retinopathy and cerebral lesions. Compared to the general population, 
migraine prevalence among CHARIOT patients was five times higher in males and nearly 
three times greater in females, using the same diagnostic criteria.13 The prevalence of Raynaud’s 
phenomenon was approximately two times higher in both sexes.14 These statistics suggest that 
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TREX1 mutations have a causal relationship to migraine and Raynaud’s phenomenon as has 
previously been reported in a genetic study of family 2.15 As both migraine and Raynaud’s 
phenomenon are common in the general population, their presence alone cannot be used for 
a definitive clinical diagnosis of CHARIOT. The same applies to other CHARIOT-associated 
symptoms such as nephropathy and hepatic dysfunction. Although typically occurring 
later, they may represent the initial manifestation of CHARIOT, but are too non-specific for 
establishing the diagnosis.
Not surprisingly, many patients were initially misdiagnosed. The vascular retinopathy 
was commonly confused with diabetic retinopathy but the differential diagnosis also includes 
branch retinal vein occlusion, hypertension, sickle cell disease, collagen vascular disease and 
radiation, or idiopathic retinopathy.1,16 The early white matter lesions in CHARIOT were often 
confused with multiple sclerosis, multi-infarct dementia, vasculitis, or other hereditary white 
matter diseases.17,18 Ring-enhancing mass lesions with a necrotic central core and surrounding 
edema were commonly mistaken for neoplasms or tumefactive multiple sclerosis in several 
patients leading to multiple brain biopsies and surgical resection. Some patients with rapid 
progression of neurological symptoms were diagnosed with acute ischemic stroke, but 
diffusion restriction corresponding to a vascular territory was not seen. Interestingly, in some 
of our patients, diffusion restriction indicative of cytotoxic edema was observed in the center 
of a mass lesion. 
The clinical and histopathologic findings are consistent with the hypothesis that the 
systemic small vessel vasculopathy of CHARIOT is caused by an endotheliopathy which 
Table 2. Proposed diagnostic criteria for CHARIOT
Major Diagnostic Criteria
Vascular retinopathy (with in the early phase hemorrhages, intraretinal microvascular abnormalities and/
or cotton wool spots)
Signs and symptoms of progressive focal and/or global brain dysfunction with neuroimaging showing 
contrast-enhancing cerebral mass lesions and/or cerebral white matter hyperintensities
Family history of autosomal dominant inheritance with middle-age onset of disease manifestations#
C-terminal frame-shift mutation in TREX1
Supportive features
Microvascular liver disease (nodular regenerative hyperplasia)




Anemia consistent with blood loss and/or chronic disease
Hypertension
Microscopic gastrointestinal bleeding
# De novo mutations may be possible although none have been reported to date.
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disrupts the vascular basal membrane and leads to progressive loss of microvascular blood 
flow. The histopathologic findings in the brain are reminiscent of delayed radiation necrosis, 
a condition which is believed to be secondary to endothelial cell-dysfunction.19 Electron 
microscopy showed multi-laminated capillary basement membranes in the brain, kidney, 
stomach, appendix, omentum, and skin.4 Capillary occlusion is suggested by retinal and 
cerebral vessel wall thickening and lumen obliteration, as well as a number of other pathologies. 
These include nodular regenerative liver hyperplasia, which is likely due to diminished hepatic 
blood flow,20 and renal arteriosclerosis, arteriolosclerosis, and glomerulosclerosis, which, like 
microscopic gastrointestinal bleeding, are probable manifestations of small vessel disease.
Several studies support a role for TREX1 in immunity. Absence of functional TREX1 
results in accumulation of single-stranded DNA in cells and multi-organ inflammation in 
knock-out mice.21 -23 In humans, mutations that abolish TREX1 exonuclease activity are 
associated with three different autoimmune diseases: autosomal recessive Aicardi-Goutières 
syndrome (AGS), autosomal dominant familial chilblain lupus (FCL), and systemic lupus 
erythematosus (SLE). AGS is associated with complete absence of exonuclease activity and 
mimics an in utero viral encephalopathy, possibly secondary to activation of the immune 
system by host DNA.24 Heterozygous TREX1 mutations are found in FCL, an autoimmune 
disease that primarily affects the skin.25,26 Rare variants in TREX1 have also been associated 
with SLE in some patients.27 Further support for a role in innate immunity comes from 
studies demonstrating that TREX1 degrades HIV-1 DNA generated during infection, thereby 
preventing an interferon-mediated immune response.28
In contrast to the mutations seen in other TREX1 diseases, CHARIOT TREX1 frame-shift 
mutations result in a mislocalized but functional exonuclease and are likely associated with 
a gain-of-function or toxic effect. Unlike the role for immunity in AGS, FCL and SLE, the 
cerebral pathology of CHARIOT does not resemble an autoimmune disease as features of 
vasculitis are missing. However, auto-immunity may play a role, especially in the derailment 
of mass lesions at a certain age.
Since the initial description of the disease in 1988,1 we have identified ten additional 
families, expanded and better delineated the clinical phenotype and discovered the causal gene. 
However, treatment to prevent, reverse or halt the disease is still lacking. Immunosuppressive 
agents, including cyclophosphamide, were given to a few individuals without benefit (Atkinson, 
unpublished data). Intra-vitreal bevacizumab was effective for the proliferative retinopathy in 
a single patient.29 Corticosteroids can reduce cerebral vasogenic edema, but do not improve the 
underlying lesions. Further research is needed to determine the pathogenesis of CHARIOT 
and develop effective treatments for this devastating disorder. 
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Table S1. Manifestation of CHARIOT for clinically affected and unaffected individuals subdivided by family 
and mutation status
MC-^ MC+
Mutation V235fs; T249fs; L287fs V235fs T236fs T249fs R284fs L287fs
Origin Dutch; US Dutch; US; Australia German US Australia Dutch
Original disease name HVR; HERNS CRV; US HVR; Dutch HERNS; US
Family number 2, 8, 11 1, 2, 3, 4, 5, 6 1 2 7 8, 9 8 10 11
Demographics
Number of mutation carriers 13 43 18 20 4 11 10 3 4
Age at last follow-up or death
Mean ± SD (yr) 35·1 ± 10·6 52·6 ± 8·3 51·0 ± 5·9 55·4 ± 9·7 41^^ 46·4 ± 9·1 44·4 ± 7·8 40·7 ± 5·0 49·0 ± 17·1
Range (yr) 18-58 35-72 41-62 35-72 N/A 32-60 32-53 36-46 34-68
Major signs/symptoms*
Retinopathy 0 (0/12) 100 (42/42) 100 (17/17) 100 (20/20) 100 (4/4) 100 (11/11) 100 (10/10) 100 (3/3) 100 (4/4)
Age at diagnosis retinopathy
Mean ± SD (yr) N/A 45·1 ± 6·9 45·0 ± 4·7 45·5 ± 8·0 39·8 ± 6·9 33·4 ± 2·6 33·4 ± 2·6 34·0 ± 8·5 44·3 ± 11·9
Range (yr) N/A 35-61 40-55 35-61 30-46 30-37 30-37 25-42 33-56
Cerebral
Focal neurological 0 (0/13) 66 (25/38) 94 (15/16) 41 (7/17) 75 (3/4) 82 (9/11) 80 (8/10) 67 (2/3) 33 (1/3)
Cognitive decline 8 (1/13) 62 (23/37) 88 (15/17) 38 (6/16) 67 (2/3) 36 (4/11) 30 (3/10) 67 (2/3) 33 (1/3)
Migraine 42 (5/12) 54 (13/24) 50 (1/2) 60 (12/20) 0 (0/2) 88 (7/8) 88 (7/8) 100 (3/3) 25 (1/4)
Psychiatric 23 (3/13) 45 (19/42) 56 (10/18) 40 (8/20) 33 (1/3) 27 (3/11) 30 (3/10) 100 (3/3) 0 (0/3)
Seizure 0 (0/12) 14 (6/43) 28 (5/18) 5 (1/20) 0 (0/4) 100 (1/1) Unknown 67 (2/3) 0 (0/3)
Neuroradiology*
White matter disease 33 (1/3) 97 (30/31#) 100 (14/14) 92 (11/12#) 100 (2/2) 100 (11/11) 100 (10/10) 100 (3/3) 100 (1/1)
Mass occupying lesions 0 (0/3) 65 (20/31) 79 (11/14) 33 (4/12) 100 (2/2) 100 (11/11) 100 (10/10) 67 (2/3) 100 (1/1)
White matter hyperintensities** 33 (1/3) 96 (23/24) 100 (8/8) 91 (10/11) 100 (2/2) 100 (6/6) 100 (5/5) 100 (2/2) 100 (1/1)
Calcifications*** Not Tested 56 (9/16) 56 (5/9) 57 (4/7) Not Tested 38 (3/8) 29 (2/7) 67 (2/3) Not Tested
Other organs involved*
LiverV Not Tested 65 (20/31) 56 (9/16) 90 (9/10) 100 (4/4) 100 (1/1) Not Tested 67 (2/3) 100 (1/1)
KidneyV 0 (0/1) 34 (10/29) 36 (5/14) 27 (3/11) 50 (1/2) 78 (7/9) 75 (6/8) 100 (3/3) 100 (1/1)
Possible associations*
Anemia Not tested 70 (21/30) 80 (12/15) 50 (6/12) Not Tested 100 (1/1) Not Tested 100 (3/3) Not Tested
Hypertension 0 (0/2) 53 (19/36) 56 (10/18) 40 (6/15) Not Tested 78 (7/9) 75 (6/8) 67 (2/3) 100 (2/2)
Raynaud’s phenomenon 54 (7/13) 49 (20/41) 6 (1/18) 85 (17/20) 0 (0/2) 0 (0/11) 0 (0/10) 0 (0/2) 100 (4/4)
Gastrointestinal bleeding/
telangiectasias
0 (0/13) 16 (7/43) 33 (6/18) 5 (1/20) 50 (2/4) 0 (0/11) 0 (0/10) 0 (0/3) 0 (0/3)
MC+: Mutation carriers with retinopathy or cerebral mass lesions; MC-: Mutation carriers without retinopathy or 
cerebral mass lesions. * Unless indicated otherwise, the disease manifestations presented in the table are shown 
as percentage of subjects followed by the number of subjects. The denominator varies according to the number 
of individuals with available data. ^ Ten mutation carriers from family 1 (mutation V235fs), 2 mutation carriers 
from family 11 (mutation L287fs), 1 from family 8 (mutationT249fs, this patient committed suicide at age 30). 
^^ Data on one patient only. N/A: Not Applicable. # One subject with no evidence of white matter hyperintensities 
had an MRI done within 1 year of diagnosis with retinopathy. ** Based on MRI scans only. *** Based on CT scans. 
V Based on laboratory values. The five patients that were excluded from the neuro-imaging section in the deceased 
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Table S1. Manifestation of CHARIOT for clinically affected and unaffected individuals subdivided by family 
and mutation status
MC-^ MC+
Mutation V235fs; T249fs; L287fs V235fs T236fs T249fs R284fs L287fs
Origin Dutch; US Dutch; US; Australia German US Australia Dutch
Original disease name HVR; HERNS CRV; US HVR; Dutch HERNS; US
Family number 2, 8, 11 1, 2, 3, 4, 5, 6 1 2 7 8, 9 8 10 11
Demographics
Number of mutation carriers 13 43 18 20 4 11 10 3 4
Age at last follow-up or death
Mean ± SD (yr) 35·1 ± 10·6 52·6 ± 8·3 51·0 ± 5·9 55·4 ± 9·7 41^^ 46·4 ± 9·1 44·4 ± 7·8 40·7 ± 5·0 49·0 ± 17·1
Range (yr) 18-58 35-72 41-62 35-72 N/A 32-60 32-53 36-46 34-68
Major signs/symptoms*
Retinopathy 0 (0/12) 100 (42/42) 100 (17/17) 100 (20/20) 100 (4/4) 100 (11/11) 100 (10/10) 100 (3/3) 100 (4/4)
Age at diagnosis retinopathy
Mean ± SD (yr) N/A 45·1 ± 6·9 45·0 ± 4·7 45·5 ± 8·0 39·8 ± 6·9 33·4 ± 2·6 33·4 ± 2·6 34·0 ± 8·5 44·3 ± 11·9
Range (yr) N/A 35-61 40-55 35-61 30-46 30-37 30-37 25-42 33-56
Cerebral
Focal neurological 0 (0/13) 66 (25/38) 94 (15/16) 41 (7/17) 75 (3/4) 82 (9/11) 80 (8/10) 67 (2/3) 33 (1/3)
Cognitive decline 8 (1/13) 62 (23/37) 88 (15/17) 38 (6/16) 67 (2/3) 36 (4/11) 30 (3/10) 67 (2/3) 33 (1/3)
Migraine 42 (5/12) 54 (13/24) 50 (1/2) 60 (12/20) 0 (0/2) 88 (7/8) 88 (7/8) 100 (3/3) 25 (1/4)
Psychiatric 23 (3/13) 45 (19/42) 56 (10/18) 40 (8/20) 33 (1/3) 27 (3/11) 30 (3/10) 100 (3/3) 0 (0/3)
Seizure 0 (0/12) 14 (6/43) 28 (5/18) 5 (1/20) 0 (0/4) 100 (1/1) Unknown 67 (2/3) 0 (0/3)
Neuroradiology*
White matter disease 33 (1/3) 97 (30/31#) 100 (14/14) 92 (11/12#) 100 (2/2) 100 (11/11) 100 (10/10) 100 (3/3) 100 (1/1)
Mass occupying lesions 0 (0/3) 65 (20/31) 79 (11/14) 33 (4/12) 100 (2/2) 100 (11/11) 100 (10/10) 67 (2/3) 100 (1/1)
White matter hyperintensities** 33 (1/3) 96 (23/24) 100 (8/8) 91 (10/11) 100 (2/2) 100 (6/6) 100 (5/5) 100 (2/2) 100 (1/1)
Calcifications*** Not Tested 56 (9/16) 56 (5/9) 57 (4/7) Not Tested 38 (3/8) 29 (2/7) 67 (2/3) Not Tested
Other organs involved*
LiverV Not Tested 65 (20/31) 56 (9/16) 90 (9/10) 100 (4/4) 100 (1/1) Not Tested 67 (2/3) 100 (1/1)
KidneyV 0 (0/1) 34 (10/29) 36 (5/14) 27 (3/11) 50 (1/2) 78 (7/9) 75 (6/8) 100 (3/3) 100 (1/1)
Possible associations*
Anemia Not tested 70 (21/30) 80 (12/15) 50 (6/12) Not Tested 100 (1/1) Not Tested 100 (3/3) Not Tested
Hypertension 0 (0/2) 53 (19/36) 56 (10/18) 40 (6/15) Not Tested 78 (7/9) 75 (6/8) 67 (2/3) 100 (2/2)
Raynaud’s phenomenon 54 (7/13) 49 (20/41) 6 (1/18) 85 (17/20) 0 (0/2) 0 (0/11) 0 (0/10) 0 (0/2) 100 (4/4)
Gastrointestinal bleeding/
telangiectasias
0 (0/13) 16 (7/43) 33 (6/18) 5 (1/20) 50 (2/4) 0 (0/11) 0 (0/10) 0 (0/3) 0 (0/3)
MC+: Mutation carriers with retinopathy or cerebral mass lesions; MC-: Mutation carriers without retinopathy or 
cerebral mass lesions. * Unless indicated otherwise, the disease manifestations presented in the table are shown 
as percentage of subjects followed by the number of subjects. The denominator varies according to the number 
of individuals with available data. ^ Ten mutation carriers from family 1 (mutation V235fs), 2 mutation carriers 
from family 11 (mutation L287fs), 1 from family 8 (mutationT249fs, this patient committed suicide at age 30). 
^^ Data on one patient only. N/A: Not Applicable. # One subject with no evidence of white matter hyperintensities 
had an MRI done within 1 year of diagnosis with retinopathy. ** Based on MRI scans only. *** Based on CT scans. 
V Based on laboratory values. The five patients that were excluded from the neuro-imaging section in the deceased 
category of Table 1 (because the last scan was made more than 5 years before death) are included in this table.
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3688_3689insG V235fs 18 1
2 Netherlands 3688_3689insG V235fs 30 2, 3
3 North America
(Ashkenazi-Jewish)
3688_3689insG V235fs 1 1
4 North America 3688_3689insG V235fs 1 6
5 Australia 3688_3689insG V235fs 2 6
6 Netherlands 3688_3689insG V235fs 1 Unpublished
7 Germany 3691_3692insA T236fs 4 8
8 North America
(Chinese)
3727_3730dupGTCA T249fs 11 4
9 North America 3727_3730dupGTCA T249fs 1 9
10 Australia 3835_3836insA R284fs 3 7
11 Netherlands 3843_3844insG L287fs 6 6
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Figure S1. Regenerative hyperplasia and capillarization of the liver. The liver shows an abnormal parenchymal ar-
chitecture (Panel A and B; hematoxylin and eosin (H&E) stains and panel C and D, reticulin stains) In A, the portal 
tracts (seen on the right) and terminal hepatic venules are unevenly spaced; in addition, a vague nodule is present 
centrally. Within the boxed area in B, the nodule is comprised of hepatic cords delineated from surrounding paren-
chyma by blood-filled sinusoids. The cords in the latter regions are atrophic (see panel C) compared to the more hy-
pertrophic cords in the center (boxed area in panel D). None of the cords, however, are greater than 2 nuclei broad. 
Panels E and F are immunohistochemical stains highlighting aberrant activation of hepatic stellate cells (boxed area 
in E, anti-smooth muscle actin) and altered sinusoidal endothelial cells with expression of anti-CD34 (boxed area in 
F). The latter signifies a process of closure of sinusoidal endothelial fenestrae and presence of basement membrane. 
These are features of “capillarization” of the sinusoids.
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Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) and Cerebral Autosomal 
Dominant Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CADASIL) 
are cerebral small vessel diseases, which serve as monogenic models for common complex 
neurovascular disorders, such as stroke, dementia and migraine. Impaired vascular reactivity 
is likely to play a role in the pathophysiology of both monogenic disorders, but it remains 
unclear whether this is due to impaired endothelium-dependent or -independent (i.e., mediated 
by direct relaxation of smooth muscle cells) mechanisms. In this study, vascular function tests 
were performed at different levels of the vascular bed to investigate functional changes in 
(arterial) stiffness, vasodilatation of resistance vessels, and endothelial function of conduit 
arteries. Eighteen RVCL and 23 CADASIL patients with TREX1 and NOTCH3 mutations, 
respectively, were compared with 26 matched control subjects. Data shown are uncorrected 
means ± SD and corrected p-values.
Vascular stiffness was assessed by pulse wave analysis and pulse wave velocity. CADASIL 
patients displayed an elevated Aortic Augmentation Index compared to controls (22,8 ± 13,3 
vs. 16,0 ± 12,7 %, p = 0.007); in RVCL patients a similar trend was shown (21,0 ± 13,3 %, 
p = 0.06). Pulse wave velocity was increased in RVCL patients compared to controls (7,8 ± 1,6 
vs. 7,0 ± 1,4 m/s, p = 0.01) and showed a trend in CADASIL patients (7,5 ± 1,5 m/s, p = 0.07 
versus controls). Vasodilatation of dermal microcirculation was reduced in CADASIL but 
not in RVCL, compared to control subjects as characterized by both an attenuated capsaicin-
induced dermal blood flow increase 40 minutes after capsaicin application (1,38 ± 0,88 vs. 
2,22 ± 1,20 Arbitrary Units (AU), p = 0.02) and a lower area under the curve over 40 minutes 
(0,52 ± 0,43 vs. 0,93 ± 0,60 AU, p = 0.02). Endothelium-dependent vasodilatation as assessed 
by flow-mediated dilatation was decreased in RVCL versus controls (2,32 ± 3,83 vs. 5,76 ± 
3,07  %, p =  0.02 versus controls), but not in CADASIL. After correction for shear rate and 
blood viscosity, flow-mediated dilatation remained reduced in RVCL (3,31 ± 7,24 vs. 10,07 ± 
5,73 %, p = 0.03 versus controls). 
We identified endothelial dysfunction in TREX1-mutated RVCL patients and confirmed 
impaired smooth muscle cell relaxation in resistance vessels of NOTCH3-mutated CADASIL 
patients. Increased vascular stiffness illustrates reduced vascular functionality in both 
syndromes. Our findings not only improve insight in RVCL and CADASIL pathophysiology, 
but may also be important to understand common disorders that are part of the disease 
spectrum of these neurovascular disorders, such as stroke, dementia, and migraine.
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INTRODuCTION
Neurovascular diseases such as migraine, (vascular) dementia and ischemic stroke are 
clinically and genetically heterogeneous disorders with a high population prevalence and 
disease burden.1 Comorbidity of these diseases suggests, at least to some extent, shared 
underlying pathophysiological mechanisms. For example, stroke and dementia commonly 
co-occur in cerebral small vessel disease.2 Moreover, migraineurs with aura have a doubled 
risk of ischemic stroke3 and an increased risk of posterior circulation territory infarcts4,5 
and deep white matter hyperintensities.4,6 However, as these common disorders are 
multifactorial and genetically complex it is difficult to identify the causal genes and disease 
pathways. We envisage that RVCL (Retinal Vasculopathy with Cerebral Leukodystrophy) 
and CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy), which are monogenic forms of cerebral small vessel disease with a 
high prevalence of stroke, dementia, and migraine, may serve as useful disease models for the 
common disorders.7,8,9,10 
RVCL is caused by heterozygous C-terminal frameshift mutations in the TREX1 gene, which 
encodes the major 3’-5’ DNA exonuclease that is thought to be involved in clearing cytosolic 
nucleic acids.9,11,12 In RVCL, truncated proteins seem to retain their exonuclease activity but lose 
normal perinuclear localization, which likely interferes with normal functioning of TREX1.9 
RVCL is a systemic vascular syndrome that primarily involves the smaller vessels in the retina 
and the brain.8,13,14,15 Neurological manifestations may include cognitive disturbances, focal 
neurological symptoms, depression, and in 59% of TREX1 mutation carriers migraine. In 
later disease stages, cerebral MRI scans frequently show characteristic contrast-enhancing 
intracerebral mass lesions. Several systemic symptoms can be present as well, including renal 
and liver dysfunction, anemia, and Raynaud’s phenomenon. 
CADASIL is caused by heterozygous mutations in the NOTCH3 gene,7 which encodes 
a cell surface receptor that is solely expressed on adult vascular smooth muscle cells. 
NOTCH3 is involved in a signal transduction pathway critical for development, homeostasis 
and differentiation of vascular smooth muscle cells (VSMCs).16 Clinically, the disease is 
characterized by recurrent transient ischaemic attacks (TIAs) and strokes leading to cognitive 
decline,17 psychiatric symptoms and dementia. Migraine with aura occurs in about one-third 
of patients, often as the first presenting symptom, years before the other symptoms.18 
Both RVCL and CADASIL are small vessel vasculopathies but with different radiological 
features.10 RVCL is characterized by contrast-enhancing cerebral mass lesions that develop 
in the end stage of the disease, typically in combination with (or preceded by the presence 
of) calcifications and non-specific white matter hyperintensities. The most prominent 
radiological features in CADASIL are white matter hyperintensities and lacunar infarcts. 
White matter hyperintensities are symmetrically distributed and located in the deep and 
periventricular white matter. Typical for CADASIL is the bilateral involvement of the 
anterior temporal lobes and external capsule. Other neuroradiological features in CADASIL 




Thickening of the vessel wall leading to lumen stenosis, is a communal feature of the 
cerebral pathology of these arteriopathies. In addition, both in the cerebral and the systemic 
circulation of CADASIL patients, there is a remarkable degeneration of vascular smooth 
muscle cells and deposition of granular osmiophilic material (GOM) in the media/adventitia,21 
with a morphologically largely normal endothelium.18 In contrast, in RVCL, muscle cell 
degeneration is minimal and electron microscopy shows irregular thickening and splitting of 
basement membranes in the vessel wall, which is primarily produced by endothelial cells.22,23 
These changes on cerebral vessels may affect their capability to dilate, which, in addition to 
luminal narrowing, may lead to hypoxia.
In CADASIL, previous studies showed reduced baseline cerebral blood flow and impaired 
hemodynamic reserve (i.e., vasodilation response to acetazolamide) related to the severity 
of white matter hyperintensities.24-26 However, it is not yet clear whether this impaired 
vasoreactivity is caused by an endothelium-independent or -dependent mechanism.27-30 
In RVCL, functional vascular properties have not been studied before. Besides radiological 
and other pathological alterations, the presence of Raynaud’s phenomenon and migraine seems 
to point to altered vascular reactivity. In Raynaud’s phenomenon impaired endothelium-
dependent vasodilatation and a mismatch between endothelium derived vasoconstrictors and 
vasodilators has been observed.31 Migraine has been linked to endothelial dysfunction,32-36 
vascular smooth muscle cell dysfunction,37 increased peripheral arterial stiffness34 and 
increased intima-media thickness.36 However, controversy over the vascular theory in 
migraine pathogenesis 38-42 and migraine treatment43,44 remains. Nevertheless, migraine (with 
aura) has repeatedly been linked with cardiovascular diseases45 including ischemic stroke3,46-48 
and coronary events.49,50 
By using different techniques at distinct levels of the vascular bed, we investigated vascular 
functional consequences of both RVCL and CADASIL in vivo, and compared results with those 
of a matched group healthy volunteers.
METhODS
Subjects
The study was approved by the Ethics Committee of Leiden University Medical Centre and 
conducted in accordance with the Declaration of Helsinki. All participants were at least 
eighteen years of age and gave written informed consent. RVCL and CADASIL patients with 
a confirmed mutation in the TREX1 (i.e., V235fs) and the NOTCH3 gene, respectively, were 
recruited from databases provided by the treating neurologist (GMT) and clinical geneticist. 
Subjects were invited to participate by a letter explaining the tests and study objectives. The 
control group consisted of spouses or friends of mutation carriers and volunteers recruited via 
public advertisements. Medical history, genetic and clinical information was obtained prior 
to the measurements and by a different investigator than the one performing the vascular 
measurements. During the measurements, participants were instructed not to reveal their 
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Clinical assessment 
Participants were asked in advance to fill out a questionnaire that included various variables on 
medical history such as neurological symptoms including (transient) ischemic attacks, other 
stepwise neurological deterioration, cognitive complaints including apathy, migraine (with 
or without aura), depression, visual symptoms, Raynaud’s phenomenon, diabetes, thyroid 
function, cardiovascular disease, airway disease, cancer, multiple sclerosis, epilepsy, intestinal 
and stomach problems, liver disease, renal and urinary tract disease and dermatological diseases. 
The questionnaire also had questions on current medical condition, current medication, 
smoking, daily intake of alcohol, caffeine and drugs, and socio-demographic parameters 
such as educational level and ethnic origin. During the interview preceding the experiments, 
diagnosis of migraine and Raynaud’s phenomenon was verified. Migraine diagnosis was made 
according to the International Classification of Headache Disorders-second edition (ICDH-2) 
and Raynaud’s phenomenon was assessed according to the criteria of Miller.51 Medication 
was also verified and subdivided in the following categories: anti-hypertensive, cholesterol 
lowering, acetylsalicylic acid (anti-platelet), anti-coagulant, acute and prophylactic migraine 
medication, analgesics (e.g., acetaminophen, paracetamol, NSAIDs), oral contraceptive. 
If possible, and in agreement with their treating physician, included subjects were asked to 
abstain from medication with vascular (side-)effects for one week prior to the measurements. 
Patients were instructed to abstain from alcohol and caffeine for 12 hours, from smoking and 
food for 6 hours and, if their health status allowed this, from medication for 7 days prior to the 
measurements. This was verified during the interview. Subsequently, weight and height were 
measured and BMI was calculated. 
Biochemical measurements
Plasma concentrations of triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), total cholesterol (TC), blood fasting glucose levels, 
creatinine, ureum, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and 
alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), lactate dehydrogenase (LDH), 
hemoglobin (Hb) and hematocrit (Ht) were determined according to standard procedures.
Experimental setup
All measurements were performed by the same investigator (SV) who was blinded for the 
diagnosis and mutation status of the subjects. Before starting the measurements, subjects had 
to lay down on a comfortable bed in supine position for acclimatization of at least 15 min in a 
room with stable ambient temperature (22 ± 1 °C).
Resting blood pressure and pulse rate were recorded at the right upper arm using a validated 
semi-automated oscillometric device (OMRON 705IT, OMRON Healthcare, Hoofddorp, The 
Netherlands). Median blood pressure and heart rate of 3 measurements was used for analyses. 
Subsequently, the following assessments were consecutively performed in a standardized 
order: i) pulse wave analysis; ii) pulse wave velocity; iii) capsaicin-induced changes in dermal 
blood flow; and iv) flow-mediated dilatation of the brachial artery. All these assessments have 
previously been described in detail, including reproducibility.52-57 
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Pulse Wave Analysis (peripheral arterial stiffness)
Augmentation index (AIx), which is a measure for arterial wave reflections and peripheral 
arterial stiffness, was determined via Pulse Wave Analysis (PWA) using SphygmoCor software 
(version 8.2; Atcor Medical, Australia). PWA was performed by applanation tonometry over 
the radial artery to obtain resting measurements of the peripheral AIx (Augmented Pressure / 
Pulse Pressure), expressing the reflected pressure wave as percentage of the forward wave 
(Supplementary Fig. 1). This non-invasive method has previously been shown a reproducible 
technique to evaluate peripheral arterial stiffness.55 Based on 10-second PWA recordings 
performed at the radial artery, aortic (central) pressure waveforms can be reliably estimated by 
the software using a validated transfer function.54 Subsequently, central pressure wave forms 
can be used for calculating the central AIx. Since AIx is influenced by heart rate,53 an index 
normalized for heart rate at 75 beats/minutes (min) (AIx@HR75) was used. Mean values of at 
least three AIx@HR75 measurements per subject were used for statistical analysis.
Pulse wave velocity (aortic stiffness)
Aortic Pulse Wave Velocity (PWV) was measured with the same SphygmoCor device as PWA, 
by sequentially recording ECG-gated carotid and femoral artery pressure waves. The intersecting 
tangent algorithm52 was used by the software to determine the characteristic points of the pressure 
wave and the R wave of the ECG for calculating the time delay. Based on 10-second recordings, 
the carotid-femoral transit time (T) was calculated. The carotid-femoral distance (L) used for 
calculating the PWV was obtained by subtracting the carotid-sternal notch distance from the 
sternal notch-femoral distance. PWV was calculated as L (cm) divided by T (m/s). If available, 
mean values of at least 3 PWV measurements per subject were used for statistical analysis.
Capsaicin-induced dermal blood flow (microcirculation in the skin)
Local application of capsaicin onto the skin results in binding to the Transient Receptor 
Potential Vanilloid type I receptor (TRPV1) at primary sensory neurons (Aδ- and C-fiber 
nociceptors). TRPV1 receptor binding of capsaicin induces a neurogenic inflammatory response 
due to predominant release of CalcitoninGene-Related Peptide (CGRP).57 CGRP is a very potent 
vasodilator causing a local increase in dermal blood flow, which can be quantified by Laser 
Doppler Perfusion Imaging (LDPI)(PeriScan PIM II®; Perimed, Järfälla, Sweden). Reproducibility 
of this non-invasive test to evaluate dermal vascular reactivity to capsaicin was confirmed 
earlier.56 After at least 20 min of supine rest the baseline dermal blood flow (DBF) was measured 
using LDPI. Subsequently, subjects received single topical doses of 1000 µg per 20 µL capsaicin 
solution (in ethanol/polysorbate 20/water) in two 10-mm rubber ‘O’-rings on the volar surface 
of one forearm. In two rings on the opposite arm, placebo (i.e., vehicle) was applied. DBF was 
measured at 10, 20, 30 and 40 min after capsaicin/placebo administration. Results are presented 
as absolute and percentage change in DBF after capsaicin application compared to placebo.
Flow-mediated dilatation (endothelial function of conduit artery)
Flow-Mediated Dilatation (FMD) of the brachial artery was assessed following existing 
guidelines58 using an echo-tracking system (Wall Track System, Pie Medical, Maastricht, The 
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Netherlands). The system consists of an ultrasound device (Esaote AU5, Esaote Biomedical, 
Genoa, Italy) equipped with a 7.5-10 MHz linear-array transducer connected to a data acquisition 
and processing unit. Measurements were performed as described earlier.34 In brief, right brachial 
artery diameter was measured 5-10 cm proximal to the antecubital crease in a longitudinal plane, 
before and after an increase in shear stress induced by reactive hyperaemia. At baseline, diameter 
and velocity profiles were recorded 3 times and the mean was used for data analysis. After baseline 
measurements, a cuff (TMC7, D.E. Hokanson, Bellevue, USA), placed around the forearm, was 
rapidly inflated to 220 mm Hg. The cuff was released after 5 min, followed by recording of the 
peak velocity profile within the first 15 seconds (s). Diameter was measured at 0.5, 0.75, 1, 1.25, 
1.5, 2, 3, 4 and 5 min after cuff release. Each diameter recording lasted 4 s.
After 15 min of recovery, following measuring baseline brachial artery diameter again, 400 μg 
sublingual nitroglycerin (NTG) was administered. Subsequently, the diameter was measured 
every minute for 6 min to assess NTG-induced endothelium-independent brachial artery 
dilatation. The endothelium-dependent FMD after 5 min of reactive hyperemia was expressed as 
the maximal absolute and percentage increase in diameter from baseline. FMD was corrected for 
the hyperemic stimulus using shear rate (= velocity/diameter) and additionally corrected for blood 
viscosity using shear stress (= shear rate*hematocrit) to calculate normalized FMD. Endothelium-
independent vasodilatation capacity after administration of the exogenous NO donor (NTG) was 
expressed as the maximal absolute and percentage increase in diameter from baseline.
Statistics
P-values were calculated by independent sample t-test for normally distributed variables, 
Mann-Whitney U test for non-normally distributed variables and χ2-test for categorical 
variables. Analysis of variance (ANOVA) was used to detect differences between controls and 
patient groups, followed by post-hoc Fisher LSD-test. Univariate associations were established 
using Spearman rank order correlations. Multiple linear regression analysis was used to adjust 
for confounders found with the univariate Spearman test. For all analyses p-values <0.05 
were considered statistical significant. All statistical analyses were performed using SPSS 17.0 
software (SPSS inc, IBM, Chicago, IL, USA).
RESuLTS
Subjects
Eighteen RVCL and 23 CADASIL patients were included in the study and compared with 
26 age-, BMI- and gender-matched healthy control subjects. Demographic details, clinical 
symptoms and laboratory values of all subjects are summarized in Table 1. All tests were well-
tolerated. No subjects reported a migraine attack due to NTG when asked in a survey by phone 
in the first week after participation in the study. Success rates for abstaining from alcohol, 
caffeine and food for the predefined period prior to the measurements was 100%, except for 
smoking in the CADASIL group (72%; five patients smoked 1-4 cigarettes in the 6 hours prior 
to the measurements), abstention from alcohol in the CADASIL group (94%; one patient used 
2 units 10 hours prior to the measurements), caffeine in the RVCL group (96%; one patient 
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Age (years) 49.0 ± 9.1 49.5 ± 12.7 50.1 ± 9.6 0.939
BMI (kg/m2) 25.2 ± 3.6 26.7 ± 4.3 25.2 ± 3.7 0.362
Female, n (%) 14 (54) 11 (48) 10 (56) 0.867
Smoking (Pack years) 3.0 ± 5.0 13.4 ± 16.0 3.7 ± 5.8 0.002
Retinopathy, n (%) 0 (0) 0 (0) 9 (56)† N.A.
TIA, n (%) 0 (0) 8/21 (38)†† 0 (0) N.A.
Brain infarction, n (%) 0 (0) 2(9) 0 (0) N.A.
Cognitive complains, n (%) 0 (0) 12 (52) 8 (44) N.A.
Concentration problems, n (%) 0 (0) 8 (35) 5 (18) N.A.
Depressive symptoms, n (%) 0 6 (26) 4 (22) N.A.
Character change, n (%) 0 (0) 5 (28) 2 (9) N.A.
Migraine, n (%) 0 (0) 6/22 (27)§ 6 (33) N.A.




































































































Values are means ± SD or number (percentage). P-values were calculated using a one-way ANOVA. Number of 
subjects that abstained from medication 7 days prior to the measurements are depicted in bold. N.A.: not applicable. 
† Retinopathy status for two patients unknown. †† Two patients could no be categorized as TIA or definitely no 
TIA. § One patient could not be classified as migraine or no migraine. ° All subjects used these painkiller for acute 
treatment of migraine, none of the subjects used acetaminophen or NSAIDs 24 hours prior to the measurements. 
°° Other medication included: glucose lowering drugs, proton pump inhibitors, gabapentin, carbamazepine, 
pyridoxine, folic acid, valproic acid, alfacalcidol, baclofen, cinnarezine, ursodeoxycholic acid, atovaquon.
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used 1 unit 6 hours prior to the measurements). Success rates of abstaining from medication 
are depicted in Table 1.
Pulse Wave Analysis (PWA) and Pulse Wave Velocity (PWV)
Peripheral (brachial) and central (aortic) systolic, diastolic and pulse pressures are presented in 
Table 2. No differences in blood pressure values were observed between the control group and 
both patient groups. PWA software was unable to calculate the augmentation index and aortic 
pressure parameters in one subject (CADASIL patient) as the result of an atypical waveform. 
PWV measurements could not be performed reliably in two CADASIL patients due to obesity 
(BMI of 29.7 and 35.4).
Univariate analysis showed a trend towards increased AIx@HR75 in CADASIL patients 
versus control subjects (22,8 ± 13,3 vs. 16,0 ± 12,7%, p = 0.08) and a trend towards increased 
pulse wave velocity in RVCL patients versus control subjects (7,8 ± 1,6 vs. 7,0 ± 1,4 m/s, 
p  =  0.10; Table 2). Univariate associations between clinical characteristics and PWA/PWV 
were assessed using Spearman correlation coefficients. (Supplementary Table 1)
Multivariate analysis resulted in a regression model for PWA (Multiple R = 0.77; Adjusted 
R2 = 0.57) with age (p < 0.001; observed power > 0.99), gender (p < 0.001; observed power 
> 0.99), peripheral diastolic pressure (p = 0.001, observed power = 0.91) and subject group 
(p = 0.02; observed power = 0.71) as covariates. This regression model for PWA with covariates 
age, gender and diastolic blood pressure, revealed a significant difference in AIx@HR75 
between control subjects and CADASIL patients (p = 0.007 and a trend in RVCL patients 
(p = 0.06) (Fig. 1).








Peripheral systolic pressure (mm Hg) 129.2 ± 20.5 126.2 ± 11.1 0.94 132.8 ± 21.7 0.71
Peripheral diastolic pressure (mm Hg) 77.8 ± 10.1 75.4 ± 6.7 0.40 75.3 ± 8.8 0.26
Peripheral pulse pressure (mm Hg) 51.3 ± 12.3 50.8 ± 9.6 0.98 57.5 ± 15.8 0.21
Aortic systolic pressure
(mm Hg)
119.6 ± 21.2 116.8 ± 12.3 0.93 122.8 ± 22.4 0.61
Aortic diastolic pressure
(mm Hg)
79.5 ± 10.6 79.8 ± 8.2 0.90 76.6 ± 9.0 0.22
Aortic pulse pressure
(mm Hg)
39.5 ± 11.7 39.2 ± 8.4 0.77 46.2 ± 16.9 0.16
Aortic Augmentation index 
@ HR75 (%)°
16.0 ± 12.7 22.8 ± 13.3 0.08 21.0 ± 13.3 0.21
PWV 
(m/s)°°
7.0 ± 1.4 7.5 ± 1.5 0.29 7.8 ± 1.6 0.10
Data presented as mean ± SD. † Difference between control subjects and CADASIL patients. ‡ Difference between 
control subjects and RVCL patients. ° PWA: pulse wave analysis; PWA software was unable to calculate the augmentation 
index and aortic pressure parameters in 1 subject (CADASIL patient) as the result of a atypical waveform. °° PWV: 
pulse wave velocity; PWV measurements could not be performed reliable in 2 subjects due to obesity.
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Multivariate analysis resulted in a regression model for PWV (Multiple R = 0.70; Adjusted 
R2 = 0.46; p < 0.001) with age (p = 0.003; observed power = 0.87), diastolic blood pressure 
(<  0.001; observed power >0.99) and subject group (p = 0.02; observed power = 0.72) as 
covariates. This regression model for PWV with covariates age and diastolic blood pressure, 
revealed a significant difference between control subjects and RVCL patients (p = 0.01) and a 
trend in CADASIL patients (p = 0.07) (Fig. 1).
Capsaicin-induced Dermal Blood Flow (DBF)
Results on capsaicin-induced DBF are summarized in Fig. 2. One subject did not undergo 
capsaicin testing due to a skin allergy to alcohol containing solutions. Another subject was 
excluded from analysis because of prophylactic anti-migraine medication (pizotifen) use. One 
subject was excluded because of coloured skin. Because measurements for RVCL and CADASIL 
Figure 1. Increased vascular stiffness observed in CADASIL and RVCL patients measured with Pulse Wave Analysis 
(PWA) and Pulse Wave Velocity (PWV) respectively. (A) Aortic augmentation pressure corrected for heart rate and 
measured at the radial artery was increased in CADASIL patients using multivariate regression with age, gender 
and diastolic blood pressure as covariates (p=0.007). (B) Carotid-femoral aortic pulse wave velocity was increased in 
RVCL patients using multivariate regression with age and diastolic blood pressure as covariates (p=0.01).
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were performed at different time points with different LDI scanners, separate matched control 
groups were used. No differences were found between RVCL patients and control subjects. 
CADASIL patients compared to control subjects displayed a lower increase in DBF 40 min 
after capsaicin application (1,38 ± 0,88 vs. 2,22 ± 1,20 Arbitrary Units (AU), p = 0.02) and a 
lower area under the curve over the total observation period of 40 min (0,52 ± 0,43 vs. 0,93 ± 
0,60 AU, p = 0.02).
Flow-Mediated Dilatation (FMD)
FMD assessments were performed in 18 RVCL, 14 CADASIL patients and in 18 control subjects. 
Because of technical difficulties and movement artefacts, a valid set of measurements could 
only be obtained in 14 control subjects and 10 subjects of the two patient groups. Results are 
summarized in Fig. 3. In RVCL patients a decreased FMD was observed compared to control 
subjects (2,32 ± 3,83 vs. 5,75 ± 3,07 %, p = 0.02). In contrast, no significant differences were found 
between CADASIL patients and control subjects (3,77 ± 3,15 vs. 5,75 ± 3,07, p = 0.14) for any of 
the parameters. The decreased FMD in RVCL patients (Fig. 3) persisted after correction for shear 
rate (p = 0.02) and shear stress (2,32 ± 3,83 vs. 5,75 ± 3,07 %, p = 0.03) (Supplementary Table 3).
Figure 2. Microvascular reactivity of the skin after topical capsaicin application is reduced in CADASIL subjects. 
Dermal blood flow was assessed using laser Doppler perfusion imaging. (A) Maximal dermal blood flow increase 
40 minutes after capsaicin application was lower in CADASIL patients than a matched control group (p=0.02). 
(B) Total dermal blood flow response over a period of 40 minutes after capsaicin application, displayed as area-
under-the-curve, was reduced in CADASIL patients (p=0.02). (C) and (D) No changes in capsaicin-induced dermal 




This study provides a detailed assessment of distinct vascular properties of two monogenic 
cerebral small vessel diseases: RVCL and CADASIL. We are the first to find evidence for 
endothelial dysfunction in RVCL. In addition, we confirm impaired endothelial-independent 
microvascular reactivity in CADASIL. The observed increased arterial stiffness in both patient 
groups further illustrates RVCL and CADASIL as vasculopathies.
Endothelial dysfunction in RVCL 
In RVCL patients, a decreased endothelium-dependent flow-mediated dilatation was observed 
in the brachial artery, supporting the hypothesis that TREX1 mutations in RVCL cause 
endothelial dysfunction, as was previously hypothesized.10,59 
In RVCL patients, capillary occlusion is suggested by histological examination of 
the retina and cerebral white matter, revealing thickening of the vessel wall with lumen 
obliteration. Additionally, nodular regenerative hyperplasia of the liver, arteriosclerosis, and 
glomerulosclerosis in the kidney, together with anemia and gastrointestinal bleeding, are 
Figure 3. Endothelial dysfunction was found in RVCL patients using Flow Mediated Dilatation (FMD) at the 
brachial artery. (A) Blood flow velocity, measured pre- and post-occlusion hyperaemia, was comparable between 
all groups. (B) Shear rate, calculated as the blood flow velocity divided by artery diameter, and shear stress, calcu-
lated as shear rate multiplied by hematocrit, did not differ between all groups. (C) The endothelium-independent 
percentage increase in brachial artery diameter measured 6 minutes after sublingual nitroglycerin administration 
did not differ between groups. (D) The endothelium-dependent maximal increase in brachial artery diameter after 
5 minutes of hyperaemia was decreased in RVCL patients (p=0.02).
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probably all manifestations of small vessel disease.10,60 Thus, RVCL is a systemic vasculopathy 
with luminal narrowing, but in contrast to CADASIL, only minimal degeneration of vascular 
smooth muscle cells. Instead, fibrinoid necrosis of small and medium vessel wall, hyalinized 
vessels and reactive gliosis is found, which is may be a consequence of endothelial cell 
dysfunction. Remarkably, electron microscopy also shows irregular thickening and splitting 
of the basement membranes in the vessel wall14, which may be produced by endothelial cells.10,14 
Impaired microvascular reactivity and increased vascular resistance 
in CADASIL 
In CADASIL patients, a decreased dermal blood flow response to capsaicin was observed. 
Capsaicin activates pre-synaptic TRPV1 receptors on Aδ- and C-fiber nociceptors and leads 
to relaxation of the VSMCs of the skin microvasculature upon CGRP release. A decreased 
dermal blood flow could result from defects at different levels in this pathway: i) less sensitivity 
of TRPV1 receptors to capsaicin; ii) impairment of CGRP release from nociceptors; iii) a 
decreased expression of functional TRPV1 and CGRP-receptors, or iv) a decreased relaxation 
of VSMCs in response to an endothelium-independent stimulus. Given the morphological 
alterations seen in the microvasculature of CADASIL patients, i.e., degeneration of vascular 
smooth muscle cells with a largely normal endothelium,18 the last explanation seems most 
plausible. Thus, our findings suggest impaired endothelium independent VSMC dilatation 
in CADASIL.
Findings from other studies that measured microvascular vasoreactivity using different 
techniques (without involvement of CGRP) are in line with our results. For example, 
endothelium-independent skin vasoreactivity, as measured by cutaneous blood flow post-
occlusive reactive hyperemia was altered in CADASIL patients.27 In addition, lower dermal 
blood flow was observed after iontophoretic application of sodium nitroprusside, an 
exogenous Nitric Oxide (NO)-donor relaxing VSMCs. Impaired endothelium-independent 
vasoreactivity to glyceryltrinitrate, another exogenous NO-donor, was also found using 
plethysmographicendo-peripheral arterial tone (Endo-PAT) measurement at the fingertips of 
CADASIL patients.30
After measuring FMD at the brachial artery, we did not find evidence for endothelial 
dysfunction in CADASIL, nor did we find differences in endothelium-independent relaxation 
of the brachial artery after NTG administration. Thus, the vascular function of conduit 
vessels, in this case the brachial artery, remains unaltered in CADASIL. These results confirm 
findings of others27,28, who also reported that FMD of the brachial artery in CADASIL 
patients was unaffected. One study29 suggested endothelial dysfunction based on L-arginine 
induced vasoreactivity of the middle cerebral artery. However, these results might be due 
to baseline differences between CADASIL and control subjects. Stenborg et al.28 reported 
impaired endothelium-dependent vasodilatation in forearm resistance arteries (i.e., the 
microcirculation) using venous occlusion plethysmography with intra-arterial acetylcholine 
infusion. Thus, although we find no evidence for endothelial dysfunction in conduit arteries 
of CADASIL patients, there is evidence for endothelial dysfunction of the microcirculation, 
which is in line with the labeling of CADASIL as a small vessel disease.
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Increased vascular stiffness in both RVCL and CADASIL
We found an increased PWV and AIx in RVCL and CADASIL, which supports increased 
vascular stiffness in both diseases. Pulse wave velocity is a marker of aortic stiffness while 
the augmentation index is related to arterial stiffness in general as well as to the intensity 
and location of reflected waves, which is largely determined by the diameter and compliance 
of small arteries. In CADASIL, significance was only reached for the AIx. These results may 
suggest that the microcirculation is more severely affected in CADASIL than in RVCL. In 
RVCL significance was only reached for PWV, which may be related to endothelial dysfunction 
found in conduit vessels. Both PWA and PWV are validated methods which have been used 
for patient outcome predictions in stroke61 and renal transplant patients,62,63 cardiovascular 
disease risk in type 1 diabetes64 as a marker for risk in cardiovascular disease65 and brain 
abnormalities.66,67 The augmentation index also predicts adverse cardiovascular events in 
coronary artery disease patients.68 Consequently, a clinical implication of our results may 
be that for both RVCL and CADASIL, and possibly other cerebral hereditary angiopathies, 
intensive monitoring and treatment of cardiovascular risk factors may be important to prevent 
neurovascular and systemic vascular complications.69 
Methodological considerations
Our study has important strengths. We are the first to assess four complementary vascular 
properties in two rare monogenic small vessel diseases (RVCL and CADASIL). All techniques 
were performed by one investigator (SV) who was blinded for the health status of the study 
subjects. A specific set of well-validated techniques was used to investigate vascular function 
at distinct levels of the vascular bed.52,56,70,71 More specifically, FMD, the absolute standard for 
testing endothelial function, was performed according to the guidelines from the International 
Brachial Artery Reactivity Task Force.58
There are also some limitations of our study that need to be considered. Because CADASIL 
and RVCL are rare diseases, sample sizes are relatively small. This limits the power of our 
observations. Unfortunately, movement artifacts, possibly related to the fact that FMD was 
the last test performed during the examination (this was done because of the systemic effect 
of NTG), led to loss of some FMD data. Notably also is the slightly larger (non-significant) 
baseline brachial artery diameter in the RVCL group. Control subjects with a smaller baseline 
diameter who display the same absolute increase in diameter, would then automatically display 
higher % FMD. However, the absolute change in diameter of the RVCL group tended to be 
smaller than in the control group. Therefore, the validity of our results remains. Whereas the 
effect of hematocrit was corrected via the shear stress, the effect of slightly lower hemoglobin 
levels in RVCL patients may have affected our measurements as hemoglobin absorbs NO, and 
a lower hemoglobin results in an increased FMD.72 However, correction for this would only 
strengthen our results and lead to an even lower FMD in RVCL. The slightly (not significant) 
reduced FMD observed in CADASIL might be the result of the mismatch in cigarette pack 
years, although it has to be said that mainly the two heavy smokers dramatically influenced 
the number of pack years. Furthermore, we did not measure endothelial function at the level of 
resistance arteries. Therefore, we are unable to state that the endothelial dysfunction we found 
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in RVCL can be extrapolated to small vessels. Therefore, iontophoresis or venous occlusion 
plethysmography with acetylcholine would be of interest as a follow-up study. Finally, the 
impact of medication use or stop of medication on our results is unknown. Although we 
attempted to minimize the effect by asking patients to stop their medication a week prior 
to the measurements, unfortunately only a few patients got permission to do so from their 
treating physician. 
Possible implications for migraine
The increased prevalence of migraine in both CADASIL and RVCL might be related to the 
altered vascular properties found in the present and previous studies. In CADASIL, where 
patients mainly display migraine with aura, the increased prevalence of migraine may be due 
to an increased susceptibility for cortical spreading depression (CSD), which is the underlying 
mechanism of the migraine aura.73,74 This hypothesis is strengthened by the fact that transgenic 
NOTCH3 over-expressor mice were shown to have a decreased threshold for CSD.75 Increased 
susceptibility to CSD may be due to alterations in smooth muscle cells and subsequent altered 
vasoreactivity of the microcirculation. These alterations may induce (subclinical) ischemia, 
which is a known trigger for CSD. In line with our results in the skin, indeed altered cerebral 
vasoreactivity in CADASIL patients has been found.75
A direct link with CSD is missing in the case of RVCL because migraine without aura is 
the more prevalent migraine subtype. A shared increased genetic susceptibility may underlie 
this co-morbidity, as was shown for RVCL in a family-based association study.76 In light of the 
present data, an increased susceptibility for endothelial dysfunction may contribute to the 
development of migraine in RVCL. This seems supported by the fact that migraine itself has 
been linked to endothelial dysfunction.32-36
Conclusions
In RVCL patients endothelial dysfunction was demonstrated and, based on pulse wave velocity, 
increased vascular stiffness was suggested. In CADASIL patients impaired endothelium-
independent vasoreactivity of the dermal microvasculature was shown. In combination with 
an increased augmentation index, suggestive for increased vascular resistance, these findings 
clearly label CADASIL as a small vessel disease. Future studies may link these vascular 
functional markers to disease progression and perhaps to individual symptoms of these 
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Supplementary Table 1. Univariate associations between clinical characteristics and pulse wave analysis 
(PWA) and pulse wave velocity (PWV)




Systolic blood pressure 0.38
Diastolic blood pressure 0.38








Systolic blood pressure 0.55
Diastolic blood pressure 0.55














Baseline (AU) 0.27 ± 0.15 0.27 ± 0.17 0.98 0.34 ± 0.08 0.39 ± 0.11 0.12
10 min (AU) 0.79 ± 0.94 0.46 ±0.39 0.16 0.55 ± 0.42 0.53 ± 0.37 0.93
20 min (AU) 1.68 ± 1.27 1.07 ± 0.76 0.08 1.20 ± 0.73 1.08 ± 0.77 0.63
30 min (AU) 2.09 ± 1.17 1.42 ± 0.94 0.06 1.50 ± 0.82 1.46 ± 0.79 0.87
40 min (AU) 2.22 ± 1.20 1.38 ± 0.88 0.02 1.54 ± 0.74 1.42 ± 0.72 0.64
AUC0-40 (AU) 0.93 ± 0.60 0.52 ± 0.43 0.02 0.59 ± 0.37 0.51 ± 0.35 0.52
Increase in DBF (%) 
40min. post-capsaicin
607 ± 474 346 ± 343 0.05 332 ± 2.21 272 ± 2.01 0.40
Data presented as mean ± SD. AUC0-40: area under the curve over the total observation period of 40 minutes. 
AU: arbitrary units. † Difference between control subjects and CADASIL patients. ‡ Difference between control 
subjects and RVCL patients. ° One subject did not undergo capsaicin test due to a skin allergy to alcohol containing 
solutions. One subject was excluded from analysis because of prophylactic anti-migraine medication (Pizotifen) 
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Pre-occlusion diameter (µm) 5655 ± 1014 5934 ± 839 0.48 6438 ± 1103 0.09
Maximal post-occlusion diameter 
(µm)
5987 ±1109 6150 ± 828 0.70 6602 ± 1252 0.22
Absolute increase in diameter 
(µm)
332 ± 187 216 ± 169 0.13 165 ± 256 0.08
FMD (%) 5.76 ± 3.07 3.77 ± 3.15 0.14 2.32 ± 3.83 0.02
Pre-occlusion velocity (cm/s) 11.7 ± 4.1 9.5 ± 3.4 0.18 13.4 ± 6.3 0.78
Maximal post-occlusion velocity 
(cm/s)
82.4 ± 24.9 81.7 ± 20.5 0.94 88.5 ± 21.4 0.56
Shear rate (s-1) 0.014 ± 0.0034 0.014 ± 0.0036 0.88 0.014 ± 0.0035 0.97
Shear rate normalised FMD (s) 4.35 ± 2.31 2.99 ± 2.33 0.20 1.32 ± 2.91 0.02
Shear stress (s-1) 0.0062 ± 0.0016 0.0060 ± 0.0015 0.78 0.0056 ± 0.0015 0.46
Shear stress normalized FMD (s) 10.07 ± 5.73 6.96 ± 5.58 0.23 3.31 ± 7.24 0.03
Pre-NTG diameter (µm) 5710 ± 844 6198 ± 1019 0.15 6190 ± 1034 0.22
Maximal post-NTG diameter (µm) 6496 ± 899 6947 ± 891 0.24 6980 ± 1193 0.27
NTG (%) 12.08 ± 5.47 11.01 ± 5.23 0.64 11.16 ± 5.84 0.70
Data presented as mean ± SD. NTG: nitroglycerine. Peak shear rate was missing in 4 subjects, therefore no corrected 
FMD could be calculated in 2 healthy volunteers and in 1 of each patient groups. † Difference between control 
subjects and CADASIL patients. ‡ Difference between control subjects and RVCL patients
157
chapter 10
Supplementary Figure 1. Augmentation Index
Artery pressure waveform is recorded by applanation tonometry.The height of the late systolic peak (P1) above the 
inflection (P2) defines the augmentation pressure, and the ratio of augmentation pressure to PP defines the AIx (in 
percent). “In the human body, wave reflections originate in various locations, including peripheral bifurcations of 
conducting arteries and smaller muscular arteries. The geometry, number of arterioles, and the architecture of the 
microvascular network play an important role in wave reflection. Indeed, arterial and arteriolar constriction results 
in reflection points closer to the heart, leading to earlier aortic wave reflections. In addition, with increased arterial 
stiffness, as observed, for example, in older subjects or hypertensive patients, the reflected wave travels more rapidly 
along the arterial tree. Thus, both small and large arteries contribute to early reflected waves which arrive in early 
systole, superimpose on the forward wave, and boost the systolic pressure further, whereas blood pressure falls 
sharply in diastole with reduced diastolic fluctuations.” Adapted from: Laurent S, Cockcroft J, Van Bortel L, Bout-
ouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and 




migRAinE And ComoRbidiTy in A gEnETiC isoLATE 
P A R T  3

shared Genetic factors in miGraine and depression: 
eVidence from a Genetic isolate
ah stam1, B de Vries2, acJW Janssens3, KrJ Vanmolkot2, ys aulchenko4, p henneman2, Ba oostra4, 
rr frants2, amJm van den maagdenberg1,2, md ferrari1, cornelia m. van duijn4, Gm terwindt1
C H A P T E R  1 1
1Department of Neurology and 2Department of Human Genetics, Leiden University Medical Center, Leiden, 
The Netherlands, 3Department of Epidemiology and 4Genetic Epidemiology Unit, Departments of Epidemiology 




Objective: To investigate the co-occurrence of migraine and depression and assess whether 
shared genetic factors may underlie both diseases. 
Methods: Subjects were 2,652 participants of the Erasmus Rucphen Family (ERF) genetic 
isolate study. Migraine was diagnosed using a validated three-stage screening method that 
included a telephone interview. Symptoms of depression were assessed using the Centre for 
Epidemiologic Studies Depression (CES-D) scale and the depression subscale of the Hospital 
Anxiety and Depression Scale (HADS-D). The contribution of shared genetic factors in 
migraine and depression was investigated by comparing heritability estimates for migraine 
with and without adjustment for symptoms of depression, and by comparison of the heritability 
scores of depression between migraineurs and controls.
Results: We identified 360 migraine cases, 209 had migraine without aura (MO) and 151 had 
migraine with aura (MA). Odds ratios for depression in migraine patients were 1.29 (95% 
confidence interval (CI) 0.98-1.70) for MO and 1.70 (95% CI 1.28-2.24) for MA. Heritability 
estimates were significant for all migraine (0.56), MO (0.77), and MA (0.96), and decreased 
after adjustment for symptoms of depression or use of antidepressant medication, in particular 
for MA. Comparison of the heritability scores for depression between migraine patients and 
controls showed a genetic correlation between the HADS-D score and MA.
Conclusions: There is a bidirectional association between depression and migraine, in 
particular MA, which can be explained, at least partly, by shared genetic factors.
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INTRODuCTION 
Migraine is a highly prevalent brain disorder that is characterized by recurrent headache attacks 
associated with nausea, vomiting, photo- and phonophobia (migraine without aura; MO). 
In one third of migraineurs, attacks are preceded by transient focal neurological symptoms 
(migraine with aura; MA).1 Migraineurs often have symptoms of depression. Population-based 
odds ratios (OR) range from 2.0 to 5.8, with strongest associations for MA.2-13 The quality of 
life of migraineurs with depression is decreased.10,14 Co-morbid depression is a risk factor for 
chronification of migraine15-17 and development of medication–overuse-headache.18 Patients 
with depression also have an increased risk for migraine, with risk estimates of 2.8-3.4 for 
migraine, 2.2 for MO and 4.0 for MA.2-4 This bidirectional relationship suggests that migraine 
and depression may share common etiological factors. 
Twin- and family-based studies have shown that both migraine and depression have a 
strong genetic basis.19-24 Heritability estimates range from 0.33-0.53 for migraine (33-53% 
of the trait is explained by additive genetic effects) to 0.61-0.77 for MO and 0.65-0.79 for 
MA.19-23 For depression, heritability estimates range from 0.17-0.78.24 Recent evidence suggests 
that both diseases share molecular pathways controlling serotonergic and glutaminergic 
neurotransmitter systems.25,26 Shared genetic factors may therefore underlie the bidirectional 
comorbidity of migraine and depression. 
Here we determined the co-occurrence of migraine and depression in a Dutch genetic 
isolate, investigated to what extent genetic factors are involved in migraine, and whether 
shared genetic factors may underlie the comorbidity of both disorders.
METhODS 
Study Population
Subjects were participants of the Erasmus Rucphen Family (ERF) study, a family-based 
study in a genetically isolated community in the Southwest of the Netherlands.27 In brief, 
the ERF study population includes 3,465 individuals that were ascertained based on 
genealogical background (not selected on phenotypes of interest), and are living descendants 
of 22  couples with at least six children baptized in the community church between 1850 
and 1900. Founding couples are related through previous generations as demonstrated by 
extensive genealogical information from detailed church and municipal records. Hence, 
study participants were all members of a large extended pedigree. All individuals of 18 years 
and older were invited to participate. Spouses were invited only for family members that had 
children of 18 years and older. 
Standard Protocol Approvals, Registrations, and Patients
The study was approved by the Medical Ethical Committee of the Erasmus MC Rotterdam and 




Extensive clinical information from ERF participants (n = 3,465) was available.27 For this 
study relevant clinical data were obtained by questionnaires (symptoms of headache and 
depression and education level) or from a visit to the research centre (use of antidepressant 
medication).
Migraine 
Migraineurs were identified between 2005 and 2007 using a three-stage screening procedure 
assessing lifetime occurrence of migraine, which was previously validated in a population-
based study28 and which was based on the Classification Criteria of the International Headache 
Society (IHS).1 In brief, in the first stage, participants were asked to fill in five screening 
questions on headache and aura symptoms. Then, screen-positives received a detailed 
questionnaire on headache and aura symptoms. Finally, screen-positives were interviewed 
by telephone for further clarification of their answers. Subjects that were screen-positive but 
did not return the extensive headache questionnaire and subjects that could not be screened 
because they did not, or incompletely, filled in the screening questions, were directly contacted 
by telephone. Telephone interviews were performed by the principal study physician (AHS), 
who is experienced in diagnosing migraine patients, and by well-trained medical students 
supervised by AHS. A final diagnosis was only made after the telephone interview and in 
consultation with a neurologist specialized in headache (GMT).
Depressive symptoms
Symptoms of depression were assessed using the Centre for Epidemiological Studies Depression 
Scale (CES-D)29 and the depression subscale of the Hospital Anxiety and Depression Scale 
(HADS-D).30 Both scales are validated, reliable self-report measures of symptoms of 
depression.31, 32 The CES-D consists of 20 items with total scores ranging from 0 to 60 and 
the HADS-D of seven items with scores ranging from 0 to 21. Higher scores indicate more 
symptoms of depression. Depression scores were analyzed both as continuous variables and 
as dichotomous variables. For the dichotomous variable, depression was defined as a CES-D 
score ≥ 1631 and HADS-D score ≥ 832 or the use of antidepressant medication. CES-D scores 
were missing for 327 and HADS-D for 104 subjects. Missing CES-D and HADS-D data were 
imputed based on data of the other depression scale, age, sex and use of antidepressants using 
SPSS version 12.0, iterative expectation-maximization method. Depression scores were not 
imputed when both scores were missing.
Control group
The control group consisted of subjects that: (i) did not report severe headache (pain severity 
score ≤ 4 on a scale from 0 to 10); ii) did not report visual aura symptoms; (iii) had never been 
diagnosed with migraine by a physician; and (iv) never used specific anti-migraine medication. 
Thus, also subjects with mild headache in combination with visual aura are excluded from the 
control group. To exclude false negative control cases, we used an even more conservative 
definition for a non-migraineurs than in our previous population-based study.28
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Statistical methods 
For statistical analysis we used data from three migraine groups (i.e., all migraine cases, 
MO, and MA) and the control group. General characteristics of the subjects of each group 
were compared using chi-square statistics for dichotomous variables and a Student’s t-test for 
continuous variables. 
All analyses were corrected for inbreeding. The coefficient of inbreeding per individual was 
calculated based on available genealogical information using PEDIG software.33 This coefficient 
reflects the probability that two alleles at a given locus in an individual are identical by descent.
To examine the co-occurrence of migraine and depression, we calculated the odds ratio 
(OR) for the risk of depression for each migraine group using multivariate mixed model 
regression analyses corrected for inbreeding, age, sex and education and taking into account 
pedigree relations between individuals (polygenic liability threshold model).34 
Mean CES-D and HADS-D scores were calculated for each group. P-values comparing 
migraine subgroups versus controls were corrected for age, sex, level of education, use of 
antidepressants, inbreeding and pedigree relations by multivariate linear mixed model 
regression, considering each migraine group as an independent variable and HADS-D or 
CES-D data as the continuous dependent variable. Because both CES-D data and HADS-D 
data deviated from the normal distribution, data were transformed by taking the natural 
logarithm (CES-D) and by taking the square root (HADS-D).
We calculated the heritability estimates (h2) as the ratio of the variance of a trait that is 
explained by additive polygenic effects to total phenotypic variance of the trait. The polygenic 
model was applied that assumes an infinite number of genetic factors with a small additive 
effect contributing to the trait variance. Analyses were adjusted for age, sex and inbreeding. 
As sibship effects, a combination of effects induced by sharing early childhood environment 
and dominant genetic variation, did not significantly influence heritability estimation, this 
covariate was excluded from the analyses. 
Involvement of shared genetic factors underlying migraine and depression was assessed 
by two complementary methods. First, heritability estimates for migraine were computed 
with and without depressive symptoms as covariate (i.e., HADS-D, CES-D scores and use of 
antidepressants included) (see also27). A difference between adjusted and unadjusted heritability 
estimates represents that part of the genetic component in migraine that is shared with depression. 
Second, we compared the heritability of depression in migraine patients to that in 
controls (i.e., assess whether a diagnosis of migraine influences the heritability of depression) 
by performing a bivariate polygenic analysis with both HADS-D and CES-D scores (i.e., 
depression score + migraine status, covariates: age, sex, inbreeding, use of antidepressant 
medication) (see for examples35,36 except here, we compared migraine versus no migraine 
status, instead of gender, to estimate the genetic correlation). The significance of a genetic 
correlation was determined using a likelihood ratio test. 
Descriptive analyses were performed using SPSS version 12.0 for windows (SPSS, 
Chicago, IL). SOLAR 2.1.2 software package (Southwest Foundation for Biomedical Research, 





Recruitment of migraine patients 
In total, 3,465 subjects participated in the ERF study. Figure 1 shows the ascertainment flow 
chart of migraine cases. The questionnaire with headache screening questions was returned 
by 2,652 (76.5%) subjects. Of these, 888 were screen-positive and 1,291 screen-negative; 473 
subjects had not or only incompletely, filled out the screening questionnaire. Of the screen-
positives, 572 (64.4%) subjects could be interviewed of which 305 proved to have migraine. Of 
the group that was incompletely screened, 286 (60.5%) subjects were interviewed of which 55 
proved to have migraine. A diagnosis could not be made in 503 subjects because of a variety of 
mainly logistic reasons. Of the in total 2,149 ERF participants who were interviewed (n=858) 
or who were screen-negative (n=1291), 360 (16.8 %) had migraine. Of these, 209 (58%) had MO 
and 151 (42%) had MA. A total of 617 subjects gave negative answers to all screening questions, 
thereby fulfilling the criteria for the control group. 
Descriptive data 
The demographic characteristics of all groups are shown in Table 1. No significant differences 
were found for the mean age. In line with the higher prevalence of migraine in women, more 
n=360  
Migraine  
(‘All migraine group’) 
n=437  






(‘MO group’)  




n=813 Did not return 











 No interview* 
n=572   n=286 
Screen-pos      Screen-inc 





Figure 1. Flowchart of ascertainment of migraine cases and the controls in the Erasmus Rucphen Family study
* Subjects were deceased or declined participation (n=122), had an incorrect (n=140) or unavailable (n=10) telephone 
number, gave no permission for a telephone interview (n=130), were not answering the phone (at least 3 attempts 
were made) (n=72) or indicated on the phone that they did not want to cooperate with the interview (n=29).
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women were present in the migraine groups. Overall, patients with migraine, in particular 
those with MA, had a lower education than controls.
Depression in migraineurs 
Of the 2,652 participants that completed the questionnaire, HADS-D scores were obtained for 
2,548 subjects and CES-D scores for 2,325. After imputation, HADS-D and CES-D scores were 
available for 2,584 subjects. Of these, 583 met our definition for depression. Of these, 91 were 
included in the migraine group and 82 in the non-migraine control group. The remaining 
subjects were not included in the current assessment because they did not meet the inclusion 
criteria for either the all migraine or control group.
Twenty-five percent (91/360) of migraineurs and 13% (82/617) of controls were found to be 
depressed (Table 2). Depression was more often seen in MA (32%; 48/151) than in MO (21%; 
43/209). The ORs were 1.43 (95% CI 1.15 -1.78) for all migraine, 1.29 (95% CI 0.98-1.70) for MO, 
and 1.70 (95% CI 1.28-2.24) for MA. Mean CES-D scores were higher (p < 0.001) in migraine 
patients compared to controls (all migraine: 12.0 ± 10.2, MO: 11.1 ± 9.7, MA: 13.2 ± 10.7, and 
controls: 7.5 ± 7.4). The mean HADS-D score was higher (p < 0.01) in the all migraine and MA 
groups compared to controls (all migraine: 6.1 ± 4.4 and MA: 6.7 ± 4.6), but was not significantly 
different between the MO and control group (MO: 5.7 ± 4.2 and controls: 4.9 ± 3.7). 










Women, % 75* 77* 73* 47
Mean age in years (SD) 46.2 (12.3) 47.0 (12.7) 45.1 (11.6) 47.8 (15.3)
Education, %
Higher 5§ 5 4§ 9
Medium 64 63 66 65
Lower 31 32 30 26
MO: migraine without aura; MA: migraine with aura. Education: Higher: college or university, Medium: secondary 
school or vocational technical training, Lower : primary or elementary school or unfinished secondary school. 
*p < 0.001 compared to controls; §p < 0.05 compared to controls. SD: standard deviation.
Table 2. Depression in migraine patients and controls
Group Depression (n, (%)) OR (95% CI) p value
Controls (n=617) 82 (13%) 1.00 -
MO (n=209) 43 (21%) 1.29 (0.98-1.70) 0.07
MA (n=151) 48 (32%) 1.70 (1.28-2.24) < 0.001
MO: migraine without aura; MA: migraine with aura. Prevalence of depression per group is given. Depression 
was defined as scoring both CES-D ≥ 16 and HADS-D ≥ 8 or use of antidepressants. Odds ratios for the risk of 
depression in migraine patients are adjusted for sex, age, education and inbreeding.
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Heritability estimates of migraine
In total 325 migraine patients (188 MO and 137 MA) and 562 control subjects were present 
in the ERF extended pedigree.27 Heritability estimates were 0.56 (95% CI 0.26-0.86) for all 
migraine, 0.77 (95% CI 0.38-1.00) for MO, and 0.96 (95% CI 0.51-1.00) for MA (Table 3). These 
estimates decreased after adjustment for depressive symptoms to 0.51 (95% CI 0.19-0.83) for 
all migraine, 0.75 (95% CI 0.32-1.00) for MO, and 0.81 (95% CI 0.31-1.00) for MA. The decrease 
was highest in patients with MA (15%), compared to a decrease of 4% in the all migraine group 
and 2% in MO patients. This would suggest that shared genetic factors particularly underlie 
the comorbidity of depression and MA.
Table 3. Heritability estimates of migraine with and without adjustment for depression 
h2 (95% CI)a
h2 (95% CI) 
(with adjustment for depression)b p valuec
All migraine (n=325) 0.56 (0.26-0.86) ** 0.51 (0.19-0.83) ** 0.81
MO (n=188) 0.77 (0.38-1.00) ** 0.75 (0.32-1.00) ** 0.95
MA (n=137) 0.96 (0.51-1.00) ** 0.81 (0.31-1.00) * 0.65
MO: migraine without aura; MA: migraine with aura. aHeritability estimates are based on a polygenic model, 
covariates: age, sex and inbreeding coefficient. bHeritability estimates are based on a polygenic model, covariates: 
age, sex and inbreeding coefficient, HADS-D, CES-D, use of antidepressant medication. cP value for the difference 
in heritability estimates before and after adjustment for depression. P values for heritability estimates: **p <0.001 
and *p <0.01.
Next we compared the heritability for depression in migraineurs and controls. A correlation 
of 1 indicates that there is no difference in the genetics of depression between patients and 
controls, while a deviation from 1 suggests shared genetic factors for depression and migraine. 
Only for HADS-D and MA a reduced genetic correlation was found (correlation of 0.36) 
indicating that genetic factors causing symptoms of depression in MA patients differ to those 
involved in depression in controls. In MO patients the correlation coefficient was 1 indicating 
no difference in genetic factors for depression in MO and controls. For CESD there was no 
difference seen between migraine patients and controls. 
DISCuSSION
We investigated the co-occurrence of migraine and depression in a large Dutch genetic isolate 
and to what extent shared genetic factors are involved. Our study is particularly suited to 
address these questions because of the following reasons: (i) our three-step diagnostic 
procedure - including a telephone interview for clarification and confirmation of the clinical 
symptoms and a final diagnosis according to the Classification Criteria of the IHS1 guaranteed 
a highly reliable diagnosis of migraine; (ii) the presence of depression was assessed using two 
different depression scales; (iii) our study population includes a very large number of well-
characterized subjects covering a broad age range from 18 to 91 years. 
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We found an increased risk of depression and depressive symptoms in migraine patients, 
in particular in those with aura. These findings are in agreement with previous studies from 
outbred populations.2-13 ORs for depression in migraine patients in those studies were larger 
(2.0 – 5.8 for MA) than ORs observed here (1.7 for MA), which may be due to differences in 
the diagnostic methods, and definitions. This seems particularly true for depression. While 
several studies addressed life-time prevalence of depression,2,4,5,9 which is notoriously difficult 
to assess reliably, we studied current depression, which is reliable to diagnose and will result 
in lower prevalence data. One might thus argue that presence of lifetime depression was 
underestimated in our study. 
Some 23.5% of the 3,465 subjects were non-responders, which may have introduced a 
selection bias leading to an overrepresentation of very depressed patients or severe migraine 
patients in the non-responder population. However, such a bias in this particular study is less 
likely, as we used a general questionnaire designed to collect information on a large number of 
traits, not only related to headache and depression. 
Heritability estimates in our study were significant for all three migraine groups and 
were substantially higher for MA than for MO. This is in accordance with studies in outbred 
populations,19-23 confirming the hypothesis that the genetic contribution in MA is stronger 
than in MO. Also in line with these studies, a lower heritability estimate was observed for 
‘all migraine’ than for MO or MA, which indicates that MA and MO share some, but not all, 
genetic factors. We observed a remarkably high heritability for MA of over 90% in ERF. This 
suggests that most of the variance in MA in ERF is explained by genetic factors. This finding 
may be particularly relevant for gene discovery and suggests that MA is the most promising 
migraine subtype to search for migraine genes. Moreover, our observation that heritability 
estimates for MA decreased when adjusting for depression, indicates that shared genetic 
factors may underlie depression and MA. For MO, a smaller decrease in heritability estimates 
was observed, suggesting that a small fraction of the comorbidity with depression is explained 
by shared genetic factors for this migraine subtype.
In our bivariate analysis, we found remarkably different results when using the two 
depression scales. When depression was determined by using the HADS-D scale, we found 
evidence for shared genetic factors for migraine with aura and depression. However, no 
such association was observed when depression was determined using the CES-D scale. This 
discrepancy may seem remarkable as both scales have been validated for the assessment of 
symptoms of depression31,32 and there is a high correlation for both depression scales in our 
study (Pearson correlation coefficient rho = 0.75; p < 0.001). However, both scales assess slightly 
different symptoms, which may well explain our findings. As the HADS-D was specifically 
designed to prevent noise signal from somatic disorders,32 it excludes ‘physical symptoms’ of 
depression, such as insomnia, fatigue or loss of appetite. In the CES-D scale, however, these 
symptoms are included. Although admittedly difficult to prove, we would like to argue that 
these physical symptoms are more likely a consequence of the migraine attacks than due 
to a depression. Consequently, we propose that the CES-D score, in a way, is confounded 
by migraine-related symptoms and therefore less suited to assess shared genetic factors in 
migraine and depression. 
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Previous studies found a bidirectional association between migraine, in particular those 
with aura, and depression.2-4 This suggests that common pathogenetic pathways, at least partly, 
underlie both disorders, rather than that one is the consequence of the other. Thus, migraine 
patients may develop depression as a result of the demoralizing experience of recurrent and 
disabling headaches. However, then a correlation with disease disability would be expected, 
which was not found in previous studies.2 Also, an even stronger association with MO should 
be seen, which in general is the more disabling form of migraine1 and usually associated with 
higher attack frequencies. Our study provides evidence that this bidirectional relationship can 
be explained, at least partly, by shared underlying genetically determined disease mechanisms. 
Support for our findings comes from a recent twin study that also suggested that shared 
genetic risk factors may underlie migraine and depression.37 Unfortunately that study has 
important limitations. First of all, it is unclear whether a correct migraine diagnosis was made 
as a diagnosis was based on ‘self-reported physician’s diagnosis’, and not on well-defined IHS 
criteria. A similar criticism can be made with respect to the diagnosis of depression. This may 
well have led to misclassification and underreporting of migraine and depression. Second, 
unlike in our study, the sample consisted of female subjects only, and results therefore cannot 
be extrapolated to male patients. Third, no distinction was made between MA and MO. This 
last limitation is very relevant in light of our observation that shared genetic effects between 
migraine and depression are particular evident for migraine with aura. 
Identification of common genetic factors may significantly improve the insight into the 
molecular basis of these common and highly disabling episodic brain disorders.
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Aim: Migraine, in particular with aura, has been associated with an increased risk for 
ischemic stroke and coronary heart disease. The underlying mechanism is unknown. In a 
cross-sectional case control study we investigated whether an enhanced risk of atherosclerosis 
in migraineurs explains this increased cardiovascular risk.
Methods: Subjects were participants from the population-based Erasmus Rucphen Family 
study. Atherosclerosis was assessed in 360 migraineurs (209 without aura and 151 with aura) 
and 617 subjects without migraine or severe headache. Atherosclerosis was quantified by 
Intima Media Thickness, Pulse Wave Velocity and Ankle-Brachial Index. 
Results: Migraineurs, especially with aura, were found more likely to smoke, have diabetes 
or a modestly decreased HDL-cholesterol. No differences were found for the atherosclerosis 
parameters. 
Conclusions: In this large population-based study migraineurs have no increased risk of 
atherosclerosis. Therefore enhanced atherosclerosis is an unlikely explanation for the increased 
cardiovascular risk seen in migraineurs.
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INTRODuCTION 
Migraine is a prevalent neurovascular brain disorder that is characterized by recurrent 
disabling attacks of headache associated with nausea, vomiting, and photo- and phonophobia 
(migraine without aura); in one-third of migraineurs, attacks may be preceded by transient 
focal neurological aura symptoms (migraine with aura).1 Both neuronal as well as vascular 
mechanisms have been implicated. There is observational, prospective and imaging evidence 
that migraine increases the risk of ischemic stroke almost two fold.2-4 Patients may also be 
at increased risk for major cardiovascular disease, including coronary heart disease and 
peripheral artery disease.2,5,6 This suggests that vascular dysfunction in migraineurs is not 
restricted to the cerebral vasculature, but is also systemically present.
The underlying mechanism for the association between migraine and ischemic 
cardiovascular disease is unknown. An adverse cardiovascular risk profile and associated 
atherosclerosis has been suggested. Some studies found an unfavorable cardiovascular risk 
profile, in particular for migraine with aura patients,5,7,8 while other studies did not find any9 
or only a modest association.10 Framingham Risk Scores for coronary heart disease (FRS-
CHD) were elevated in migraineurs in most,5,7,8,11 but not all studies9,12 studies. None of the 
studies reported on the Framingham Risk Score for ischemic stroke (FRS-Stroke) in migraine 
patients, probably because the electrocardiogram data that are necessary to calculate this risk 
score were not available.
The atherosclerotic process, one of the strongest risk factors for stroke and coronary 
heart disease, can be assessed by means of non-invasive preclinical functional and structural 
markers of changes in the vessel wall.13 In the present study, we investigated atherosclerosis in 
a large group of migraine patients from the Erasmus Rucphen Family study. 
METhODS
Study population 
We performed a case-control study nested within the population-based Erasmus Rucphen 
Family study. The ERF study is a family-based cross-sectional study in a genetically 
isolated community in the Southwest of the Netherlands.14 The study population includes 
3,465 individuals who were ascertained for genetic-epidemiological studies based on their 
genealogical background (i.e., not selected on phenotypes of interest). All individuals 18 years 
or older were invited to participate. For this epidemiological study we did not use genetic or 
genealogical data, but the genetic and environmental homogeneity of the population can be an 
advantage. The study was approved by the Medical Ethical Committee of the Erasmus Medical 
Center Rotterdam and all participants gave written informed consent. 
Migraine patients and controls
Migraineurs were identified using a three-stage screening procedure assessing lifetime 
occurrence of migraine, which was previously validated in a population-based study15 and 
which was based on the second edition of the International Classification of Headache Disorders 
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(ICHD-II).1 The sensitivity of this case-finding procedure was 0.93 and the specificity was 0.36. 
The positive predictive value was 0.65 and the negative predictive value was 0.91. Thus the 
screening procedure picked up many false-positives and missed some true-positives.15 Only 
patient with “definite” migraine with and without aura are included. Patients with probable 
migraine are excluded from the study.
Details on the migraine case-finding procedure have been published before.16 In brief, in 
the first stage, participants were asked to fill out five screening questions on headache and 
aura symptoms. Then, screen-positives received a detailed questionnaire on headache and aura 
symptoms. Finally, screen-positives were interviewed by telephone for further clarification of 
their answers. Subjects who were screen-positive but did not return the extensive headache 
questionnaire and subjects who could not be screened because they did not (completely) 
fill out the screening questions were directly contacted by telephone. Telephone interviews 
were performed by the principal study physician (A.H.S.), who is experienced in diagnosing 
migraine patients, and by well-trained medical students supervised by A.H.S. A final diagnosis 
was only made after the telephone interview and in consultation with a neurologist specialized 
in headache (G.M.T.). 
The control group consisted of subjects who 1) did not report severe headache in their 
lifetime (only headache up to pain severity score ≤ 4 on a scale from 0 to 10); 2) did not report 
visual aura symptoms; 3) had never been diagnosed with migraine by a physician; and 4) never 
used specific antimigraine medication. Thus, subjects with mild headache in combination 
with visual aura are excluded from the control group. To exclude false negative control cases, 
we used an even more conservative definition for non-migraineurs than in our previous 
population based study as from this study we know that about 10% of migraineurs is missed 
using this screening procedure.15
Assessment of cardiovascular parameters
Participants (n = 3,465) were asked to attend the research center located within the community. 
Extensive clinical examinations were performed, including the collection of fasting blood 
samples, anthropometric measurements, cardiovascular assessments, and personal interviews 
by physicians. Participants were also asked to fill out questionnaires assessing various variables, 
among which symptoms of headache and their level of education. The interview included 
questions on cigarette smoking status, alcohol consumption and medical history. Alcohol 
consumption was measured in units per week and was categorized as < 28 consumptions 
per week and >= 28 consumptions per week. Current smoking was categorized as yes and 
no. Participants took all prescript medication to the research center and antihypertensive 
treatment and the use of oral contraceptives (OAC) was verified by a physician. Height and 
weight were measured with the participant in light underclothing and body mass index 
(kg/m2) was computed. An electrocardiogram (ECG) was performed and each was scored by 
an experienced cardiologist. Blood pressure was measured twice on the right arm in a sitting 
position after at least 5 minutes rest using an automated device (OMRON 711, automatic IS; 
Vernon Hills Illinois, USA). The average of the two measures was used for the brachial blood 
pressure in the analyses. Plasma concentrations of triglyceride (TG), high-density lipoprotein 
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cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) 
were determined according to standard procedures, as described previously.14 Diabetes was 
defined as the use of blood glucose-lowering medication or sober glucose levels of ≥7 mmol/L 
or both. Total plasma adiponectin was analyzed with the Human adiponectin RIA kit (catalog 
number: HADP-61HK) of Linco Research (St. Charles, MO, USA). Total plasma C-reactive 
protein (CRP) was analyzed with the US C-reactive protein enzyme-linked immunosorbent 
assay (ELISA) (catalog number: DSL-10-42100) of Diagnostic Systems Laboratories, Inc. 
(Webster, TX, USA). All measurements were performed conform the manufacturers’ protocol. 
Plasma CRP levels showed a high level of kurtosis. Therefore, upper plasma CRP levels 
exceeding three times the standard deviation of the mean were removed from further analyses. 
We used the Framingham Risk Scores for coronary heart disease (FRS-CHD)17 and stroke 
(FRS-Stroke)18 to summarize the data. The FRS-CHD estimates the 10-year probability of CHD, 
defined as myocardial infarction or CHD death. The score assigns points for age, HDL-C, TC, 
smoking status, and systolic blood pressure stratified by sex and treatment for hypertension. 
The FRS-Stroke estimates the 10-year probability of stroke. The score assigns points for age, 
systolic blood pressure, treatment for hypertension, history of diabetes mellitus, smoking 
status, cardiovascular disease (i.e., history of myocardial infarction, angina pectoris, coronary 
insufficiency, intermittent claudication or congestive heart failure), and atrial fibrillation and 
left ventricular hypertrophy on ECG, all stratified by sex. The individual points for both the 
FRS-CHD and FRS-Stroke scores are summed and converted into 10-year risk percentages. 
Functional and structural vascular assessment 
The atherosclerotic process can be assessed by means of non-invasive preclinical functional 
and structural markers of changes in the vessel wall, including intima media thickness (IMT), 
pulse wave velocity (PWV, measure of arterial stiffness), and ankle-brachial index (ABI).13 
These measures correlate with central (IMT, PWV) or peripheral (ABI) atherosclerosis.13 
Intima media thickness (IMT) was measured by ultrasonography with a 7.5-MHz linear array 
transducer (ATL Ultra-Mark IV; Advanced Technological Laboratories, Bothell, WA, USA) 
of the left and right common carotid artery. The maximum carotid IMT was determined 
as the mean of the maximum IMT of near and far wall of both common carotid arteries.14 
Carotid–femoral PWV was measured by means of an automatic Complior SP device with 
subjects in supine position. The time delay between the rapid upstroke from the base point 
of simultaneously recorded pulse wave curves in the carotid and the femoral arteries were 
assessed, and the distance between the carotid and the femoral arteries was measured over 
the surface of the body with a tape measure. PWV was calculated as the ratio between the 
distance traveled by the pulse wave and the time delay and expressed in meters per second.14 
Ankle blood pressure was measured in both the posterior tibial arteries by using an 8 MHz 
continuous Doppler probe. Blood pressure was measured twice at the right arm in sitting 
position. The Ankle Brachial Index (ABI) was calculated for each leg by dividing the ankle 
systolic pressure by the mean brachial systolic pressure. The lowest of the two ABI values was 





Analyses were performed for all migraine, migraine without aura and migraine with 
aura separately. A two-sided p-value of alpha < 0.05 was considered significant. General 
characteristics were compared between groups using a Student’s t-test for age and a Chi-square 
test for sex and education. Means for continuous variables and proportions for dichotomous 
variables were calculated for cardiovascular risk parameters. Means of cardiovascular 
parameters were compared according to migraine status using analyses of covariance, 
adjusted for age, sex and education. Mean PWV, IMT and ABI were corrected for age, sex, 
education, HDL-C and smoking. Proportions were compared by binary logistic regression 
with the risk factor as the outcome (dependent) variable and migraine status as independent 
variable, adjusted for age, sex and education. Odds ratios for having a FRS-CHD or FRS-
Stroke >10%, were calculated using logistic regression adjusted for age, sex and education. 
We had 80% power to detect a difference of 0.23 m/s for PWV, 0.03 mm for IMT and 0.016 for 
ABI. These power calculations are based on the number of participants with data available 
for that parameter. 
Analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, USA). Significant 
results were corrected for inbreeding using SOLAR 2.1.2 software package (Southwest 
Foundation for Biomedical Research, San Antonio, TX, USA), which is necessary because 
subjects are part of a genetic isolate. The absolute numbers of cases and controls with 
diabetes was too small to correct for inbreeding. The coefficient of inbreeding per individual 
was calculated based on available genealogical information using PEDIG software. The 
inbreeding coefficient indicates, for each person in ERF, the probability that two alleles at a 
given locus in an individual are identical by descent and thus is a measure for relatedness. 
Subjects of the ERF population are the living descendants of 22 couples with at least six 
children baptized in the community church between 1850 and 1900. Thus, they are part of 
a large extended pedigree and therefore are more related than individuals from the general 
population. In isolated populations such as ERF, genetic drift may lead to an increase of risk 
allele frequencies and this may (falsely) increase associations between traits. Correction for 
relatedness prevents this and better reflects the association in the general population.  
RESuLTS
Recruitment of migraine cases and controls
Results on ascertainment of migraine cases and controls have been described elsewhere and 
are depicted in the flowchart (see Chapter 11, Figure 1).16 In total, 3465 subjects participated in 
the study, from which we recruited 360 migraine patients (151 with aura, 209 without aura) and 
617 control subjects. Comparing subjects included (n=977) versus those not included (n=2488) 
in the present study showed that included subjects were significantly younger (p < 0.001) and 
higher educated (p=0.03) compared to those not included, but there was no difference with 
regard to gender (p=0.20). 
182
12
atheroScleroSIS In mIgraIne 
Cardiovascular parameters
Baseline characteristics are shown in Table 1. In line with the higher prevalence of migraine in 
women, more women were present in the migraine group. Migraineurs, in particular those with 
aura, had lower levels of education. Smoking was more prevalent in migraineurs, in particular 
in those with aura (49% versus 31% of controls, p < 0.001). Migraine with aura patients had a 
modestly decreased HDL-C (uncorrected difference 0.05 mmol/L, p < 0.001). After correction 
for menopause status, alcohol consumption and smoking status, which are known to influence 
HDL-cholesterol levels, the difference between migraine with aura patients and controls 
remained significant. Migraine patients were more likely to have diabetes (5.4% migraine with 
aura, 5.5% migraine without aura versus 3.2% controls, p <0.05). The mean 10-year probability 
of CHD (FRS-CHD) or stroke (FRS-stroke) was similar in migraine patients and controls 
(Table 1). None of the odds ratios for having a Framingham 10-year risk for stroke or coronary 
heart disease larger than 10% reached statistical significance (Data not shown). 
Functional and structural measures for atherosclerosis
ABI data were available for 408 control subjects, 179 MO patients and 140 MA patients, IMT 
data for 470 control subjects, 167 MO patients and 123 MA patients, PWV data for 542 control 
subjects, 185 MO patients and 133 MA patients. Baseline characteristics including predicted 
Framingham 10-year risk for stroke and coronary heart disease were not significantly different 
between the subjects with and without missing data. No difference was observed in mean 
Intima Media Thickness (IMT), carotid-femoral Pulse Wave Velocity (PWV), or Ankle 
Brachial Index (ABI) between migraineurs and controls (Table 2). All values observed for these 
three measurements were within the normal range.13 
DISCuSSION 
The aim of this study was to investigate whether migraine patients are at increased risk for 
atherosclerosis. Our main finding is that atherosclerosis, assessed by three complementary 
noninvasive measures, is no more prevalent in migraineurs than in controls. 
Several studies assessed atherosclerosis in migraine patients using comparable functional 
and structural markers, but with contradictory results. One clinic-based study found a small 
decrease in ABI in migraine patients compared to controls.20 In line with our findings, another 
larger clinic-based study found no difference.21 Three studies on PWV found increased values 
in migraine patients but were clinic-based and excluded patients with known cardiovascular 
risk factors,21-23 which hampers comparison of results with our population-based study, where 
no selection for migraine or cardiovascular disease risk was made. Seven studies measured 
IMT in migraine patients with conflicting results.9,23-37 Comparison between these studies is 
hampered by different case selection methods, such as clinic-based23,25-28 versus population-
based,9,24 and exclusion of participants with known cardiovascular risk factors23,25-28 versus 
correction for these risk factors.9,24 The two largest population-based studies,9,24 with over 
100 migraine patients (unselected with regard to cardiovascular risk factors) found slightly 
decreased values of IMT, which is in line with our findings.
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Table 1. Baseline characteristics of the study population by migraine subtype
 
All 
migraine MO MA Controls
n=360  p  value n=209 n=151  p value n=617
Age , yr 46.2 (12.3) 0.149 47.0 (12.7) 45.1 (11.6) 0.105 47.8 (15.3)




Higher 5 0.02 5 4 MA: 0.04
MO: 0.10
9
Medium 64 63 66 65
Lower 31 32 30 26
Body Mass Index, kg/m2 27.1 (5.1) 0.10 27.2 (5.3) 26.9 (4.9) 0.24 26.8 (4.5)
SBP, mm Hg 135.3 (18.2) 0.22 135.4 (18.6) 135.2 (17.6) 0.42 139.4 
(19.5)
DBP, mm Hg 79.2 (9.2) 0.13 79.3 (9.5) 79.0 (8.8) 0.33 79.7 (9.8)
LDL-C, mmol/L  3.75 (0.97) 0.10 3.73 (1.01) 3.78 (0.93) 0.19 3.66 (0.94)
HDL-C, mmol/L 1.30 (0.35) 0.02 1.35 (0.36) 1.23 (0.34) MA: <0.001
MO:0.53
1.28 (0.34)
Triglycerides, mmol/L 1.27 (0.67) 0.36 1.25 (0.66) 1.31 (0.69) 0.46 1.31 (0.77)
Total cholesterol, mmol/L 5.6 (1.1) 0.32 5.6 (1.1) 5.6 (1.0) 0.60 5.5 (1.0)
Diabetes, % 5.5 0.01 5.5 5.4 MA: 0.02
MO: 0.04
3.2
Current smoking, % 45 0.005 41 49 MA: <0.001
MO: 0.11
31
Alcohol consumption, u/w 5.4 (7.8) 0.06 5.0 (7.8) 5.8 (7.8) 0.15 8.2 (10.4)
CRP, mg/L 5.3 (4.3) 0.24 5.0 (4.1) 5.6 (4.4) 0.23 5.4 (4.5)
Adiponectin, mmol/L 11.1 (6.0) 0.58 11.3 (6.0) 10.8 (6.1) 0.69 10.2 (5.2)
FRS-Stroke, % 5.7 (0.3) 0.55 5.8 (0.4) 5.6 (0.3) 0.80 5.9 (0.2)
FRS-Stroke>10
(% of  subjects)
12 14 10 15
FRS-CHD, % 5.0 (0.2) 0.82 5.0 (0.4) 5.0 (0.3) 0.97 5.1 (0.2)
FRS-CHD >10
(% of subjects)
12 12 11 22
Continuous values are mean (standard deviation (SD)), categorical values are proportions. P values are adjusted 
for age, sex and education. Significant p values were adjusted for inbreeding as well, except for diabetes. u/w: units 
(glasses) per week; MA:migraine with aura; MO: migraine without aura; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; 
CRP:  C-reactive protein. Education level was divided in lower (primary or elementary school or unfinished 
secondary school), medium (secondary school or vocational technical training) and higher (college or university). 
FRS-Stroke: Framingham risk score for stroke; FRS-CHD: Framingham Risk Score for coronary heart disease; 
percentages for these scores represent the 10 year risk of stroke or coronary heart disease. 
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Compared to previous studies our study has important strengths. We assessed the largest 
group of migraine patients thus far, including a large group of patients with aura (n≥120). Three 
complementary measurements that quantified both central and peripheral atherosclerosis 
were used. Migraine diagnoses were made after a telephone interview in consultation with 
a neurologist and according to criteria of the International Headache Society. Our sample 
was unselected for a particular disease phenotype, and included a broad age range of adults 
(18-87 years), thus preventing ascertainment bias. Participants were from a population-based 
study with relatively homogenous genetic and environmental background. Finally, data on a 
large number of cardiovascular risk factors were available and allowed us to calculate both the 
FRS-CHD as well as FRS-Stroke. 
Our study has some limitations. First, we were unable to assess directly the mediating 
effect of atherosclerosis in migraineurs with a cardiovascular event due to the size of the study 
population (i.e., ≤10 migraineurs had a myocardial infarction or stroke). Second, data on 
functional and structural measures for atherosclerosis were missing for a substantial proportion 
of cases and controls. We do not think this affected our outcome since power calculations 
were based on the available number of participants and showed a reasonable power to detect 
differences in mean values. Moreover, baseline characteristics were not significantly different 
between subjects with and without missing data, making selection bias unlikely. Third, we 
were unable to assess the effect of migraine attack frequency. This would have been interesting 
as the association of migraine with cardiovascular disease varies by attack frequency.29 Fourth, 
IMT and ABI are indicative of clinical atherosclerotic disease and perhaps limit conclusions 
on variability in the normal range. However, we have also included a measure that measures 
subclinical arterial stiffness (PWV). Last, as our study population has a homogeneous genetic 
and environmental background future studies are needed to assess to what extent our findings 
can be replicated in other populations of migraine patients. Although our study has a larger 
percentage of migraine with aura, we feel this is not a disadvantage of our study as the risk for 
cardiovascular events is highest among migraine with aura cases
We assessed the FRS-Stroke in migraineurs and showed no increased odds for a higher 
score, which suggest that traditional cardiovascular stroke predictors are not relevant in the 
Table 2. Functional and structural measures of atherosclerosis in migraine patients versus controls
  All migraine MO MA Controls p-value
Common carotid IMT, mm 0.77 (0.16) 0.77 (0.17) 0.77 (0.14) 0.79 (0.20) 0.55
Pulse wave velocity, m/s 9.0 (1.5) 9.0 (1.5) 9.1 (1.5) 9.3 (1.9) 0.55
Ankle Brachial index 1.07 (0.11) 1.06 (0.11) 1.07 (0.10) 1.07 (0.12) 0.62
Values are mean (SE). Means and p-values (all migraine versus controls) are corrected for age, sex, education, 
HDL-C and smoking. MO: migraine without aura; MA: migraine with aura. ABI data were available for 408 control 
subjects, 179 MO patients and 140 MA patients, IMT data for 470 control subjects, 167 MO patients and 123 MA 
patients, PWV data for 542 control subjects, 185 MO patients and 133 MA patients. Baseline characteristics 
including predicted Framingham 10-year risk for stroke and coronary heart disease were not significantly different 
between the subjects with and without missing data. Power calculations were performed for each measure based on 
actual number of cases and controls with available data.
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migraine-stroke association. This is in line with our data on atherosclerosis parameters. In 
addition, several previous observations support this conclusion. First, in most prospective 
cohort studies the increased risk of ischemic stroke appeared independent from traditional 
cardiovascular risk factors30 with the exception of use of oral contraceptives and smoking in 
women. Second, population-based MRI studies showed no difference in cardiovascular risk 
factors between migraineurs with and without posterior circulation territory infarct-like 
lesions and white matter lesions.31,32 Third, the Women’s Health Study showed an increased 
risk for myocardial infarction in migraine patients with a high FRS-CHD, while increased 
stroke risk was observed among migraine patients with a low FRS-CHD.11 This supports 
the idea that the mechanisms underlying the migraine-stroke association are different from 
atherosclerosis.
Based on these data, it seems unlikely that the higher risk of cerebro- and cardiovascular 
disease in migraineurs is mediated by atherosclerosis, although it might be possible that the 
process of atherosclerosis plays a role on a subclinical level with endothelial dysfunction 
as presumed early marker.33 Larger, preferably prospective studies are necessary to further 
clarify the role of atherosclerosis in incident vascular events in migraineurs. Potential 
other explanations for the migraine-stroke relationship include the association of migraine 
with specific etiologies of stroke (i.e., micro emboli caused by patent foramen ovale), the 
association with a pro-inflammatory, pro-coagulatory state, the use of vasoconstrictive drugs 
in migraineurs or the (genetic) lowered threshold for spreading depression leading to either 
migraine with aura or ischemia.34 The latter hypothesis is supported by recent data in migraine 
(FHM1 CaV2.1) transgenic mice that, after transient ischemia, developed earlier onset of anoxic 
depolarization and more frequent peri-infarct depolarization resulting in larger infarcts and 
worse neurological outcomes compared to wild-type mice.35 
These data suggest that enhanced susceptibility to ischemic depolarization akin to 
spreading depression predisposes migraineurs to infarction during mild ischemic events, 
thereby increasing the stroke risk. In humans, migraine with aura is associated with strokes 
with good functional outcome,36 which seems contradicting with these mouse data. However, 
disability might be related to the size and type of the infarcts rather than of their specific 
underlying mechanism and thus does not rule out susceptibility to spreading depression as a 
causal factor in humans as well. More translational studies are needed to provide more insight 
in the migraine-stroke relationship and to develop prophylactic treatment strategies to prevent 
cerebro- and cardiovascular events in migraine patients.
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chapter 13
For this thesis, clinical genetic investigations on migraine, its comorbid diseases and 
migraine syndromes were performed. The main migraine syndrome studied is monogenic 
Familial Hemiplegic Migraine (FHM) which is considered a good model for the common 
forms of migraine because of clinical similarities. The second migraine syndrome is Retinal 
Vasculopathy with Cerebral Leucodystrophy (RVCL, later termed CHARIOT), a monogenic 
syndrome with complex migraine as part of the clinical spectrum. Lastly, common migraine 
was studied by identifying migraine cases in a Dutch genetic isolate to investigate comorbidity 
with major depression and atherosclerosis. For depression it was assessed whether the disease 




pART I: FhM: A MONOGENIC MIGRAINE SYNDROME
13.1 Genetic and clinical spectrum of FHM
Familial hemiplegic migraine (FHM) is genetically heterogeneous with mutations in the 
CACNA1A (FHM1), ATP1A2 (FHM2) and SCNA1 (FHM3) genes.1-3 Identification of novel and 
recurrent mutations in these genes is important to better characterize the clinical and genetic 
spectrum of the genes, which can have implications for genetic testing. Moreover, increasing 
the number of mutation carriers with a specific mutation allows for more meaningful 
genotype-phenotype comparisons. This thesis describes several novel FHM mutations with 
the corresponding clinical spectrum: i.e., CACNA1A missense mutation V1696F in chapter 3, 
ATP1A2 missense mutation G855R in chapter 5 and SCN1A missense mutation L263V in 
chapter 6. In addition, genotype-phenotype correlation studies were performed on recurrent 
CACNA1A missense mutations R1347Q and S218L (chapters 2 and 4). The results do not 
only have implications for FHM, but also for associated phenotypes such as ataxia, epilepsy, 
alternating hemiplegia of childhood and the occurrence of lethal brain edema upon mild head 
trauma (especially in children). 
Findings in the FHM1 CACNA1A gene
CACNA1A encodes the α1 subunit of voltage-gated neuronal CaV2.1 (P/Q-type) calcium 
channels.1 To date, almost 30 FHM1 (and/or SHM1) mutations have been identified, all 
involving missense mutations. A spectrum of symptoms exists ranging from pure FHM 
without additional clinical symptoms to FHM associated with such features like epilepsy and 
ataxia, and at the extreme end, trauma-triggered FHM attacks that induce cerebral edema, 
that can lead to death of the patients. Chapter 2 illustrates well the broad clinical spectrum 
in FHM in four families carrying the FHM1 R1347Q mutation. R1347Q mutation carriers 
can suffer from pure FHM or from FHM with slowly progressive ataxia. Notably, attacks 
can be triggered by head trauma and be accompanied by altered consciousness in some. In 
addition, focal seizures may occur (with or without secondary generalization) during or 
independent of hemiplegic migraine attacks. The study also established R1347Q as the fourth 
recurrent FHM1 mutation, next to T666M,1,4-8 R583Q8-12 and S218L.13-15 Chapter 3 shows that 
screening of FHM genes is also worthwhile in patients with symptoms that are less typical 
for FHM. A monozygotic twin pair was shown to carry a novel de novo missense V1696L 
mutation in CACNA1A. The mutation causes an interesting overlap syndrome between 
FHM and alternating hemiplegia of childhood (AHC)16; an early-onset severe neurological 
disorder characterized by episodes of alternating hemiplegia or quadriplegia and progressive 
neurological features beginning before the age of 18 months. The study emphasizes that 
FHM and AHC may share pathophysiological mechanisms that involve calcium channel 
dysfunction. Previously, screening of FHM1, -2 and -3 genes17,18 (SCN1A unpublished data) 
revealed no mutations in typical AHC patients. However, recently some 70% of typical 
AHC patients were shown to have a heterozygous de novo missense mutation in the ATP1A3 
gene19,20 that belongs to the same family as the FHM2 ATP1A2 gene, implicating indeed 
related pathophysiological mechanisms between FHM and AHC. 
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In chapter 4 the severe end of the FHM disease spectrum was investigated in patients with 
the CACNA1A S218L missense mutation, which exhibit a particularly complex phenotype that 
is best characterized as ’early seizures and cerebral edema after trivial head trauma’, which 
we consequently termed ESCEATHT. The combination of symptoms was recognized in two 
S218L patients. By reviewing 11 additional S218L mutation carriers from literature, it became 
clear that every mutation carrier does not exhibit all clinical features, but certainly is at risk 
for ESCEATHT. Consequently, clinicians need to be made aware if they see a combination 
of symptoms in line with ESCEATHT, even when typical FHM attacks have not occurred. 
Concomitantly with our study, a fourteenth patient with the S218L mutation was published 
confirming our hypothesis that a specific severe phenotype is indeed associated with the 
mutation.13 In addition, in 2011, a fifteenth case was described linking the S218L mutation to 
hemiconvulsion-hemiplegia-epilepsy syndrome.21 
Findings in the FHM2 ATP1A2 gene
ATP1A2 encodes the α2 subunit of sodium-potassium pumps.2 To date nearly 50 ATP1A2 
mutations have been reported, most of which are associated with pure FHM.22,23 However, 
rarely, ATP1A2 mutations are associated with for instance, cerebellar signs,24,25 permanent 
mental retardation,26 and epilepsy.22,27 Whether these associations are coincidental or true 
remains to be seen. For instance, in a family in which both FHM and benign familial infantile 
convulsions (BFIC) segratated, an ATP1A2 mutation was described as the causal factor for 
both diseases.28 However recently it was shown that mutations in the PRRT2 gene cause BIFC,29 
which also appeared to be the case in this family (unpublished data). 
In chapter 5 we further established the link between the ATP1A2 gene and epilepsy by 
studying an FHM family in which patients carried the ATP1A2 G855R missense mutation 
and had febrile seizures. The proband of this family also suffered from frequent unprovoked 
episodes of severe ataxia since early childhood. Whether cerebellar ataxia in FHM2 is 
coincidental or based on a functional effect of the underlying ATP1A2 mutation still needs to 
be established.
Findings in the FHM3 SCN1A gene
SCN1A encodes the α1 subunit of neuronal NaV1.1 voltage-gated sodium channels.
3,30 To 
date five FHM3 mutations have been identified. Notably, SCN1A is a well-known gene for 
childhood epilepsy, with well over 100 mutations that are associated with severe myoclonic 
epilepsy of infancy (SMEI) or generalized epilepsy with febrile seizures (GEFS+).31,32 
Besides, elicited repetitive daily blindness can occur in FHM3 patients with mutation 
Q1489H and F1499.33,34 In contrast to the FHM1 and -2 genes, no recurrent FHM3 mutation 
has been reported. In chapter 6, for the first time, we describe a novel SCN1A mutation 
(L263V), which is associated with both FHM and epilepsy in multiple mutation carriers. 
This finding further expands the clinical spectrum associated with SCN1A mutations 





13.2 Pathophysiology of FHM gene mutations – a common pathway? 
How do FHM mutations cause disease? The functional consequences of FHM1 CACNA1A 
mutations have been studied by various methodologies mainly involving electrophysiology, 
both in cellular models, i.e., in cell lines or cultured neurons expressing recombinant CaV2.1 
channels, and in transgenic knock-in mouse models expressing FHM1 mutations R192Q or 
S218L. The R192Q mutation causes pure FHM1 without associated neurological features, 
whereas the S218L mutation causes severe hemiplegic migraine that can be accompanied 
by (sometimes fatal) brain edema (see below and chapter 4 on ESCEATH).35,36 The 
electrophysiological studies revealed that FHM1 mutations exhibit gain-of-function effects, 
namely an increased opening probability of CaV2.1 calcium channels and, thereby, an increased 
calcium influx through these channels35-38 leading to enhanced neuronal activity with more 
cortical glutamate release.39
In line with the severe clinical consequences observed in S218L patients, electrophysiological 
studies show that particularly the S218L mutation has the largest gain-of-function effect (i.e., 
inactivation is more slow and recovery from inactivation is faster than with other FHM1 
mutation).37 Corresponding to these more extreme electrophysiological abnormalities on 
CaV2.1 channel function, transgenic knock-in mice with the S218L mutation, exhibit even 
a lower threshold for and a higher propagation speed of CSD waves compared with R192Q 
knock-in mice.36,40 Notably, homozygous S218L mice exhibit a phenotype that closely resembles 
that in S218L patients.15,36 Besides a transient hemiparesis after CSD events, these mice show 
increased mortality that is likely due to the occurrence of generalized tonic-clonic seizures, 
they respond more dramatic to mild head trauma, and exhibit cerebellar ataxia. The clinical 
similarities between patients and mice suggest that similar pathways related to an increased 
neuronal activity and susceptibility to CSD are the underlying cause of ESCEATHT in humans.
In contrast to FHM1, FHM2 ATP1A2 mutations most often result in loss-of-function of 
the Na+,K+ ATPase pump protein as was demonstrated by e.g., cell survival assays (showing 
partial or no cell survival in specific tests).26 For instance, in chapter 5 HeLa cells expressing 
the FHM2 G855R mutant showed a significantly reduced rate of cell survival. This indicates 
that the expressed mutant protein, which had been made insensitive to Na+,K+-ATPase activity 
blocker ouabain, was not able to compensate adequately for the loss of endogenous Na+,K+-
ATPase activity, due to the action of ouabain, in the survival assay. 
FHM3 SCN1A mutations affect the function of neuronal NaV1.1 sodium channels. 
Electrophysiological studies of wildtype and mutant NaV1.1 sodium channels showed divergent 
effects.41 Two mutations, i.e., Q1489K, and L1649Q, which are associated with pure FHM 
in patients, showed clear loss-of-function effects, whereas FHM3 missense mutation L263V, 
which is associated with FHM and generalized tonic‐clonic epilepsy in a number of mutation 
carriers (see chapter 6) exhibited gain-of-function features on NaV1.1 channel functioning. 
It was hypothesized that loss of Nav1.1 channel activity primarily disturbs the functioning 
of inhibitory neurons, where the Nav1.1 channels normally are expressed
42,43 whereas gain of 
activity might have its predominant effect on excitatory neurons. This divergent behavior was 
not reported for mutations in NaV1.1 channels linked to childhood epilepsy, although this has 
not been investigated thoroughly.
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The study of the functional consequences of FHM genes has been crucial for furthering 
insight in the pathophysiology of FHM, and migraine in general. FHM1 mutations lead to 
increased neuronal calcium influx and concomitant increase of neurotransmitters, for instance 
glutamate in cortical neurons. Mutations in the FHM2 sodium potassium pump gene predict a 
reduced re-uptake of K+ and, as a consequence, less uptake of glutamate from the synaptic cleft 
into glia cells. Mutations in the FHM3 sodium channel gene may also result in hyperxcitability 
in vivo, most likely due to an imbalance of excitatory and inhibitory neurotransmitter release. 
Thus, FHM mutations all convert to a mechanism of increased cerebral levels of K+ and 
glutamate in the synaptic cleft, which would increase neuronal excitability, and thereby can 
explain the increased susceptibility to CSD. CSD plays an important role in initiating aura 
symptoms,44 and, at least in experimental animal models, can activate the TGVS,45 although it 
is unclear whether this occurs in humans.
Functional studies may increase insight in pathways that can explain the association of FHM 
with other diseases, such as in ESCEATHT (as already discussed), epilepsy and ataxia. Like FHM, 
idiopathic monogenic forms of epilepsy, often result from mutations in voltage-gated ion channels, 
such as those for sodium, potassium and chloride.46 Spreading depolarizations occur in epilepsy.47 
Based on this, comorbidity of FHM and epilepsy likely can be explained by the fact that both 
diseases result from a disturbed balance between excitatory and inhibitory (cortical) mechanisms, 
which is, at least in a proportion of patients, related to ion channel dysfunction. Overlapping 
mechanisms may also explain the therapeutic overlap between these diseases. Indeed, for some 
of the currently available prophylactic migraine treatments that are originally prescribed as anti-
epileptic drugs (e.g., valproate and topiramate), experimental evidence in rats has shown that 
chronic daily, but not acute, administration dose and duration-dependently suppressed KCl-
induced CSD frequency by 40–80%, and increased the triggering threshold for inducing CSD.48 
Why a proportion of FHM1 patients show slowly progressive ataxia is at present unclear. 
In FHM1 patients that show ataxia, cerebellar atrophy can be seen on MRI and in homozygous 
S218L mice, which have an ataxic phenotype, alterations in Purkinje cell morphology have been 
found. It has been suggested, that these morphological alterations may result from changes in 
intracellular calcium concentration and lead to a disturbed firing pattern of Purkinje cells 
causing ataxia.36 
The knowledge of functional consequences could serve as a starting point in the development 
of new migraine therapies. For example, a drug that shifts the activation of Cav2.1 channels 
to more depolarized voltages may inhibit CSD and thereby prevent or abort migraine attacks. 
In line with the central role of increased release of glutamate in FHM patients and mouse 
models, a glutamate receptor antagonist may reduce severity and duration of aura symptoms 
and perhaps headache. Indeed, Ketamine, an N-methyl-D-aspartate receptor antagonist, was 
shown to reduce severity and duration of aura symptoms in FHM patients,49 but more effective 
drugs with less side effects are needed.50
13.3 FHM as a model for common migraine
An important reason to study a rare migraine subtype such as FHM is to ultimately be able 




shared pathophysiological mechanisms may underlie both types of migraine, although there 
is debate to what extent this is the case. For instance, several genetic studies investigated the 
role of FHM1 and -2 genes in the common forms of migraine, with inconclusive results; that is 
they reported some evidence for the involvement of CACNA1A 51-53 or ATPA1A254, while others 
found no such evidence.55-57 Admittedly, many of these studies were severely underpowered. Still, 
a large candidate gene study investigating over 150 ion transporter genes in a large cohort of 
migraine patients provided no evidence for a major involvement in migraine susceptibility.58 
Recent genome-wide association studies (GWAS) reproduced these genetic data as there are 
many SNPs that cover the FHM1-3 gene regions that did not reveal significant association with 
common migraine.59-62 It shows that genes in rare monogenic and common multifactorial forms 
of migraine may differ, but this does not imply that the central conclusion of a key role of for 
instance glutamate, does not apply to common migraine. The fact that the GWAS studies surfaced 
several genes (i.e., PGCP, MTDH, LRP1) that are involved in glutamate signaling, indicates that 
there may indeed be shared molecular disease pathways in common migraine and FHM. 
In a Danish study, two known triggers for migraine without aura, i.e., CGRP (calcitonin 
gene-related peptide) and GTN (glyceryl trinitrate; an nitric oxide donor), failed to induce 
more migraine aura or headaches in FHM1 and -2 patients compared to controls. This result 
was claimed as argument against such shared pathophysiology.63-65 However, given the fact 
that nitric oxide prevents CSD events, a lack of a clear effect of GTN in FHM patients (in which 
CSD is very prominent and likely the main trigger of attacks), is not surprising.66 It merely 
shows that the triggering paradigm (CGRP and GTN administration) has different effects in 
common migraine and FHM. 
A role for ion channel involvement in common migraine, namely familial migraine with 
aura, came from a study by Lafreniere and co-workers, who reported an inactivating truncating 
mutation in TRESK (a TWIK-related spinal cord potassium channel that is encoded by the 
KCNK18 gene).67 However, a successive publication of the same group showed that heterozygous 
inactivating TRESK mutations also occur in control subjects, casting serious doubt on their 
original claim of causality of a TRESK mutation in familial migraine with aura.68
pART II: ChARIOT/RVCL: A MONOGENIC MIGRAINE-
ASSOCIATED SYNDROME
13.4 The clinical and genetic spectrum of CHARIOT/RVCL
Migraine can also be part of the clinical spectrum of certain monogenic diseases, which 
provides unique opportunities to unravel shared pathological molecular mechanisms. 
The clearest example is the monogenic small vessel disease CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leucoencephalopathy), where migraine 
with aura, but not without aura, is present in about 20-40 % of mutation carriers, often as 
the presenting clinical symptom.69 A hypothesis for the increased prevalence of migraine 
with aura in CADASIL could be that vascular changes make the cortex more susceptible to 
CSD, thereby leading to migraine with aura. This hypothesis is strengthened by the fact that a 
transgenic Notch3 mouse model has an increased susceptibility to CSD.70
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A second example of a monogenic migraine-associated syndrome is cerebral hereditary 
angiopathy with vascular retinopathy and impaired organ function caused by TREX1 
mutations (CHARIOT). What is now called CHARIOT was originally described in three 
families under different disease names and abbreviations (i.e., cerebroretinal vasculopathy 
(CRV)71, hereditary vascular retinopathy (HVR)72 and hereditary endotheliopathy, 
retinopathy, nephropathy and stroke (HERNS).73 The disease loci were mapped to a sinlge 
locus on chromosome 3p21.1-p21.3.74 In chapter 8 we describe the identification of the disease 
gene TREX1, that encodes the major mammalian 3′-5′ exonuclease trex1, with disease-
causing mutations that result in premature truncation of the trex1 protein. At the time of the 
gene discovery, the disease was termed Retinal Vasculopathy with Cerebral Leukodystrophy 
(RVCL), based on limited phenotypic knowledge of the disease. Moreover, previous 
separate clinical descriptions suggested phenotypic variability between families and TREX1 
mutations. For example, stroke en nephropathy were thought to be specific for HERNS73 and 
the development of cerebral mass lesions in the end stage of the disease were not described for 
HVR.72 Therefore, in chapter 8 we described the clinical, radiological and pathological data 
of eleven RVCL families with five different mutations in the TREX1 gene (in total 78 mutation 
carriers were investigated). Unlike previously suggested clinical variability, our study shows 
remarkably shared phenotypic characteristics between different RVCL mutations and between 
families. Based on our data, updated diagnostic criteria were composed. In addition, because 
we found no evidence for leukodystrophy, we renamed the disease CHARIOT. Diagnosis 
of CHARIOT should be considered in families with unexplained autosomal dominant 
progressive vascular retinopathy accompanied by contrast-enhancing white matter cerebral 
mass lesions. Signs and symptoms of (mild) liver and/or kidney impairment and white matter 
hyperintensities can be supportive. In addition migraine, Raynaud’s phenomenon, anemia 
and hypertension can be present.
As CHARIOT can present with retinal, cerebral, and systemic symptoms a primary consult 
of patients may be for different medical disciplines, such as ophthalmology, rheumatology, 
internal medicine and neurology. In the literature several other families with diseases that 
resemble CHARIOT are reported, i.e., cases with a retinopathy with cerebral mass lesions 
and systemic involvement. Of them, only the family reported by Niedermeyer et al.75,76 was 
screened for TREX1 mutations, but no mutation was identified, suggesting that there may 
be genetic heterogeneity. The disease described differs from CHARIOT in the sense that it 
seems to have a recessive inheritance and the two patients described also had abnormalities 
characteristic of Fanconi’s anemia. Families reported by Gutmann and Winkler77,78 might also 
be linked to the TREX1 gene, unfortunately, no DNA is available for testing this hypothesis.
13.5 RVCL/CHARIOT as a model for migraine? 
In RVCL/CHARIOT, the pathophysiological process causes a vasculopathy that affects the 
integrity of cerebral and systemic small vessels. The mechanism by which this vasculopathy 
can increase the risk of migraine is unknown. Several explanations can be put forward, such 
as spurious association, a shared genetic factor, or an increased risk for CSD or endothelial 





We observed a migraine prevalence of 59% among TREX1 mutation carriers (chapter 9). This is 
more than three times higher than what is usually reported as lifetime prevalence of migraine 
in the Western general population using the same criteria.79 Even assuming that none of the 
35 mutation carriers, for whom no reliable information on their migraine status is available, 
had migraine, the migraine prevalence in RVCL/CHARIOT would still be 37%, which is still 
twofold higher compared with the general population. In addition, except for mutation T236fs, 
migraine occurred in association with every TREX1 mutation. Therefore a spurious association 
seems an unlikely explanation for the co-occurrence of RVCL/CHARIOT and migraine.
Shared genetic factor
The co-occurrence with migraine may be causally related to TREX1 mutations. In this scenario, 
the gene may be considered to increase the susceptibility for migraine (i.e., serve as genetic 
modifier). A genetic, family-based, association study demonstrated that the RVCL/CHARIOT 
locus indeed slightly enhances the susceptibility for migraine in a large Dutch family.80 On the 
other hand, in a genetic association study with 5 polymorphisms that cover the TREX1 gene 
region using two Dutch samples from the general population (i.e., the Genetic Epidemiology 
of Migraine study n=860 and the Erasmus Rucphen Family study n=360 cases) no major role 
of common TREX1 variants was found (unpublished data). In any case, other risk factors must 
be involved as well.
Vascular: endothelial dysfunction
There is evidence that migraine attacks are associated with endothelial dysfunction.81-83 
Migraine prevalence seems increased in persons with polymorphisms linked to endothelial 
function84-90 and associated with elevated markers of endothelial activation.91 In chapter 10 we 
showed that, in contrast to CADASIL, RVCL/CHARIOT patients have a clear dysfunctional 
endothelial homeostasis, this may add to the increased risk of migraine. This may also 
provide a biological link between migraine and the increased cardiovascular risk found in 
migraine patients. 
Neuronal
CSD is thought to be the underlying mechanism of the migraine aura. As RVCL patients 
mainly suffer from migraine without aura an increased CSD susceptibility causing migraine 
in RVCL/CHARIOT patients seems less likely. 
pART III: MIGRAINE AND COMORbIDITY IN A GENETIC 
ISOLATE
The study of comorbidity may provide epidemiological or biological novel insights in 
mechanisms involved in migraine. Various conditions are reported to be comorbid with 
migraine. Among these are psychiatric disorders (depression, anxiety, bipolar disorder), 
neurological disorders (epilepsy), vascular disorders (Raynaud’s phenomenon, ischemic and 
hemorrhagic stroke), heart disease (patent foramen ovale (PFO), coronary heart disease) and 
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others such as asthma and systemic lupus erythematosus (SLE) and comorbid pain disorders 
(for review see Le et al., 201192 and Scher et al., 200593) Some of the reported associations show 
conflicting results. Conditions that have shown a consistent positive association with migraine 
include are stroke,94 depression,95 and epilepsy.96
13.6 Migraine and depression
In chapter 11 of this thesis we studied the comorbidity of migraine and depression in a 
genetically isolated population in the southwestern region of the Netherlands. Findings of 
a bidirectional influence between migraine and depression suggest common neurobiological 
mechanisms.95,97-98 There is some evidence of involvement of similar neurotransmitters in 
migraine and depression, such as serotonine, dopamine and glutamate.99-101 Also, stress-related 
mechanisms have been implicated in both disorders.102 Finally, the increased prevalence of 
migraine and depression in women indicates a role for hormonal factors in both disorders.103 
In ERF we identified 360 migraine cases: 209 had migraine without aura (MO) and 151 had 
migraine with aura (MA). Odds ratios for depression in patients with migraine were 1.29 (95% 
confidence interval [CI] 0.98-1.70) for MO and 1.70 (95% CI 1.28-2.24) for MA. Heritability 
estimates were significant for all migraine (0.56), MO (0.77), and MA (0.96).
As overlapping pathophysiological pathways have been suggested for migraine and 
depression, this would imply that DNA variants involved in these pathways may confer an 
increased risk to develop both of these diseases. In our study we found some evidence for 
the existence of shared genetic factors between both traits. That is heritability estimates for 
migraine decreased after adjustment for symptoms of depression or use of antidepressant 
medication, in particular for MA. Comparison of the heritability scores for depression 
between patients with migraine and controls showed a genetic correlation between HADS-D 
score and MA. This knowledge can be of importance as migraine and depression might be 
considered an endophenotype, which could facilitate gene identification. The general idea is 
that an endophenotype may be more robust and uniform than the original trait (i.e., migraine) 
itself, and perhaps may even reduce locus heterogeneity. This strategy has proven successful in 
the gene identification of schizophrenia and bipolar disorder.104,105 
The suggestion of shared genetic factors in migraine and depression that came from our 
study needs to be interpreted with caution. First, our heritability for migraine with aura is 
rather high and exceeds prior estimates. Second, confidence intervals in our analyses are very 
brought, leading to, at best, only marginally significant observations. This is perhaps inevitable, 
even in a very large sample such as ERF with some 3000 study subject, when analyzing a binary 
trait (with only 330 cases). Statistical uncertainty might limit the conclusion on the small 
reduction of heritability after correction for depression. Thus our results clearly should be 
confirmed in other studies. 
Two other twin studies indeed confirmed our results. In parallel with our study, a study 
of Schur et al estimated that 20% of variability in depression and migraine is due to shared 
genetic factors.106 Also a study from Ligthart et al., showed an increased genetic correlation 




Having statistically established that there are indeed shared genetic factors an important 
question is how to identify these factors? Several approaches can be put forward. One approach 
is to identify genomic regions with linkage analysis in migraine families and explore 
positive genomic regions in patients with migraine and depression, or the other way around. 
Alternatively, an association study can be performed with cases with migraine and depression 
versus controls, where depression may also be used as a quantitative trait. Two studies did a 
first attempt to actually identify shared risk variants for migraine and bipolar disease,108,109 but 
no such studies were performed with depression thus far. 
13.7 Migraine and cardiovascular disease
The association between migraine and cardiovascular disease, including ischemic stroke and 
subclinical brain lesions is well established for migraine with aura.110,111 The mechanism for this 
association, however, is less clear. In chapter 12 we investigated whether cardiovascular risk 
factors and atherosclerosis may be involved, but find no evidence for this. The jury is still out on 
whether this is indeed true as there is discrepancy with other studies.81,112 Other explanations 
and mechanisms include CSD, vascular changes that predispose to both migraine and stroke 
(endothelial dysfunction), migraine-specific medication, or PFO. The latter may predispose 
to microemboli in the cranial circulation which may lead to triggering of CSD. Notably, in 
an experimental rat model it was shown that emboli can trigger CSD without causing actual 
visible infarcts on MRI.113 
Shared genetic factors between migraine and stroke may also play a role. Indications come 
from monogenic migraine syndromes that predispose to stroke, such as CADASIL. Another 
example is MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes)114 in which stroke-like events are associated with migrainous headache. 
Further indications for a shared underlying genetic susceptibility may come from genes 
that have been implicated to play a role in stroke and migraine, including angiotensin 
converting enzyme (ACE)115,116 and genes related to endothelial function117,118 and homocysteine 
metabolism.87,115, 119,120 For example the 677C>T variant in the 5’,10’-methylenetetrahydrofolate 
reductase (MTHFR) gene has been investigated for stroke and migraine. The T allele impairs 
enzyme activity and carriers have modestly increased levels of homocysteine.121 In a meta-
analysis the MTHFR 677TT genotype was associated with a modestly increased risk for 
ischemic stroke.122 Similarly, the T allele has been associated to migraine with aura, which was 
confirmed in two meta-analysis,115,123 but negative findings have also been reported.119 Kurth 
et al. studied the mediating effect of stroke on the association between migraine and MTHFR 
T allele in the Women’s Health Study (WHS). In contrast to other studies, a protective effect 
of the TT genotype for migraine with aura was observed, however in patients with migraine 
with aura and the TT genotype an increased risk of ischemic stroke was observed. This might 
implicate that the MTHFR 677TT genotype is a marker for an increased risk of ischemic 
stroke in patients with migraine with aura.120 Similarly, a modulatory effect of the ACE D/I 
polymorphism was found in the migraine-stroke association in women.116 Also a GWAS study 
was published, that provides suggestive evidence for a shared genetic etiology of migraine and 
ischemic stroke. In women with migraine two SNPs located in the MEPE (matrix extracellular 
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phosphoglycoprotein) and IRX (iroquois homeobox protein 4) gene associated with ischemic 
stroke.124 The function of these variants with regard to the risk of cardiovascular disease is 
unknown. However no independent replication was performed for the initial association 
signal so results should be interpreted with caution. 
13.8 Future perspectives 
The clinical and genetic spectrum of FHM was explored in this thesis. As detailed knowledge 
on this spectrum is now available, sequence analysis of known FHM genes remains mainly 
relevant for genetic diagnosis. As not all FHM families are linked to FHM1-3, it is still 
worthwhile identifying additional FHM genes as they can provide novel and valuable insights 
in the pathogenesis of FHM. Therefore, the collection of novel - and extension of existing - 
FHM families remains important. When clinical material is available, identification of genes 
will be relatively ‘effortless’ compared to the past with currently available dense SNP arrays 
designed for linkage studies and the “Next Generation Sequencing” technology which allows 
for high-throughput sequencing in increasingly large samples.
Transgenic mouse models can be used as tools to study the functional consequences of 
mutated FHM genes in vivo, which may refine genotype-phenotype relations and may increase 
our understanding of the actions of anti-migraine drugs. These studies can be complemented 
by investigating biochemical compounds in Cerebrospinal Fluid (CSF) and/or with MR brain 
spectroscopy (MRS) of FHM and migraine patients to correlate genetic findings to biochemical 
changes.
The identification of the TREX1 gene for RVCL/CHARIOT opened new routes to obtain 
insight in the syndrome itself and in its relation with migraine. Future investigations of 
progression of the disease by detailed follow-up of mutation carriers will be important. 
How vascular changes in RVCL/CHARIOT arise is an unanswered question, but endothelial 
dysfunction may be involved, as was apparent from studies in chapter 10. Further studies of 
endothelial function may include assessment of markers for endothelial function in blood and 
CSF, and assessment of endothelial function in cerebro by functional imaging. On a molecular 
level a developed Trex1 antibody could be used in immunohistochemical and electron 
microscopy studies, which may shed more light on the exact location of (mutated) Trex1 in 
cells and tissues. In a recently generated RVCL/CHARIOT Trex1 knock-in mouse model the 
functional consequences of mutated Trex1 can be assessed in vivo. Together these initiatives 
hopefully contribute to the development of a treatment option for this devastating disease. 
In recent years, many GWAS have been performed for complex neurological disorders,125,126 
and identification of common genetic variants for migraine has also been successful.59-62 
Most identified loci (12 in total) are located in or immerdialtely outside genes with a known 
function in synaptic or neuronal regulation, pain pathways and some interact with each other. 
Further functional studies of identified variants and correlation with endophenotypes will 
be of great importance to translate the genetic findings to detailed pathways and potential 
treatment options for patients. It is unlikely that common genetic variability entirely explains 
the heritability of migraine and in the coming years much is expected from exome and 




intermediate and rare high risk disease alleles.127 Finally, it is expected that a large proportion 
of heritability of migraine may not be accounted for by the (combined) effect of identified 
genomic variants, but that epigenetic, post-genomic and/or regulatory events are also 
involved.128 It will be a future challenge to capture these factors.127
The efficient web-based diagnostic process for migraine and evolving, interactive, biobank 
LUMINA (Leiden University MIgraine Neuro-Analysis program),129 that combines clinical 
material, DNA and CSF and imaging data of migraine patients, will be of great relevance 
for future large-scale multidisciplinairy studies. Whether diagnostic categories defined in 
clinical practice have a common underlying genetic cause remains to be seen. Yet (unknown) 
endophenotypes may exist which are composed of a combination of disease features, as was 
suggested for migraine and depression in this thesis. Therefore, collecting data on comorbidity 
will remain a potentially very rewarding research activity. 
In conclusion, the studies in this thesis improved our understanding of migraine and 
comorbid conditions and provide examples of how migraine syndromes and comorbidity can 
be used as a tool to learn more about the genetic factors involved in migraine. Together these 
findings contribute to a better understanding on how migraine attacks start. It remains vital 
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In this thesis genetic aspects of migraine and related migraine syndromes were investigated. 
The research can be divided in three parts: the study of syndromes associated with Familial 
Hemiplegic Migraine (FHM), a monogenic variant of migraine (Part I); the study of a 
migraine-associated syndrome termed Retinal Vasculopathy with Cerebral Leukodystrophy 
(RVCL; later renamed CHARIOT) (Part II); and the study of migraine and comorbidity in a 
Dutch genetic isolate (Part III). 
In part one, clinical genetic studies on FHM are described. FHM can present as pure FHM 
(only hemiplegic migraine attacks), or be accompanied by additional clinical features. Further 
insight in the associated clinical symptoms of FHM1 (caused by mutations in the CACNA1A 
gene) came from a study of four families with the R1347Q mutation (Chapter 2). The study 
reinforces the wide clinical spectrum of FHM1 including (trauma-triggered) hemiplegic 
migraine with and without ataxia, loss of consciousness and epilepsy. A direct implication of 
the study is that genetic screening in hemiplegic migraine patients should focus on screening 
for recurrent mutations, such as R1347Q, first. 
In Chapter 3 a monozygotic twin is described with clinical features of AHC (alternating 
hemiplegia of childhood) and FHM, which lead to difficulties in the differential diagnosis. 
By identifying a novel de novo mutation it became evident that FHM and atypical AHC may 
share pathophysiological mechanism that involves calcium channel dysfunction. It builds on 
a previous observation that a family with atypical AHC was shown to have an FHM2 (i.e., 
ATP1A2) mutation. Recently it was shown that the majority of AHC patients have de novo 
missense mutations in the related ATP1A3 gene.
The clinical consequences of the S218L mutation in the CACNA1A gene were investigated 
in Chapter 4. CACNA1A S218L mutation can cause “early seizures and cerebral edema after 
trivial head trauma” (ESCEATHT), at least in three of thirteen mutation carriers. These 
clinical features are at the extreme severe end of the FHM disease spectrum. Cerebellar 
ataxic symptoms and hemiplegia, the latter often being triggered by trivial head trauma, were 
present in the far majority of cases; seizures were reported in seven patients. The importance 
of the study is that all S218L mutation carriers are at risk for developing ESCEATHT with its 
devastating consequences. In knock-in mice the S218L mutation increases the propensity for 
CSD and increases the risk of epilepsy and mild head trauma-triggered edema. This indicates 
that the same pathway, i.e., increased susceptibility for CSD, may cause the ESCEATHT 
phenotype in humans.
In Chapter 5 an ATP1A2 mutation is described that causes FHM2 associated with febrile 
seizures. This study strengthens the concept of shared molecular pathways in migraine and 
epilepsy. Additional support for this link comes from the study described in Chapter 6. In 
the well-known “epilepsy gene” SCN1A, a third FHM3 mutation (i.e., L263V) was found in a 
Portuguese family, in which three out of five mutation carriers exhibited generalized epilepsy, 
in addition to FHM. The findings support the association of a wide continuum of episodic 
brain disorders with this gene.
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In chapter 7 the role of the SCL1A3 gene, encoding the glutamate transporter EAAT1, in 
episodic ataxia (EA) families without a CACNA1A gene mutation, is explored. The EAAT1 
protein is responsible for removal of glutamate from the synaptic cleft and herewith is 
involved in the same pathway as the FHM1-3 genes. Reason to perfom this study was given by 
publication of a sporadic patient with a P290R mutation in SCL1A3 with severe episodic and 
progressive ataxia, seizures, alternating hemiplegia and migraine headache. A missense C186S 
mutation was identified in one of 20 tested EA probands. This mutation segregated in three 
affected family members. Clinical symptoms in these patients were much milder compared 
to the previously reported sporadic patient. This milder phenotype could be explained by 
functional analysis of the mutation, which showed only a modest dysfunctional glutamate 
transporter compared to the P290R mutation.
In part two, genetic and clinical studies on TREX1, the gene for Retinal Vasculopathy with 
Cerebral Leukodystrophy (RVCL) are described. The original three published RVCL families 
were known under different names: CerebroRetinal Vasculopathy (CRV), Hereditary Vascular 
Retinopathy (HVR), and Hereditary Endotheliopathy, Retinopathy, Nephropathy and Stroke 
(HERNS). The identification of TREX1 mutations in all of them, indicated that the original 
names were reflections of the broad clinical spectrum of the RVCL syndrome (Chapter 8). 
RVCL mutations in the TREX1 gene, encoding a 3’-5’-exonuclease, result in C-terminal 
truncated proteins that retain their exonuclease activity, but lose their normal perinuclear 
localization. The clinical spectrum of 78 mutation carriers of eleven RVCL families carrying 
five different TREX1 mutations is presented in Chapter 9. RVCL was renamed CHARIOT 
(Cerebral Hereditary Angiopathy with vascular Retinopathy and Impaired Organ Function 
caused by TREX1 Mutations) because this acronym better reflects the clinical spectrum of the 
disease and because leukodystrophy (indicated by the “L” in RVCL) is not the right term for the 
radiological and pathological cerebral abnormalities seen in this syndrome. It was demonstrated 
that the CHARIOT syndrome consisted of a broad range of clinical manifestations, without an 
apparent genotype-phenotype correlation, that include vascular retinopathy, focal neurological 
symptoms, cognitive and psychiatric complaints, migraine (mainly without aura) and 
systemic symptoms (renal and liver impairment, Raynaud’s phenomenon). Neuroradiological 
abnormalities include punctate white matter lesions, contrast-enhancing intracerebral mass 
lesions and calcifications. Histopathology revealed a stenotic vasculopathy mainly in the brain 
and retina. In addition basement membrane abnormalities in the small vessels of the cerebral 
white matter and other organs were found, however the significance of this finding is unclear. 
How mutated truncated TREX1 causes disease is unknown. In chapter  10, we investigated 
vascular properties and endothelial function in CHARIOT, compared to controls and patients 
with a second neurovascular migraine syndrome CADASIL (cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy). The latter syndrome is 
pathologically characterized by degeneration of arteriolar vascular smooth muscle cells, which 
in CHARIOT is only marginally present. From the study it became clear that CHARIOT 
patients have endothelial function in conduit arteries, in contrast to CADASIL where vascular 
impairment seems to be due to defect in smooth muscle cell functioning in resistance arteries. 
Because of the overlapping clinical features, CHARIOT may serve a model for various common 




The third part investigates comorbidity of common migraine with other diseases and 
describes how comorbidity may be helpful for genetic studies of migraine. Chapter 11 
describes the identification of migraine cases in a genetically isolated Dutch population; the 
Erasmus Rucphen Family (ERF) study. Genetic isolates may help to identify new genes because 
of reduced genetic and clinical heterogeneity. The use of endophenotypes may further reduce 
heterogeneity as it will result in more robust phenotypes.
In Chapter 11 the co-occurrence of migraine and depression in ERF was investigated. 
There is a bidirectional association between migraine and depression which suggest a common 
etiology. Therefore it was also assessed whether shared genetic factors may underlie both 
diseases. In total, 360 migraine cases were ascertained: 209 of them had migraine without aura 
(MO), 151 had migraine with aura (MA). Odds ratios (OR) for depression in migraine patients 
were significantly increased, in particular for migraine with aura. Heritability estimates 
in migraine (subtypes) were significant and decreased after adjustment for symptoms of 
depression or use of antidepressant medication, in particular for MA. This confirms migraine 
to be a highly genetic disorder and indirectly that the bidirectional association between 
depression and migraine (and particularly in MA), at least in part, can be explained by shared 
genetic factors. 
Migraine patients have an increased risk for ischemic stroke en possible also for other 
major cardiovascular diseases. This could be explained by a predisposition to atherosclerosis 
caused by an unfavorable cardiovascular risk profile. Therefore, in chapter 12 various markers 
for atherosclerosis (i.e., Pulse Wave Velocity, Intima Media Thickness, and Ankle Brachial 
Index) were assessed in migraine patients and controls from the ERF study. It was concluded 
that migraineurs have no increased risk for central or peripheral atherosclerosis, making 
it an unlikely explanation for the relation between migraine and ischemic cardiovascular 
events. Other suggested mechanisms, such as a general endothelial dysfunction, increased 
susceptibility to CSD or a shared genetic susceptibility, should be considered.
Chapter 13 places clinical and genetic findings from the previous chapters in a broader 
perspective. Pathophysiological mechanisms for the various migraine syndromes and its 
value as a model for common migraine are discussed, as well as the potential for comorbidity 







Dit proefschrift onderzoekt genetische aspecten van migraine en gerelateerde migraine 
syndromen. Het onderzoek is opgedeeld in drie delen: onderzoek naar syndromen geassocieerd 
met Familiaire Hemiplegische Migraine (FHM), een monogenetische migraine variant (deel 1); 
onderzoek naar een syndroom gepaard gaande met migraine genaamd Retinale Vasculopathie 
met Cerebrale Leukodystrofie (RVCL, later genoemd CHARIOT) (deel 2); en onderzoek naar 
migraine en comorbiditeit in een Nederlands genetische isolaat (deel 3). 
Deel 1 behandelt klinisch genetisch onderzoek naar FHM. FHM kan zich uiten als puur 
FHM (alleen aanvallen van hemiplegische migraine) of kan gepaard gaan met bijkomende 
klinische verschijnselen. Meer inzicht in de klinische symptomen die samengaan met FHM1 
(veroorzaakt door mutaties in het CACNA1A-gen) werd verkregen door bestudering van 
vier families met de mutatie R1347Q (hoofdstuk 2). De studie benadrukt het brede klinisch 
spectrum van FHM1, inclusief (door hoofdtrauma uitgelokte) aanvallen van hemiplegische 
migraine met of zonder ataxie, stoornis in het bewustzijn en epilepsie. Een directe implicatie 
van deze studie is dat bij genetische screening van hemiplegische migraine patiënten eerst 
gescreend moet worden op terugkerende, zogenoemde recurrent mutaties, zoals R1347Q, 
alvorens het gehele gen te screenen. 
In hoofdstuk 3 wordt een monozygote tweeling beschreven met een combinatie van 
klinische verschijnselen van AHC (alternerende hemiplegie op de kinderleeftijd) en FHM, 
waardoor de differentiële diagnostiek lastig was. Door identificatie van een nieuwe de novo-
mutatie werd duidelijk dat FHM en deze atypische AHC een gedeeld pathofysiologisch 
mechanisme lijken te hebben waarbij dysfunctie van calciumkanalen een rol speelt. Het 
onderzoek borduurt voort op voorgaand onderzoek waarbij een familie met atypische AHC 
een FHM2-(ATP1A2-)mutatie bleek te hebben. Recent werd aangetoond dat de meerderheid 
van AHC patiënten mutaties in het, aan ATP1A2 verwante, ATP1A3-gen hebben.
De klinische consequenties van de S218L-mutatie in het CACNA1A-gen worden 
onderzocht in hoofdstuk 4. De CACNA1A-S218L-mutatie veroorzaakte in tenminste 3 van 
de 13 mutatiedragers “vroege convulsies en cerebraal oedeem na triviaal hoofd trauma” 
(ESCEATHT). Deze klinische kenmerken vormen de meest ernstige variant van van 
het FHM-ziektespectrum. In de meerderheid van de gevallen was cerebellaire ataxie en 
hemiplegie aanwezig, dit laatste vaak uitgelokt door triviaal hoofdtrauma; in zeven patiënten 
bleken convulsies voor te komen. Het belang van de studie is dat alle S218L-mutatie dragers 
risico hebben op de ontwikkeling van ESCEATHT met uitermate ernstige consequenties. 
cacna1a-S218L-knock-in-muizen hebben een verhoogde gevoeligheid voor CSD (cortical 
spreading depression) en een verhoogd risico op epilepsie en cerebraal oedeem uitgelokt door 
hoofdtrauma. Dit duidt erop dat eenzelfde mechanisme, nl. een verhoogde gevoeligheid voor 
CSD, ESCEATHT kan veroorzaken in mensen. 
Hoofdstuk 5 spits zich toe op een ATP1A2-mutatie die FHM2 en koortsconvulsies 
veroorzaakt. Dit onderzoek draagt bewijs aan voor het concept van gedeelde moleculaire 
mechanismen tussen migraine en epilepsie. In hoofdstuk 6 wordt de link tussen migraine 
en epilepsie verder bekrachtigd. In het SCN1A ‘epilepsie’ gen werd een derde FHM3 mutatie 
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(i.e., L283V) gevonden in een Portugese familie, waarin 3 van de 5 mutatie dragers, naast FHM 
ook gegeneraliseerde epilepsie aanvallen hadden. De bevindingen bevestigen dat een breed 
continuüm van episodische aandoeningen met dit gen geassocieerd zijn.
In hoofdstuk 7 wordt de rol onderzocht van het SCL1A3-gen bij episodische ataxie (EA) 
families die geen mutatie hebben in het CACNA1A-gen. Het SCL1A3-gen codeert voor de 
glutamaat transporter EAAT1. Dit EAAT1-eiwit is verantwoordelijk voor de verwijdering 
van glutamaat uit de synaptische spleet en past daarmee in eenzelfde mechanisme als de 
drie FHM-genen. Aanleiding tot de studie was publicatie van een sporadische patiënt met 
een P290R mutatie in SCL1A3 met ernstige episodische en progressieve ataxie, convulsies, 
alternerende hemiplegie en migraineuse hoofdpijn. Een missense C186S mutatie werd 
geïdentificeerd in 1 van de 20 geteste episodische ataxie patiënten. Deze segregeerde in drie 
familieleden met EA. De klinische symptomen in deze patiënten zijn veel milder dan die van 
de eerder gerapporteerde sporadische patiënt. Functionele analyse van de P290R mutatie liet 
een beperktere dysfunctie van de glutamaattransporter zien, dan de eerder beschreven P290R-
mutatie, correlerend met de mildere klinische verschijnselen. 
Deel 2 behandelt genetisch en klinisch onderzoek naar TREX1, het gen voor retinale 
vasculopathie met cerebrale leukodystrofie. Eerder gepubliceerde RVCL families waren 
bekend onder verschillende ziekte namen: CerebroRetinale Vasculopathie (CRV), Hereditaire 
Vasculaire Retinopathie (HVR) en Hereditaire endotheliopathie,Retinopathie, Nefropathie en 
Beroerte (HERNS). De identificatie van TREX1 mutaties in deze drie families liet zien dat de 
originele ziekte namen het brede klinische spectrum geassocieerd met het RVCL syndroom 
reflecteerden (hoofdstuk 8). RVCL-mutaties in het TREX-gen, coderend voor het 3’-5’ 
exonuclease, resulteren in C-terminaal getrunceerde eiwitten die hun exonuclease activiteit 
behouden, maar hun normale perinucleaire lokalisatie verliezen. In hoofdstuk 9 wordt het 
klinisch spectrum van 78 mutatiedragers uit 11 RVCL families onderzocht. RVCL werd 
CHARIOT (cerebrale erfelijke angiopathie met vasculaire retinopathie en disfunctionerende 
andere organen veroorzaakt door TREX1 gen mutaties) genoemd omdat dit acronym een betere 
reflectie geeft van het klinisch spectrum van deze aandoening en omdat leukodystrofie (de “L” in 
RVCL) niet de juiste beschrijving geeft van de afwijkingen die gezien worden bij beeldvorming 
en pathologische anatomisch onderzoek van de hersenen. Er werd aangetoond dat het RVCL 
syndroom bestaat uit een breed spectrum van klinische manifestaties, zonder een duidelijke 
genotype phenotype correlatie, namelijk vasculaire retinopathie, focaal neurologische 
symptomen, cognitieve en psychiatrische klachten, migraine (grotendeels zonder aura) en 
systemische symptomen (nierfunctie stoornissen, verhoging van leverenzymen, het fenomeen 
van Raynaud). Neuroradiologische afwijkingen bestaan onder andere uit witte stof laesies, 
intracerebrale ruimte innemende aankleurende processen en calcificaties. Histopathologisch 
onderzoek laat een stenoserende vasculopathie zien, met name in de hersenen en retina. 
Tevens wordt een afwijkende basaal membraan in vaten in het brein maar ook in andere 
organen (waaronder de nier) gevonden, echter de betekenis hiervan is onduidelijk. In 
hoofdstuk 10 werd onderzoek gedaan naar vasculaire eigenschappen en endotheel functie 
van CHARIOT patiënten en vergeleken met gezonde controles en een tweede neurovasculair 




met subcorticale infarcten en leukoencephalopathie). Het laatst genoemde syndroom wordt 
pathologisch ondermeer gekarakteriseerd door degeneratie van gladde spiercellen van 
arteriolen, dit in tegenstelling tot CHARIOT waar dit maar marginaal aanwezig is. Uit de 
studie werd duidelijk dat CHARIOT patiënten endotheliale dysfunctie van grote vaten 
hebben, in tegenstelling tot CADASIL patiënten waarbij de stoornis in vasculaire functie lijkt 
te worden veroorzaakt door een defect in functioneren van gladde spiercellen in kleine vaten. 
Vanwege overlappende klinische symptomen, zou CHARIOT een model kunnen vormen voor 
meer voorkomende neurovasculaire ziekten zoals vasculaire dementie en migraine. 
Deel 3 onderzoekt comorbiditeit van migraine met andere ziekten en beschrijft hoe 
comorbiditeit behulpzaam kan zijn bij genetisch onderzoek naar migraine. Hoofdstuk  11 
beschrijft de identificatie van migraine patiënten in een Nederlands genetisch isolaat, het 
Erasmus Rucphen familieonderzoek (ERF). Genetische geïsoleerde populaties zouden 
kunnen helpen bij de identificatie van genen omdat zowel de heterogeniteit van genen als 
omgevingsfactoren kleiner is. Het gebruik van endophenotypen kan de heterogeniteit verder 
kunnen reduceren omdat het resulteert in meer robuustere fenotypen. 
Hoofdstuk 11 gaat over de comorbiditeit van migraine en depressie in ERF. Er is een 
bidirectionale relatie tussen migraine en depressie, wat een gedeelde etiologie suggereert. 
Daarom werd onderzocht of er gedeelde genetische risicofactoren zijn tussen beide ziekten. In 
totaal werden er 360 migraine patiënten geïdentificeerd: 209 hadden migraine zonder aura, 151 
migraine met aura. De odds ratios (OR) voor depressie in migraine patiënten was significant 
verhoogd, in het bijzonder voor migraine met aura. Heritabiliteits-schattingen voor migraine 
(subtypen) waren significant en verminderden na correctie voor depressieve symptomen 
of gebruik van antidepressiva, in het bijzonder voor migraine met aura. Dit bevestigt dat 
migraine een grote genetische component heeft en indirect dat de bidirectionele associatie 
tussen depressie en migraine (in het bijzonder MA), tenminste ten dele, kan worden verklaard 
door gedeelde genetische factoren. 
Migraine patiënten hebben ook een verhoogd risico op het krijgen van een herseninfarct en 
mogelijk op andere cardiovasculaire aandoeningen. Een predispositie voor het ontwikkelen van 
atherosclerose door een ongunstig cardiovasculair risicoprofiel zou een mogelijke verklaring 
kunnen zijn. Daarom werden in hoofdstuk 12 diverse markers voor atherosclerose (pulse wave 
velocity (PWV), Intima Media dikte (IMT) en Enkel arm index (ABI)) onderzocht in migraine 
patiënten en controles uit ERF. Hieruit bleek dat migraineurs geen verhoogd risico hebben 
op centrale of perifere atherosclerose, waardoor het een onwaarschijnlijk verklaring wordt 
voor de relatie tussen migraine en ischemisch cardiovasculaire ziekten. Andere mechanismen, 
zoals endotheel dysfunctie, verhoogde gevoeligheid voor CSD of een gedeelde genetische 
gevoeligheid moeten worden overwogen.
Hoofdstuk 13 ten slotte plaatst de klinische en genetische bevindingen uit voorgaande 
hoofdstukken in een breder perspectief. Pathofysiologische mechanismen voor de verschillen 
migraine syndromen en de waarde als model voor het veel voorkomende migraine met en 
zonder aura worden besproken, evenals het potentieel voor de comorbiteit van complex 







AIx  augmentation Index
AHC  alternating hemiplegia of childhood
AGS  Aicardi-Goutière syndrome
ATP  adenosine tri-phophate
BFIC  benign familial infantile convulsions 
CADASIL  cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy
CGRP  calcitonin-gene related peptide
DNA  deoxyribonucleic acid
CNS  central nervous system 
CRV  cerebrovascular retinopathy
CSD  cortical spreading cepression
CHARIOT  cerebral hereditary angiopathy with vascular retinopathy and impaired 
organ function caused by TREX1 mutations 
DBF  dermal blood flow 
EA  episodic ataxia 
EAAT1  excitatory amino acid transporter 1
EEG  electroencephalogram
ERF  Erasmus Rucphen Family (study)
ESCEATH early seizures and cerebral edema after trivial head trauma
FMD  flow-mediated dilatation 
FHM  familial hemiplegic migraine
FP  fluorescent protein
GEFS+   generalized epilepsy with febrile seizures plus
GWAS   genome-wide association study
HERNS  hereditary endotheliopathy, retinopathy, nephropathy and stroke
HVR  hereditary vascular retinopathy
IHS  International Headache Society 
ICHD  international classification of headache disorders
KI  knock-in
LDPI  laser doppler perfusion imaging 
LD  linkage disequilibrium
LOD  logarithm of odds
MA  migraine with aura
MO  migraine without aura
MRI  magnetic resonance imaging
NTG  nitroglycerin
NO  nitric oxide 
PCR  polymerase chain reaction
PWA  pulse wave analysis 
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PWV  pulse wave velocity 
RVCL  retinal vasculopathy with cerebral leukodystrophy
SCA6  spinocerebellar ataxia type 6
SHM  sporadic hemiplegic migraine
SMEI  severe myoclonic epilepsy of infancy
SNP  single nucleotide polymorphism
TGVS  trigeminal vascular system
TREX1  three prime repair exonuclease 1
TNC  trigeminal nucleus caudalis
TRPV1  transient receptor potential vanilloid type I receptor 
VSMCs  vascular smooth muscle cells 
WMH  white matter hyperintensities
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